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Abstract  
The aim of this thesis was to identify some of the ethical issues of HIV positive 
asylum seekers and refugees participating in clinical trials in Britain. While all 
individuals are to some degree vulnerable in clinical trials, I have shown in this thesis 
that this group is particularly vulnerable in a number of areas. Many will not have 
English as a first language and while they may be able to understand everyday 
language, the participant information sheet (PIS) may be difficult to comprehend both 
in terms of language and content. Cultural aspects may also influence the individuals’ 
participation in a clinical trial. Many will have come from a hierarchical culture where it 
would be unthinkable to refuse to participate if requested to do so by someone of a 
higher social status, such as physicians. Individuals may also be reluctant to decline 
an invitation to participate in a clinical trial if asked to do so by their own clinician, if 
they are reliant on him/her to provide letters of support for the immigration authorities.    
 
While the clinical trials regulations suggests ways in which the vulnerable can be 
given additional protection in the research setting, HIV positive asylum seekers and 
refugees are not always considered by researchers to be vulnerable. As such, the 
additional protection afforded is denied to them. In this thesis I have suggested a 
number of measures which will afford additional protection to HIV positive asylum 
seekers and refugees who participate in clinical trials.  
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Chapter 1 
Introduction 
Before the era of antiretroviral therapy the prognosis for individuals infected with HIV 
was poor, with many dying within ten years of being infected. Cooper (2008) reports 
that since the advent of highly active antiretroviral therapy (HAART) individuals who 
commence on treatment can now expect to live into their sixties. For those who start 
treatment with a high CD4 count, this increases to seventy years of age. HIV 
treatment and care is free in the UK under the NHS.  However, not all those who are 
HIV positive are eligible.   
 
In the UK, the Health Protection Agency (2010) reported that out of the 6630 newly 
diagnosed individuals, 2430 acquired their infection abroad. While many of these 
individuals will be eligible for NHS treatment and care, a small proportion will not.  
Following The Court of Appeal Judgement in ‘R (YA) -v- Secretary Of State for Health 
(2009), it has been increasingly difficult for failed asylum seekers or refugees to 
continue to access NHS treatment and care. The African HIV Research forum (2010) 
reported that a small but increasing number of HIV positive individuals had been 
accessing pharmaceutical industry sponsored clinical trials. Some of these individual 
were asylum seekers or refugees who had failed their appeal to remain in the UK, 
and were reported to be entering clinical trials in order to have continued access to 
treatment and care. The Refugee Council (2006) also reported that some individuals 
who were in the process of applying for asylum had enrolled in clinical trials. These 
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individual were under the misapprehension that the immigration authority and health 
authority automatically shared information, and entering a clinical trial would support 
their asylum appeal. Anecdotal evidence from HIV clinicians also supports these 
findings. However, there is little if no documented evidence of the numbers of 
individuals involved.     
 
While participating in clinical trials may be one means of continuing access to HIV 
treatment and care for asylum seekers and refugees, there are some ethical issues to 
be considered. The first two chapters of this thesis will provide the reader with some 
background information about HIV and clinical trials. This will include HIV 
transmission, prognosis and treatment and current provision of NHS care for asylum 
seekers and refugees. Following this, I will go on to discuss the attributes HIV positive 
asylum seekers and refugees possess which make them invaluable as research 
participants. I will then discuss the potential harms and benefits of participating in 
clinical trials, including the role of ethics committees in limiting harm to participants. I 
will go on to discuss the issue of consent, including provision of information and 
voluntariness. In the concluding chapter, I will offer some recommendations which will 
go some way to ensuring that HIV positive asylum seekers and refugees are not 
disadvantaged by participation in clinical trials.   
 
HIV positive asylum seekers and refugees who have access to NHS treatment and 
care face different issues from those who do not. While I will address any differences 
between the two groups in the thesis, the reader should bear in mind that a proportion 
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of those who currently have access to treatment will become ineligible should they 
lose their appeal to remain in the UK.  
 
Little has been written on the participation of asylum seekers and refugees in clinical 
trials in the UK. There may be a number of reasons for this. It is difficult to estimate 
numbers involved; HIV positive refugees and asylum seekers may not disclose their 
immigration status to researchers, for fear of being denied access to the trial. Thus 
researchers themselves may be unaware of the immigration status of the potential 
participant. Those researchers who are aware that the prospective participant is an 
asylum seeker may not appreciate that this has any bearing on their participation in 
the trial. While this thesis focuses on the problems faced by HIV positive asylum 
seekers and refugees who participate in clinical trials, it is likely that asylum seekers 
and refugees with other chronic medical conditions will face similar issues accessing 
on-going medical care.   
 
My interest in writing on this topic stems from twenty-five years of working with people 
living with HIV both in Africa and the UK. While I have seen great improvements in 
HIV treatment over the years, accessing treatment remains as much a problem for 
the vast majority in need as it always has. Having worked both as a researcher in HIV 
clinical trials, and having sat on a research ethics committee for ten years, I have 
been increasingly aware of the issues of asylum seekers and refugees accessing 
clinical trials. I hope that this thesis will highlight some of these concerns and that any 
recommendations made may seek to address the problem.   
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Chapter 2  
Background of HIV and current access to treatment and care for asylum 
seekers and refugees 
 
In this chapter I will ‘set the scene’ for the thesis by providing an overview of HIV 
including the global and UK statistics. I will go on to outline some of the problems 
asylum seekers and refugees have accessing NHS treatment and care, and look at 
how these issues can impact on the health and well-being of the individual.   
 
HIV 
In order to understand why having access to treatment is so important to those living 
with the Human Immunodeficiency Virus (HIV), it is necessary to have a basic 
understanding of how HIV affects the individual. The discovery of HIV as the cause of 
Acquired Immune Deficiency Syndrome (AIDS) occurred in 1985. Scientists Luc 
Montagnier and Robert Gallo were credited as having identified the virus. The 
identification of the virus followed investigations into a number of unexplained 
illnesses and deaths affecting gay men in both the United States and Europe. 
Scientists thought at that time that the virus was sexually transmitted through 
unprotected anal intercourse. It would be some years before other modes of 
transmission were identified. As such early publicity campaigns to reduce the spread 
of the virus were aimed predominately at the gay community. This led to the fallacy - 
still held by some today - that HIV only affects homosexuals.  
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Transmission 
It is now known that HIV is transmitted in blood, semen, vaginal secretions and breast 
milk. As such, it can be acquired through unprotected sexual intercourse with a 
positive individual, passed from an HIV positive mother to her baby through breast 
milk or during vaginal delivery, contracted through infected blood and blood products 
or by contaminated injecting equipment. The immune system is responsible for 
fighting infection. HIV slowly destroys the cells of the immune system, including the 
CD4 or T. cells. Once the number of cells has been depleted, the individual is no 
longer capable of fighting infections. Some infections only occur when the immune 
system is not functioning properly; these are called opportunistic infections, as they 
take advantage of a weakened immune system. Contracting any one of these 
infections gives the individual a diagnosis of Acquired Immune Deficiency Syndrome 
(AIDS). Without effective treatment, people with AIDS will rapidly progress to death. 
Prior to effective treatment, a person diagnosed with HIV could be expected to 
develop AIDS within five years. The first antiretroviral medication, Zidovudine (AZT), 
was licensed in 1990. While this was effective to some extent it was only in 1997, 
when Highly Active Antiretroviral Therapy (HAART) became available, that physicians 
were able to significantly extend the life of a person with HIV by delaying the 
progression towards AIDS. The Lancet (2008) reported on the findings of fourteen 
cohort studies investigating the long term prognosis of individuals receiving 
antiretroviral therapy in the West. The report concluded that most individuals taking 
treatment were expected to live into their sixth decade. The medication cannot, at the 
present time, eradicate the virus. Once a person has commenced on treatment they 
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will need to continue to take it for the rest of their lives. While treatment is effective, it 
can have side effects such as an increase in lipids and blood sugar. There is also a 
risk of developing drug resistant viruses if the antiretrovirals are not taken correctly or 
stopped abruptly.   
 
Prevalence of HIV 
The UNAIDS (2010) estimate that thirty-three million individuals world-wide are HIV 
positive, the majority of whom live in sub-Saharan Africa. However, only fifty percent 
of adults and thirty percent of children who are need in need of antiretroviral 
medication are receiving it. The Health Protection Agency (HPA) report for 2010 
estimated that 86,500 individuals are living with HIV in the United Kingdom. 
Heterosexuals account for fifty-four percent of new diagnosis in the UK. Of these, 
sixty-three percent were black Africans, sixty-eight percent of whom had acquired 
their infection abroad, mainly in sub-Saharan Africa.  
 
There has also been a change in migration over the years to the United Kingdom. 
Civil wars and resulting poverty have resulted in many individuals leaving their home 
countries to seek refuge and a better life in the West. Some individuals from former 
British Colonies came to join family and friends who were already established in the 
United Kingdom. Others came to pursue a course of study, whilst some sought 
asylum from oppressive regimes. HIV testing is not readily available in all African 
countries. As such, many of those newly arrived in Britain will not have had the 
opportunity to test for HIV prior to their arrival. The Sexual Health Strategy for 
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England and Wales (2001) set targets to increase HIV testing of all sexually active 
individuals to sixty percent by 2007. In order to meet this target, HIV testing was 
actively encouraged in many health care settings such as sexual health clinics, GP 
practices and antenatal clinics. The Strategy stated that normalising the HIV test and 
incorporating it into a routine health check would increase the uptake of testing. The 
British HIV Association (BHIVA) (2008) also recommends that GPs should routinely 
offer the test when registering new patients. Under the National Health Service 
(charges to overseas visitors) Regulations (2011) the HIV test is free to all people 
irrespective of their immigration status, but only those who are eligible for NHS 
services can access treatment and care. This policy may not be communicated to 
those invited to test, or even be known to health care professionals offering testing. 
Concerns around access to treatment may act as a barrier to testing; some people 
may choose not to test if they would be unable to access treatment should they have 
a positive result.  
 
Asylum seekers/Refugees 
The terms ‘asylum seekers’, ‘refugees’ and ‘migrants’ are used interchangeably in the 
tabloid press.  
 Article 1a (2) of the United Nations Convention defines a refugee as: 
 
“A person who has a well-founded fear of persecution for reasons of race, 
religion, nationality, membership of a particular social group or political opinion 
and who is outside the country of his nationality or former habitual residence 
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and is unable or, owing to such fear, is unwilling to avail Himself of the 
protection of that country or to return to it” 
 
Economic migrants are defined as people who leave their country of origin to seek a 
better standard of living, but do not fulfil the requirements of the UN convention.  
 
Once a refugee has gained admission to the UK, they can claim asylum under the 
United Nations Convention Relating to the Status of Refugees (1951). At this point 
they become eligible for NHS treatment and care. Some refugees and asylum 
seekers who test HIV positive in the UK may decide to apply to remain in the UK if it 
is unlikely that they would have access to treatment in their country of origin. 
Applications by HIV positive individuals to remain in the UK on compassionate 
grounds are usually made under Article 3 of the Human Rights Convention. 
Individuals applying to remain under these terms have to prove that they would suffer 
torture, inhumane or degrading treatment if they were to return to their country of 
origin. Solicitors for HIV positive individuals argue that being unable to access 
antiretroviral medication in their country of origin fulfils these conditions, as the lack of 
proper medical care constitutes inhumane treatment.  Without medication it is unlikely 
that they will continue to enjoy good health, and so will have a reduced life 
expectancy. However, changes in government policy has made it increasingly difficult 
for HIV positive asylum seekers and refugees to be granted leave to remain in the UK 
on these grounds (English, 2005). The Home Office receives country specific reports 
on the availability of antiretroviral treatment. Based on these reports, they decide if 
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there is a need for the individual to remain in the UK to access treatment, or if they 
could access treatment in their country of origin. Soome (2008) challenged this 
assertion. She found that Home Office reports on the availability of medication were 
based on flawed information. In many cases where antiretroviral medication was 
available, supply was sporadic and only a limited range of drugs were available. It 
may be very difficult, if not impossible, for an individual to have access to the drugs 
they were prescribed in the UK. This is of particular concern if the individual has some 
degree of drug resistance. Second or third line treatment may not be available which 
means that they will not have access to effective treatment.  
 
Antiretroviral Treatment in developed Countries 
HAART has been available in developed countries since 1997. HAART consists of 
three or more antiretrovirals from different classes given in combination. The aim of 
this combination is to disrupt the replication of the virus at various points in its life 
cycle. When the virus replicates, it enters and destroys the CD4 cells which are part 
of the immune system. A reduction in these cells leads to a weakened immune 
system which is unable to fight infection. People with a normally functioning immune 
system have a CD4 count of between 500 to 1500 cells per cubic ml (AIDSmap, 
2007). Once this drops to below 300, the individual is at risk of developing an 
opportunistic infection. In order to prevent these infections, the British HIV Association 
(BHIVA) guidelines (2008) suggest that the optimum time to commence antiretroviral 
therapy is when the CD4 count is around 350 cells per cubic ml. The BHIVA 
guidelines state that when initiating treatment, the clinician should weigh up the 
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benefits of starting treatment with the potential drug toxicity, difficulties with long term 
adherence and the potential development of drug-resistant virus. If treatment is 
commenced when the CD4 count is high it could potentially lead to early resistance to 
antiretrovirals. However, it is possible to access treatment at this early stage as part 
of a clinical trial where the individual will be closely monitored.  
 
Antiretroviral treatment in less economically developed countries (LEDCs) 
In recent years, antiretroviral medication has become available in some LEDCs. 
However, the range of available antiretrovirals may be limited by cost. In addition, the 
availability of drugs can be sporadic and individuals are not guaranteed a regular 
supply, potentially leading to drug resistance. In the West, it costs approximately 
£8,000 per annum to supply an individual with medication. Due to the Trade Related 
aspects of International Property Rights (TRIPS) agreement, the cost of medication in 
the developing world can be a little as $300 per annum. While this would appear at 
first to be welcome news, one should remember that this figure may be greater than 
the annual salary of those living in developing countries. Coupled with high levels of 
unemployment and ill health, treatment may still be beyond the means of those who 
need it. Antiretrovirals are seldom free unless supplied through a clinical trial or 
through international aid schemes. In some cases medication is free, but individuals 
are still charged a consultation fee which may be prohibitive. Often - when treatment 
is available - it is limited to members of the countries’ armed forces, members of the 
ruling parties and those with sufficient funds to pay for medical care (Elbe 2005). 
While trade agreements have resulted in subsidised treatment, the cost of medication 
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is beyond the financial means of the majority of individuals. The World Health 
Organisation (WHO) Three by Five Campaign was designed to provide three million 
individuals with antiretrovirals by the year 2005, but failed to reach its target. In 
response to this, the WHO set another target which aimed to provide HIV treatment, 
prevention and care for eighty percent of those in need by 2010. Again, this target 
was not met. In 2011 the WHO released its global health strategy for 2011-2015. In 
order to achieve universal access to HIV treatment, it has concentrated on four key 
areas; reducing new infections by fifty percent in young people, reducing TB related 
mortality by fifty percent, eliminating new infections in children and reducing HIV 
related mortality. Meeting these targets is truly daunting. In many developing 
countries, the infrastructure is seldom in place to ensure that treatment reaches those 
in need. Hornbeck (2005) describes how corruption at high levels has seen 
medications destined for out-lying villages in Africa emerge on the black market in 
Eastern Europe. De Mendoza (2009) voiced concerns that patients may not have 
access to supporting blood tests that allow physicians to monitor the efficacy and 
potentially life threatening side-effects of treatment. However, this has been refuted 
by Mugyenyi (2010) who has shown that supporting blood tests may not always be 
necessary. The problem of provision of antiretrovirals is compounded by emerging 
resistance to the virus. In order for treatment to be effective, drug levels in the blood 
need to be kept within a specific level. This is achieved by taking antiretrovirals at 
regular intervals throughout the day. The BHIVA guidelines (2008) states that unless 
ninety-five percent compliance is achieved, the virus will become resistant to 
antiretroviral medication. Should this occur, the individual will need to change to 
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another class of antiviral therapy which may not be available in resource limited 
countries.  
 
Access to NHS services 
The rules relating to access of NHS services for asylum seekers and refugees has 
been changed repeatedly over the last few years, leading to confusion for both 
patients and clinicians. National Health Service (charges to overseas visitors) 
regulations (2011) stated that asylum seekers whose application to remain in the UK 
failed, and all appeals have been exhausted, were only eligible to limited NHS care. 
This included emergency treatment in accident and emergency services, compulsory 
psychiatric treatment and treatment of infectious diseases, excluding HIV. HIV is not 
considered to be an ‘infectious disease’ in this instance as it cannot be communicated 
passively from one person to another. For example, pulmonary tuberculosis, which is 
considered to be an infectious disease, can be contracted from sitting in close 
proximity with someone with an active infection. This is not true of HIV, which can 
only be communicated if the individual were to have unprotected sexual intercourse 
with the person sitting next to him or sharing equipment related to the taking of drugs.  
 
The changes relating to NHS treatment and care followed the court decision of Shah 
v Barnet London Borough Council (1983) 2 AC 309, where an asylum seeker or 
refused asylum seeker, who had been granted temporary admission pending further 
action (including removal) on his or her case, could be considered an ordinary 
resident of the UK. The Secretary of State can make regulations for certain types of 
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health services to be charged. He can also make regulations for people who are not 
regarded as having ‘ordinary residence’ to be charged. Ordinary residency means 
that an individual must be living in the UK lawfully, voluntarily and as part of the 
regular order of his or her life. In 2008, Mr A, a failed asylum seeker, was refused 
access to NHS treatment. Mr A appealed and the case was heard by Mr Justice 
Mitting. The case, A V Department of Health and West Middlesex University Hospital 
NHS Trust (2008), found that the ruling was wrong in failing to recognise a refused 
asylum seekers’ right to free treatment despite the 1989 Regulations. Asylum seekers 
who met the ordinary residents test were eligible to receive NHS care.  
 
In response to the findings from the review, the BMA produced guidelines for doctors 
(The BMA, 2008). These stated: 
 
The Department of Health guidance was judged to be unlawful in not stating 
that refused asylum seekers can be considered ‘ordinary resident’ in the UK. 
The resultant ruling makes it possible for asylum seekers whose application 
has been unsuccessful to be considered ‘ordinarily resident’ in the UK and 
therefore entitled to free NHS hospital treatment.  
 
In effect, failed asylum seekers who were considered ‘ordinarily resident’ in the UK 
were now entitled to free NHS hospital treatment. Unfortunately, this ruling did not 
cover all asylum seekers and refugees, as some were not considered ‘ordinarily 
resident’. This group was still not eligible for free NHS treatment and care. In addition, 
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the guidance from the Department of Health (2008) on what constituted an ‘ordinarily 
resident’ remained unclear, leaving it to the discretion of individual NHS Trusts to 
decide who could and could not access services. The Department of Health appealed 
against the ruling. The Court of Appeal (2009 ECWCA CIV 225) rejected the High 
Court’s approach, finding that refused asylum seekers could not be lawfully resident 
in the UK. However, the Court of Appeal found that the current guidance in relation to 
the interpretation of ‘urgent’ and ‘immediately necessary’ treatment was too 
restrictive. Patients who could no longer argue that they were lawfully resident in the 
UK could access treatment by arguing that they need it because it is urgent or 
immediately necessary and that they were unable to return home at the present. They 
would still liable to be charged but treatment could not be refused if they could not 
pay.  
 
The 2009 ruling meant that NHS Trusts could again charge refused asylum seekers 
for treatment. They had the discretion to initiate treatment prior to payment if the 
individual could not (as opposed to would not) pay. The Department of Health 
guidance in relation to when people should receive treatment if they could not pay 
and could not return home had been deemed unlawful under The Court of Appeal 
ruling (2009 ECWCA CIV 225). Hospitals could not use the guidance to refuse to treat 
patients. If they did so they would be acting unlawfully. However, the guidance was 
interpreted differently by NHS Trusts and there remained inequity of the provision of 
treatment. 
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How did this relate to failed asylum seekers who were HIV positive? HIV positive 
asylum seekers and refugees were unclear if they were eligible for NHS treatment 
and care at their hospital. Those individuals who commenced treatment prior to 
having their asylum claim rejected were able to continue treatment until such times as 
they left the country or the course of treatment concluded. However, they were 
charged for any new courses of treatment. Unfortunately, changes to antiretroviral 
medication are quite common due to side effects or the development of drug 
resistance. THT (2010) reported that some NHS Trusts were interpreting a change of 
antiretroviral regime as starting a new course of treatment, and charging patients. 
This interpretation of the guidance caused confusion for both health care staff and 
patients. The British Medical Association (BMA) (2011) stated that doctors should not 
be expected to assess the eligibility of their patient to free NHS care. The BMA 
suggested that this responsibility should be left to administrative staff. In reality, the 
staff responsible for administrating the legislation had no clinical knowledge. While 
doctors did not want to be involved with assessing eligibility criteria, their input was 
essential to ensure that administrative staff did not interpret changes of antiretroviral 
medication as commencing a new course of treatment. The change to the law 
provided a challenge to advocates from HIV support groups, who had to assess each 
individual case on its own merits. THT reported that while each case was being 
assessed, some patients experienced an enforced treatment break, potentially 
leading to the development of drug resistant HIV.  
 
While the changes to treatment could still be denied under the NHS, clinical trials 
19 
 
continued to be funded by the pharmaceutical industry. As such, individuals who were 
unable to access or change their medication under the NHS would be able to do so 
as part of a clinical trial. Information regarding new HIV clinical trials and inclusion 
criteria were published by HIV organisations such as the National AIDS Trust, and 
were readily accessible to all patients. The change in eligibility may have contributed 
to the reported increase of failed asylum seekers seeking to enter HIV clinical trials as 
a means of continuing to access medication. 
 
Caring for those patients who no longer had access to treatment and care was 
challenging for medical staff. As discussed earlier, many of the failed asylum seekers 
and refugees had been diagnosed in a sexual health clinic and would have continued 
to remain under the care of the HIV team led by the consultant. Like other chronic 
medical conditions, HIV patients see their doctor on a regular basis. In addition to the 
clinical care of the patient, doctors are actively involved in both the psychological and 
social aspects of care. They will have discussed the effects of HIV on patient’s 
relationships. They will have offered support to the patient when they disclosed their 
HIV status to family members and will have been involved with testing partners and 
children, in addition to arranging support to the extended family over a period of time. 
They will have attended multidisciplinary meetings and will be aware of the effects of 
HIV on the patient’s social situation, such as housing and benefits. The doctor may 
have been one of the first to know that an asylum claim has failed and will have been 
acutely aware of the clinical implications if their patient is no longer eligible for 
treatment. Some physicians may have been able to continue to prescribe treatment 
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due to the inconsistencies in the interpretation of the legal rights of failed refugees 
and asylum seekers. Others would have been informed by their NHS Trust that as the 
individual was no longer eligible they could no longer continue to provide treatment 
and care. While the individual may not have been eligible for treatment and care, 
there was - and continues to be - a significant delay between the notification of a 
failed asylum appeal and deportation. Amnesty International (2006) reported that 
asylum seekers and refugees who had exhausted all their appeals were expected to 
leave Britain within twenty-one days. However, there were often delays with some 
individuals remaining in the Britain for as long as ten years. During this time the 
individual would not be eligible for NHS care and would very likely experience 
deterioration in their medical condition. While it was difficult for the doctor to continue 
to prescribe NHS care without falling foul of the authorities, he could suggest that the 
individual consider enrolling in a clinical trial as a means of continuing treatment. 
While there was limited evidence to suggest that this was common practice, Hamill 
(2004) found that some doctors had reported doing so. Continuing to access 
treatment via a clinical trial may have been one means of accessing treatment but it 
was not a viable option for all. The patient may not have fulfilled the inclusion criteria 
of the trial, or they may not have been a suitable clinical trial running in a site within 
travelling distance. Encouraging patients to access clinical trials as a means to 
continue treatment did not address the main issue which faced doctors at this time. 
They were in effect being asked to withdraw medical care to an individual with whom 
they had an established duty of care. This was not based on the availability of 
treatment but on a legal principle. The 1951 Geneva Convention relating to the Status 
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of Refugees requires host countries to provide only basic standards for treatment for 
refugees. The host countries are free to apply additional domestic law at their own 
discretion, which the British government had done in this situation. Their argument 
that they were fulfilling their statutory obligation in regard to treatment and care was 
met by derision from most clinicians. While I do not intend to discuss the rationale for 
the government’s decision here, many clinicians felt that this was driven more by 
political pressure to be seen to be ‘tough’ on refugees than by any financial 
consideration. No matter what the reason, the effect of the policy would mean the 
physical and psychological decline in health for a substantial number of individuals. It 
was gratifying to see the response from clinicians and the voluntary sector to the new 
law. Many clinicians declared that they would continue to prescribe as before and 
were prepared to be taken to court over their decision, stating that it would be unlikely 
that any court would find against a doctor who was caring for his patient. They argued 
that while they accepted that the NHS had limited funds, to deny lifesaving treatment 
was in conflict with the principle of non-maleficence. Others argued on more 
pragmatic grounds. Without access to treatment, HIV positive individuals would soon 
succumb to opportunistic infections, many of which require admission to an ITU 
department, which was covered in the change as emergency care. The cost of 
treating an individual in ITU would be significantly more than providing on going HIV 
treatment and care. Meanwhile, the HIV voluntary sector lobbied politicians and 
challenged the media view on the treatment of asylum seekers and refugees. I 
strongly supported both the actions and the arguments given by the clinicians. 
However, I could not help but reflect that the government’s decision to the withdraw 
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treatment affected only the most vulnerable in society, namely refugees and asylum 
seekers who are additionally burdened by having a potentially life threatening medical 
condition. Any attempts by the government to impose a policy denying lifesaving 
drugs to the general public would be met with an outcry. While it could be rightly 
argued that there are restrictions on some drugs under the NHS, patients can access 
alternative treatments. At present, the only effective treatment for HIV is 
antiretrovirals.  
 
Refugees and asylum seekers have few political rights, nor are they regarded in a 
sympathetic light by the media. With the duty to accept refugees into a country comes 
the duty to treat them humanely. Withdrawing medication which will lead to ill health 
and eventually death cannot conceivably be regarded as humane treatment. Some 
might argue that once an asylum seeker or refugee has had their appeal rejected, 
Britain no longer has any statutory obligation to continue to care for them. While this 
may be correct under the letter of the law, the fact remains that it may take several 
months - if not years - before they are eventually deported. These individuals do not 
have any money and cannot purchase a ticket back to their country of origin; they are 
prohibited to work, and have no legal means of raising the funds to buy one. As such, 
I would argue that until the process for deportation has been improved, the 
government must either continue to care for failed asylum seekers until they are 
deported, or to relax the employment laws allowing them to work to support 
themselves. The latter will also enable them to pay National Insurance and contribute 
towards the cost of treatment. We cannot claim that we are a progressive and tolerant 
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country if we stand back and let the most vulnerable people die for lack of drugs 
which are readily available.    
 
Following vociferous campaigning, the NHS (charges to Overseas Visitors) 
Regulation was amended yet again. From the 1st October 2012 HIV positive asylum 
seekers and refugees who had had their asylum appeal rejected were now eligible to 
continue to access HIV treatment and care until they had been deported. However, 
the changes do not include treatment for other health conditions which remain 
chargeable. While this change was welcome news, THT has shown that a number of 
HIV positive asylum seekers are still unaware that they can now access treatment 
and care. More concerning, a number of NHS Trust also seem to have limited 
understanding of the new changes. A number of HIV positive individuals are still 
enrolling in clinical trials as a means of continuing treatment. One participant, who 
has been waiting for a ruling on his asylum appeal for some time, commented ‘I have 
seen so many changed in the law over the last few years. I would rather be sure of 
getting my medication this way (clinical trial) than be stressed about any more 
changes.’   
 
Conclusion 
This section has briefly outlined the background to the provision of HIV treatment to 
asylum seekers and refugees in the UK. HIV treatment is complex and constantly 
changing as our knowledge and understanding of the virus increases. We now have 
the ability to treat those living with HIV, but as of yet are unable to eradicate the virus. 
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Also changing is the social context for treatment, and how it affects the lives of those 
affected by the virus. For those failed asylum seekers and refugees who test HIV 
positive in the UK, life can be very challenging. Liberty (2008) outlined some of the 
issues facing these individuals; they are not permitted to work and are unable to buy 
the nutritious food needed for their continued good health. They may have to rely on 
friends and charities to provide shelter. For those who are on treatment the decision 
to remain in the UK is not one they take lightly. While they may remain physically well, 
they are apart from their family and friends. Those who decide to return home may 
not be able to access to treatment and will see deterioration in their health. While HIV 
positive asylum seekers and refugees are now eligible to NHS treatment and care, 
there remains confusion about eligibility both from patients and those providing care. 
As such some individuals may choose to continue to access antiretroviral therapy via 
a clinical trial. 
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Chapter 3   
Clinical trials  
In this chapter, I will provide the reader with a basic understanding of clinical trials 
which will inform the next chapters of this thesis. I will begin by outlining the 
background to clinical trials legislation and the rationale for conducting trials. I will go 
on to describe the different types of clinical trials. I will give a brief overview of the 
process required to gain ethical approval for clinical trials in the UK.  
 
Background to clinical trials  
Twyman (2004) provides a brief history of clinical trials. Prior to 1900, there was little 
legislation to govern clinical trials. Research tended to be conducted by physicians 
who were also responsible for the general medical care of the patient. It was unusual 
for the physician to fully inform the individual that the treatment was new, or to seek 
consent from them prior to commencing research. While patients were aware of this 
practice, the high regard in which doctors were held resulted in few concerns. 
Patients were much less likely to question the judgement of their doctor, expecting 
him to act in their best interest. In 1900, Prussia drew up the first regulations about 
non-therapeutic research Vollman (1996 p.1445). Under the Berlin Code of Ethics 
(1900), the Royal Prussian Minister of Religion, Education, and Medical Affairs 
guaranteed that: 
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All medical interventions for other than diagnostic, healing, and 
immunization purposes, regardless of other legal or moral authorization 
are excluded under all circumstances if, 
  
i. the human subject is a minor or not competent due to other 
reasons;  
ii. the human subject has not given his unambiguous consent;  
 
This followed on from concerns that prisoners were being used as research 
participants without their consent. Weimar Germany followed with guidelines for new 
therapy and human experimentation in 1931 Rothman (1992, p. 320).     
 
More structured regulations on research followed the Nuremberg war trials in 1947. 
Katz (1996) reflected on the treatment of individuals who had been imprisoned under 
the Nazi regime for both criminal and socio-ideological reasons, such as Jews and 
homosexuals. These individuals had been subjected to the most appalling clinical 
experimentation. These experiments, conducted by medical practitioners without the 
consent of the individual, endangered the individual’s lives and future well-being. The 
doctors who had conducted the trials were brought before a military tribunal in the city 
of Nuremberg. They argued that while the experiments were conducted without 
consent from the individuals and caused undue harm, they were justified as the 
information gained would have had long term scientific value. This view was not 
shared by the tribunal, who found that their research had no scientific merit and was 
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little more than torture. Those found guilty of involvement were sentenced either to 
death or were given long term prison sentences. Following the Nuremberg trials in 
1946, a code of conduct for researchers involved in clinical trials was drawn up. This 
was initially called the Nuremberg Code (U.S. Gov Printing Office 1949, p.181) which 
set out ten principles that physicians were expected to follow when conducting 
research on humans. The first principle underlined the need to obtain informed 
consent from the individual prior to his participation in any clinical trial; the individual 
had the right to discontinue participation in the trial at any time. The code went on to 
outline the need for the experiment to yield fruitful results. Researchers were 
expected to conduct trials on animals prior to research in humans. When conducting 
trials in humans, they were to ensure that participants did not experience 
unnecessary suffering. They were also expected to ensure that the trial would not 
result in death or debilitating injury. Research was to be conducted only by 
scientifically qualified individuals. The researcher also had to ensure that participation 
in the trial would be terminated at any stage if the individual was at risk of injury, 
disability or death. The principles of the Nuremberg Code were incorporated in the 
Declaration of Helsinki, set out by the World Medical Association in 1964 (WMA 
1964). The requirement of clinical trials to be reviewed by an independent ethics 
committee was added to the Declaration of Helsinki in 1975 (WMA 1975, 1.2). The 
Declaration has been amended over the years to accommodate the increasing 
changes in medical knowledge, such as the genetics (WMA statement on Genetics 
and Medicine, 2009). However, the protection of the individual participant remains at 
its core. In the UK, the Medical Research Council (MRC) issued its first statement on 
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‘Responsibilities in Investigations in Human subjects’ in 1963 (MRC 1963). This was 
intended to provide additional information and support to medical practitioners who 
were involved in research. The MRC continues to update its recommendations to this 
day and provides written information on all aspects of clinical trials for investigators.  
 
In response to the Declaration of Helsinki, the Royal College of Physicians (RCP) in 
the UK produced a report proposing that research ethics committees (RECs) were to 
be formed.  The recommendations were issued in 1967 and distributed to those 
concerned with research by the Department of Health (Rosenheim 1967, p.429).  By 
1975, the Department of Health and Social Security had endorsed the RCP proposals 
on the setting up of ethics committees. This opened the way for hospitals and 
universities to establish local ethics committees. The purpose of RECs was - and still 
is - to ensure that the research participant is protected from injury, distress or 
discomfort. RECs also protect the researcher from litigation by ensuring that any 
research is conducted with regard to current legislation and will protect the good 
name of institutions where the research is being conducted, by ensuring that the 
researchers meet any required standard (RCP, 2007). In 1984, The Royal College of 
Physicians published its first ‘Guidelines on the Practice of Ethics Committees in 
Medical Research’ (RCP 1984), which was helpful to those involved with the setting 
up of these committees. However, there was no uniformity between different ethics 
committees. This was rectified in 1991 when the Department of Health produced a 
document outlining how research ethics committees should be organised (DOH, 
1991). Researchers who intended to conduct research at more than one site were 
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expected to submit identical applications to local research ethics committees at each 
site. This was very burdensome for the investigator and caused long delays in gaining 
ethical approval. In order to rectify this problem, Multi-Centre Research Ethics 
Committees (MRECs) were established in 1997 (DOH 1997). The MRECs were 
managed by the newly established Central Office of Research Committees (COREC). 
COREC was subsumed within the National Patient Safety Agency in 2005 and is now 
known as the National Research Ethics Service (NRES).  
 
Rationale for HIV related trials 
World economy 
Undoubtedly, HIV is a growing global health concern. It has been estimated that over 
twenty million people have died due to AIDS-related causes. The UNAIDS (2007) 
estimates that there are now forty million people living with HIV world-wide. Of those, 
two million are children. The health impact of HIV can also affect the economic 
development of countries. The UNAIDS (2007) estimates that ninety percent of HIV 
positive individuals live in less economically developing countries (LEDCs).  
 
The World Economic Forum conducted a survey amongst company chief executives 
to establish the level of concern they were experiencing regarding the impact of HIV 
on their businesses (WEF, 2006). Eleven thousand companies were contacted in one 
hundred and seven countries. Over half of those contacted responded. Most said that 
HIV was already having a negative impact on their businesses, and were concerned 
that this could get worse in the future. They cited several areas of concern. The first 
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was the effect HIV had on the physical health of the individual employee. Individuals 
at the highest risk of contracting HIV are those in their peak economic production 
years. Around half of all HIV positive individuals become infected by age twenty-five 
and die of an AIDS related illness before they reach their thirty-fifth birthday (WHO, 
2006).  HIV is a progressive illness characterised by periods of ill health. During this 
time, the employee will most likely have prolonged periods away from the work place 
- either for hospital visits or to recover from HIV related infections. This was of 
particular concern to those companies which employed skilled workers, such as 
engineers. Companies often support workers to gain additional qualifications. In 
return, they are expected to use their newly acquired skills for the benefit of the 
company. If the employee is unable to work through ill health, the company loses both 
the investment they have made in that individual and any future contribution they 
would have made. The loss of one employee may not place great burden on the 
company. However, the rising prevalence of HIV suggests that a high proportion of 
the workforce will become affected. As it takes time to train a skilled worker, the 
company may not be able maintain a skilled work force as employees become too ill 
to work. This will have a detrimental effect on the ability of that company to meet 
targets and compete in the market place. If this pattern is reflected in other industries, 
HIV could affect the economic stability of countries in the developing world. The 
World Economic Forum estimates that by 2015, four million people who could be 
eligible for work will be unwell due to HIV infection (WEF, 2006). These individuals 
will be unable to sustain full-time employment. The WEF goes on to project that 
without access to effective treatment, forty-eight million of the world wide labour force 
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will be lost to HIV by the year 2010. This projection is increased to seventy-four 
million by the year 2015. Some may ignore the AIDS epidemic, thinking that it will 
have no personal impact on them. However, economically developed countries rely 
on LEDCs to supply them with raw materials and cheap manufactured goods. Hecker 
(2009) reported on the potential effects of HIV on LEDCs. She stated that it is likely 
that without affective treatment for HIV, LEDCs will be unable to continue to meet the 
demand of the West. Farmers will be unable to tend their crops, leading to a reduction 
in the supply of food stuffs. There will also be a shortage of skilled teachers to 
educate the next generation who will be needed to replace those already lost to the 
virus. HIV will also affect public sector workers such as the police, which will have a 
negative impact on handling crime.  Avert (2006) reported that health care workers 
such as doctors and nurses will also be affected. By 2005, Botswana had lost 
seventeen percent of its health care workers due to AIDS. UNAIDS (2006) reports 
that this loss is reflected in other African countries, further reducing the health care 
provision to an already desperate people. It is likely that without cost-effective 
treatment, HIV will negatively affect the global economy, impacting society as we 
know it.   
 
Accessing treatment is not a viable option for the majority of those living with HIV in 
LEDCs. Only twelve percent of those needing HIV medication in the developing world 
receive treatment (WHO, 2008). The most compelling reason for the lack of access to 
treatment is the affected countries inability to pay. When a drug has been developed, 
the pharmaceutical company can apply for a patent.  During the life of the patent no 
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other company is permitted to produce that drug. The companies are able to set the 
cost of the drug at a level calculated to recoup the cost of development. In the United 
States of America a drug patent lasts for twenty years. However, the clock starts 
when the clinical trial begins, so in effect the patent may be effective only for seven to 
twelve years. This time frame may differ in other countries. There have been moves 
by several developing countries to break these patents. This would enable generic 
HIV treatments to be manufactured at a fraction of the cost, making them more 
accessible for those who need them. These initiatives have the backing of the former 
president of the USA, Bill Clinton (Guardian, 2008). The Health Minister for Thailand 
stated that at present, their Government is only able to provide HIV drugs for a fifth of 
the population which needs them (Guardian, 2008). However, if they were able to 
manufacture generic brands, it would be possible to provide treatment for a greater 
number of the population. This in turn would have a positive impact on the economic 
development of their country. The World Trade Organisation (1994) issued a directive 
which enabled governments to issue compulsory drug licenses for non-commercial 
use in the case of national emergency. The steadily increasing levels of HIV and the 
negative impact this has on the economic development and health of nations could 
certainly be deemed a national emergency. Despite this agreement, countries which 
produce generic HIV medications could face trade sanctions. If the pharmaceutical 
companies continue to demand intellectual rights and sanctions are placed on 
countries which develop generic HIV drugs, the impact on the world economy will 
continue to be devastating. Pharmaceutical companies argue that the cost of 
developing new medications is so high that they must rely on the income from these 
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drugs to recoup research and development costs. Loss of this income will affect both 
the company and those who have invested in it, thus delaying the development of 
other potentially lifesaving drugs. Pharmaceutical companies are concerned by the 
increasing trend of developing countries producing generic versions of patented 
drugs. Brazil is the most recent country to issue a compulsory license to begin to 
import a generic antiretroviral. The proposed move to import the generic version of 
Efavirenz, one of Brazil’s most widely used HIV drugs, has been condemned by the 
parent company Merick. Merick issued a statement in which it said that this ‘sends a 
chilling signal’ to companies of the risks of developing drugs which are used in the 
developing world. The statement went on to say that pharmaceutical companies 
‘cannot sustain a situation in which developed countries alone are expected to bear 
the cost for essential drugs’ (Massarani, 2008). This may deter them from future 
investment in developing new HIV treatment.  
 
There have also been concerns raised that generic medications are not as effective 
as those manufactured under patent. There have been reported incidences of viral 
rebound, and the development of multi-drug resistant strains of the virus developing 
in those taking generic HIV medications (Avert, 2006). The reason for this may be 
multi-factorial. It could be, as the HIV organisations claim, that the antiretrovirals do 
not have the same potency as patented treatment. The World Citizens Advice Bureau 
(2005) reported that the World Health Organisation had removed some generic 
brands of HIV medication from its quality assurance list following irregularities in 
clinical trials, which were designed to show that generic HIV medications are as 
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effective as patented ARV’s. Even if the generic medications were identical to the 
branded product - both in content, strength, safety and efficacy - the infrastructure 
designed to ensure that clients are aware of how to correctly take the medication, and 
how to limit the potential for drug resistance may not be in place in some countries 
supplying generic medication. No matter what the reason, the need for effective, 
easily administered, cost effective antiviral medication cannot be denied. 
Pharmaceutical companies should not be discouraged from investing in new 
medications. This must be balanced against the urgent need to provide treatment to 
those who need it. As the effects of HIV continue to affect world economy a global 
solution is needed. I suggest that new strategies are needed. These could involve 
financing drug development at a national or global level. The cost for research, 
development, production and supply of HIV treatments could be shared by countries, 
thereby reducing the devastating effects of HIV on the world economy. This in turn 
would enable pharmaceutical companies to continue development without fear of loss 
of income.   
 
Economic impact on families 
While we have seen the effect HIV has on the global economy, some groups bear a 
disproportionate burden of the disease. Women in particular are greatly affected by 
HIV WHO, (2009). While the role of women in the family has changed over the years, 
most societies still expect that women will be responsible for managing the welfare of 
the family. In LEDCs this role is more exacting than that expected of western women. 
In addition to normal household chores, women in LEDCs may be expected to tend 
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the fields and sell any excess crops they grow; this raising money to provide food for 
the family and educate their children. The women may also have to travel long 
distances to source fresh water or food. Women not only care for the needs of the 
nuclear family, but also that of extended family members. If a family member 
becomes unwell, the burden of caring for them will fall on the woman. The time spent 
caring for them may impact on her ability to fulfil her other duties, such as looking 
after crops. The income which she receives from farming will be substantially 
reduced, leading to lack of food and increased poverty. Any savings she has may be 
spent on health care, causing additional worry and more financial burden on the 
family. Should she contract HIV and become unwell, she may find it impossible to 
continue to care for her family.  
 
Due to gender inequalities, women often have little say in their personal lives. HIV 
prevention schemes are often aimed at women, giving them information about harm 
reduction. However, unless their husband is in agreement, it is unlikely that they will 
be able to insist on the use of condoms to prevent transmission of HIV and sexually 
transmitted infections. Gender inequalities also make it difficult for them to access 
HIV treatment. If there are limited funds available to the family, it is likely that these 
will be used to purchase medication for the male partner before the women or 
children (Matlin, 2000).   
 
There are many types of clinical trials taking place in HIV. Some researchers are 
looking into the development of vaccines which may prevent onward transmission of 
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HIV.  Researchers are hoping that a single course of the vaccine may be able to 
significantly reduce the risk of HIV transmission. If vaccine trials were successful, they 
would be particularly beneficial to women. Even if women were not in a position to 
negotiate safer sex with their partners, the vaccine may protect them against the 
virus. It is likely that if a vaccine were to be developed, a single course to prevent 
transmission would be much more cost effective than becoming infected and having 
to take life-long medication. As such, the development of new HIV treatments will 
benefit both the individual and have a positive impact on developing economies.     
 
Impact on children  
HIV has the greatest impact on children. Avert (2007) estimates that more than fifteen 
million children worldwide have been orphaned due to AIDS. Some of these children 
will be infected themselves. I want to look first at children infected by HIV. Connor et 
al (1994) found that the risk of vertical transmission to the child can be reduced to 
less than one percent in a pregnant woman if she takes antiretroviral therapy in the 
last trimester of pregnancy. However, in LEDCs the availability of medication is 
restricted to those who can afford treatment, or those who are fortunate enough to 
access government programs or as part of an HIV clinical trial. Without antiretroviral 
medication in pregnancy, twenty-five–forty percent of children born to HIV positive 
mothers will be positive (AIDSMAP 2007). As such, three-quarters of a million 
children each year are infected by the virus through maternal transmission (UNAIDS, 
2007). Even if the virus has not been transmitted during pregnancy and childbirth, the 
child may still be at risk of contracting the virus via breast milk. Coovadia et al (2007) 
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identified specific risks relating to HIV transmission via breast milk. They found that in 
women who breast feed exclusively for six months, the risk of transmission to the 
child is around four percent. However, if the baby is mix-fed, it is eleven times more 
likely to become infected. The study also found that babies who are exclusively breast 
fed for six months were more likely to survive than those fed formula alone in the first 
three months. As such, the WHO (2009) is now recommending that HIV positive 
mothers who are unable to afford formula breast feed exclusively for six months. 
While this guidance may help to reduce HIV transmission, it may not be readily 
accepted by mothers. UNICEF (2009) reports that mixed feeding is common in 
LEDCs, with breast feeds being supplemented with water, tea and porridge within the 
first few weeks of life. Mothers are often concerned that their breast milk will not 
provide sufficient nutrients to their babies if they themselves are malnourished. If 
exclusive breast feeding initiatives are to be successful, women will have to be 
convinced that their babies will not be harmed.  
 
Should the child become infected, without access to treatment they have a poor 
prognosis. AIDSmeds (2008) estimates that most infected children will die before their 
fifth birthday. However, with access to treatment and care, approximately half of all 
children will live to graduate from high school. With the advances in HIV therapy, the 
prognosis of children undergoing treatment is looking increasingly bright. 
Unfortunately, children are less likely to have access to HIV treatment programs than 
adults. Parents may be too unwell themselves to tend to the medical needs of their 
children. It may be impossible for sick parents to transport equally sick children to a 
38 
 
hospital some distance away. The parents may be unable to provide the child with 
enough nourishment to enable them to withstand infections. When the parents can no 
longer look after their child, it may be placed in the care the extended family. The 
extended family may be in no better position to offer care than the parents. While they 
may be able to provide shelter and food, they may not be able to fund treatment.  
 
Even without antenatal treatment, only twenty-five percent of infants born to HIV 
positive mothers will develop HIV (WHO, 2011). HIV negative children born to HIV 
positive mothers can also be affected by HIV. Stein (2003) found that young children 
whose parents were HIV positive had to take on responsibilities beyond their years. 
This included physical care of parents and other siblings, in addition to providing 
psychological support. A study conducted by the WHO (2007) found that these 
children often had to leave school in order to look after their parents. In addition to 
providing care, they often worked part-time in order to earn money to support the 
family. The loss of a normal childhood affected the children’s psychological 
development. Having to abandon their education impacted on the child’s future ability 
to find skilled work. The World Education Fund (WEF 2007, p31) found that HIV 
infection in the family affects literacy rates in poorer countries. Without the ability to 
read or write, employment prospects are reduced. This in turn perpetuates the cycle 
of poverty. 
 
Children orphaned by AIDS are at greatest risk from poverty. Traditional African 
culture expects the extended family to support each other. Orphaned children are 
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provided with love, food, shelter and education. However, as the number of people 
infected by HIV rises, it becomes difficult for families to support the increasing number 
of those in need (Avert, 2011). Some children may be fortunate to have relatives who 
can support them. For many families the desire to help remains, but they are 
financially unable to provide care for all in need. Some children may have access to 
care provided by charities. For the majority however, the future is not so bright. UN 
AIDS (2007) estimates that only ten percent of AIDS orphans receive public support 
or services. The children lack basic needs such as shelter, food, and clothing. In 
order to survive, some turn to a life of crime. Others survive by forming an association 
with other children in the same situation, scavenging for food and surviving from hand 
to mouth (Salaam, 2005).   
 
Without cheap, effective treatment HIV will continue to have devastating effect in 
LEDCs. The number of deaths will continue to rise, as will the number of people who 
are too ill to work. This will have a knock on effect on the global economy. While the 
‘holy grail’ of HIV research is to develop a cure, it is unlikely that this will happen in 
the near future. In the meantime, research is essential to advance our knowledge of 
HIV and develop more cost-effective treatment with a better resistance profile. The 
more information we can gain about the virus through research, the greater the 
chance we have of reducing onward transmission. New treatments would not only 
improve the lives of those living with the virus, but have a positively influence on the 
global economy.   
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HIV undermines the global efforts to reduce poverty and promote development. This 
was summed up succinctly in 2006 by the World Economic Forum: 
 
Affecting predominantly young and middle aged adults who are the mainstay of 
the economic and principal support of their families- AIDS destroys the fabric 
of society 
 
Why conduct HIV clinical trials in the UK?  
While very few would deny the need for clinical trials to develop effective HIV 
treatment, some would argue that there is no need to conduct this type of trial in the 
UK. The number of HIV positive individuals in the UK has steadily risen over the 
years, but in comparison to the developing word the figures are small in comparison 
to the developing world.  UNAIDS (2008) reported that forty million people world-wide 
were infected with HIV. Twenty two million of those affected live in sub-Saharan 
Africa, while only one million live in Europe. These figures illustrate that there are 
more people living with HIV in Africa, and therefore more potential recruits for clinical 
trials. As access to antiretroviral therapy is limited, it is likely that potential recruits will 
have had less exposure to treatment. As discussed earlier, those who are 
antiretroviral naïve are much better candidates for new HIV clinical trials. As such, 
HIV positive individuals from sub-Saharan Africa are more likely to possess the 
biological assets required by researchers than their counterparts in the West who are 
likely to have had previous exposure to antiretrovirals.  
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In the UK, it can take up to sixty days from submitting a trial proposal to receiving 
ethical approval (NRES 2009). This does not include the time taken to prepare the 
application nor write the patient information sheet. Only once ethical approval has 
been received, can the company begin to set up the trial and begin recruitment of trial 
subjects.  
 
In the developing world, the process of gaining ethical approval may be much faster. 
As such, set up and recruitment can begin earlier. Goggins (2005) reported that the 
development of a new drug can cost a pharmaceutical company around £550 million. 
If companies are struggling to recruit the required number of participants, any delay in 
completing the clinical trial will result in additional costs. Having a greater pool of 
potential recruits may result in speedier recruitment thereby reducing time taken to 
complete the study. This is of particular importance if companies are competing 
against each other to get a similar drug to market. The first company to gain a licence 
to sell the new medication will have a real financial advantage over their competitors. 
The development cost of conducting clinical trials in the developing world is also 
lower than in the West due to cheaper infrastructure costs, including lower staff 
salaries and overheads. Some would argue that trial standards are also less stringent 
than are required in the West, making it easier both to recruit and complete trials in a 
timely manner. Taking these factors into consideration, why would pharmaceutical 
companies then choose to conduct clinical trials in the West? There are a number of 
reasons. Firstly, while the numbers may be small the potential participants will have 
been closely monitored enabling researchers to have robust baseline characteristics. 
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This may not be the case in LEDCs where CD4 count and viral load monitoring is not 
routine.  Secondly, research will be conducted in centres which have an established 
research track record supported by experts in the field. These centres also have 
access to laboratories and processes in place to ensure that samples are dealt with 
as per protocol. Protocols are also in place to ensure that clinical trials are closely 
monitored and deviation from these protocols or safely concerns are reported swiftly, 
thereby ensuring that the data which is collected can be validated. Finally, and more 
importantly, the ethical standards for conducting trials in the UK are stringent ensuring 
that participants are protected from harm.  
 
While the number of participants may be small, the results from HIV trials based in 
the UK add enormously to our understanding of HIV and to the development of new 
classes of antiretroviral therapy.  
 
Types of clinical trials 
Clinical trials of new medications are generally sponsored by the pharmaceutical 
industry. It may take around twelve years from commencing development on a new 
drug until it is given a license for use on patients. The International Conference on 
Harmonisation of Technical requirements for Registration of Pharmaceuticals for 
Human Use (ICH) (CPMP/ICH/286/95, 2000) recommends that all medications for 
human use must first be tested on animals. If the safety profile is acceptable, the 
medication may go on to be tested in humans. However, in order to begin trials on 
humans, the drug must first be certified by a national licensing authority. In the UK, 
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this is the Medicines Control Agency or the European Medicines Evaluation Agency. 
Only when this approval has been granted can the company begin clinical trials to 
establish its efficacy, safety profile and dosing levels. If the study medication fails to 
meet the safety or efficacy criteria at any time, development will cease. For every new 
medication which is successful in gaining a license, many hundreds will be rejected.  
The cost of developing a new drug varies.  However, the standard cost from inception 
to licensing is in excess of $800 million (GlaxoSmithKline, 2011). The new medication 
will only have a patent for twenty years, during which time the pharmaceutical 
company will try to recoup its developmental costs. 
 
There are different types of clinical trials. The first of these, Phase One trials, are 
designed to test the safety of a drug on healthy volunteers and the effects of the 
medication on the body. As this type of clinical trial looks at the first use of the 
medication in humans they carry more risk to the participants. Most Phase One trials 
in the UK are conducted by contracted research organisations. As Phase One trials 
are designed to test the safety of a new medication, companies have to take great 
care to safeguard the well-being of volunteers. Medication is titrated, starting below 
the safe level of dosage given to animals. Volunteers are kept under close 
observation to ensure that any unexpected side-effects are dealt with. This type of 
trial also looks at how quickly the medication is absorbed and how long it remains 
active in the body. Phase One trials test new medications against placebo drugs in 
order to check their efficacy. Volunteers are randomly assigned to either arm, and are 
‘blind’ to what treatment they are receiving. This is done by trying to ensure that both 
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the placebo and the new medication are similar in appearance and are given by the 
same method. i.e. both are given orally or intravenously. Phase One trials tend to 
take two years to complete. However, individual volunteer participation is generally 
only for a few weeks (Quintiles, 2010).  
 
There are some ethical considerations specific to Phase One trials. These trials 
depend on the use of volunteers, many of whom are students or those on a gap year 
between school and university. The volunteers are generally fit, not on any 
medication, free to commit the time needed to participate and compliant to the needs 
of the trial. As such, they are perfect Phase One research participants. However, 
some concerns have been raised regarding the payment of volunteers. The level of 
payment was set by the ABPI (ABPI, 1988) and the RCP (RCP 1986). These 
guidelines state that payments must not be so generous as to influence participation. 
The level of payment must also take into account the length of residence in the 
research facility, level of discomfort, number of visits and inconvenience. While it is 
accepted that volunteers should get paid for these aspects of participation, they do 
not receive payment for risk. This is inconsistent with other walks of life where risk 
taking is compensated. For example, commercial divers get paid for the risk they take 
in addition to their role. Phase One trials are classed as non-therapeutic research. As 
such, it is not expected that those volunteering will gain any health benefits from 
participation. Any health benefits which they do gain are incidental to the aim of the 
study. While no benefit is anticipated, this type of trial may carry some risk to the 
individual as the study medication has not been previously used in humans. Animal 
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studies do give some indication of which side effects may be expected. However, no 
matter how good these trials are, human physiology is very different from that of 
animals. This was demonstrated recently at the Phase One clinical trials unit at 
Northwick Park Hospital, where a new monoclonal antibody (TGN1412) for the 
treatment of rheumatoid arthritis was tested on humans for the first time. Animal 
studies had found no safety concerns. However, the antibody response on the human 
subjects led to serious organ failure (Moberly 2007 p.342). 
 
In order to reduce the risk from participation in phase one trials, ABPI guidelines 
(ABPI 2007) suggest that volunteers must leave a period of four months between 
participating in clinical trials. This period can be extended if the volunteer had been 
involved in a clinical trial of a biological agent, which may take longer to ‘clear’ from 
the body. Other organisations such as the RCP and the EU GCP offer no guidance 
on the length of time between trials. Volunteers who participate in these trials often do 
so for financial benefits. When enrolled in a Phase One trial, volunteers stay in the 
research facility where their accommodation and food is free. Combined with the fee 
for participating, some individuals find it very tempting to try to enrol in ‘back to back’ 
trials. In order to help alleviate this problem, a voluntary register called ‘The Over-
Volunteering Prevention System’ (TOPS) was set up by centres conducting phase 
one trials (Boyce 2003, p.418). Participants are asked to produce ether a passport or 
a national insurance number and are photographed. Participating centres can then 
check to see if the volunteer has waited the requisite time between trials. While this 
scheme is voluntary, twenty-eight out of thirty-one units which conduct Phase One 
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clinical trials in the UK subscribe to it. (Personal communication with Malcolm Boyce, 
May 2008). This helps to regulate the participation in trials and helps to safeguard the 
well-being of participants.  
 
In Phase Two trials, the drug is used for the first time in patients who have the 
condition the medication is designed to benefit. The trial is designed to test the 
efficacy of the medication on patients, look at short-term safety, establish the 
optimum dose of the drug and establish if it causes any side-effects. Phase Two trials 
are generally placebo controlled, as this is required by some licensing authorities 
such as the Federal Drug Agency in America (Code of Federal regulations Title 21, 
2011). Some patients will receive the active medication, while others will receive an 
active substance which looks identical to the trial drug.  Placebos are used to check if 
the effects of the new medication are real and not imagined. People often report that 
they feel better having had a drug when in effect they have received an inactive 
substance. The use of a placebo also helps to overcome bias in reporting the effects 
of the new medication. The Declaration of Helsinki (1996) article 2.3 recognises that: 
 
In any medical study, every patient - including those in a control group, if any - 
should be assured of the best proven diagnostic and therapeutic method.  This 
does not exclude the use of inert placebo in studies where no proven 
diagnostic or therapeutic method exists. 
 
Despite this, there are some concerns around the use of placebos in clinical trials. 
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The first of these is ensuring that the patient is fully aware that they might not be on 
active treatment for the duration of the study. This information should be clearly 
outlined in the participant information sheet (PIS) and during the consent process. I 
will discuss the ethical issues of PIS in chapter 6. The second consideration is the 
potential risk to the patient from treatment being withheld during the trial period. This 
is not such a concern for trials investigating a condition which may have no proven 
standard treatment. However, in some other trials withdrawal of medication may 
involve some level of discomfort for the patient. Clinical trial protocols generally allow 
rescue medication which can be used to alleviate any symptoms the patient may 
experience as a result of withholding treatment. When ethics committees review trial 
protocols, they ensure that there is some means of identifying any medical 
deterioration as soon as possible, withdrawing the patient from the trail should this 
occur. An alternative to placebo controlled trials is to compare the new medication 
against standard treatment.  This is not always possible where the licensing authority 
demands a placebo controlled trial to prove the efficacy of a new medication when 
there is already an established medication for the condition on the market. This 
demand conflicts with the Declaration of Helsinki (2000), which suggested that 
placebos should only be allowed in a clinical trial where there was no recognised 
treatment for the condition under investigation. Drug companies respond to this by 
countering that the standard treatment in use for some time may never have been 
subject to such stringent testing. In order to address the confusion over the 
interpretation of the existing guidelines, The World Medical Association (WMA) (2001) 
issued a note of clarification on the use of placebos in clinical trials. It reiterated that 
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the use of placebos was not acceptable where there was already an established 
treatment for the condition being investigated. Placebos could be used where there 
were ‘compelling and scientifically sound methodological reasons the use of placebo 
controlled trials are necessary to determine the safety and efficacy of drugs’ (Human, 
2001).  Human gave an example of the use of placebos in a clinical trial investigating 
the treatment of baldness or allergic rhinitis where the participant would be at no 
additional risk for the use of a placebo. Placebos were also acceptable in clinical trials 
where patients were not denied standard therapy. In HIV clinical trials the use of 
placebos is generally not permitted, as antiretrovirals are the ‘gold standard’ of 
treatment. However, placebos may be used as part of the background therapy, where 
the trial participant will still be receiving the gold standard treatment in addition to the 
study medication.   
 
If the Phase Two trial has demonstrated that the drug is beneficial to patients and the 
side effect profile is acceptable, it will go on to a Phase Three trial. Phase Three trials 
are also conducted on patients who have the condition the study medication is 
designed to treat. These trials are designed to look at long-term efficacy and safety in 
order to gain a license to market the drug. Phase three trials recruit greater numbers 
of research subjects, and participation is much longer. Phase Three trials generally 
compare the new drug with an existing drug in an attempt to demonstrate its 
superiority. Patients are randomised to different groups, one group will receive the 
new treatment, and others will receive the standard treatment. The comparator drug 
is one which is the ‘gold standard’ treatment for the condition which is being 
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investigated. Phase Three trials may also involve a third group of patients which are 
given a placebo. However, the investigators have to demonstrate to the ethics 
committee that procedures are in place to ensure that patients who are in the placebo 
group will not be adversely affected by lack of treatment. Both patients and 
investigators are not aware which group the patient is in to remove possible bias.  
 
If the clinical trial has found the study medication to be efficacious and safe, the 
pharmaceutical company may make it available on a compassionate basis to 
individuals who participated in the trial prior to the medication being granted a licence. 
Continuing a study medication on this basis is usually only permitted if there is no 
other treatment available for the condition, and the participant has responded to the 
treatment. The participant will continue to be followed up by the company until such 
times as the medication is licensed. The compassionate use of study medication has 
been available to some HIV positive individuals who had developed drug resistance 
and were found to have had a good response to the new treatment.   
 
Once a drug has been granted a licence, the pharmaceutical company may choose to 
conduct a Phase Four trial. This type of trial is again conducted on patients and is 
designed to look at the continued efficacy of the drug, long-term side-effects and any 
advantage the new medication may have over other drugs licensed for this indication. 
Phase Four trials may also look at alternate dosing of the drug, for example, giving it 
once a day instead of twice daily. It may also look at why some patients do not 
respond to the drug.  
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Submitting an application for ethical approval 
The clinical trials legislation requires that clinical trials in medicinal products 
(CTIMPS) be reviewed by RECs that are legally recognised by the United Kingdom 
Ethics Committees Authority, (UKECA). The process of submitting an application to 
the ethics committee for a clinical trial relating to a medicinal product is outlined in the 
Standard Operating Procedures (SOPs) for the Research Ethics Committees 
(UKECA 2007). These SOPs meet the obligations of the UK Government under 
directive 2001/20/EC of the European Parliament and the Council of the European 
Union for the operation of ethics committees in relation to Clinical Trials of 
Investigational Medicinal Products. 
 
The application for ethical review is submitted by the chief investigator (CI). It is then 
placed on the data base and given a unique REC number. The NRES central 
allocation system allocates applications for Phase Two and Phase Three trials to the 
appropriate committee. Applications and supporting documentation must be 
submitted within four days of booking an application, which in turn must be submitted 
both electronically and on paper with signatures. The REC co-ordinator then has five 
days to validate the application and respond to the CI. The ethics committee then has 
a sixty day period after validation of the application to give ethical approval. If the 
REC requires further information before confirming its opinion it can make one 
request only for that information during which time the sixty day clock will stop. Ethical 
opinion can only be given following a REC meeting.  
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Each committee meets monthly, with at least ten meetings per annum. The meeting 
requires a quorum of seven members, including chair or vice chair, one lay and one 
expert member. The role of the ethics committee is to review the research protocol to 
ensure that the proposed research will not harm the individual, the researcher or the 
name of the institute where the research is being conducted. Prior to the committee 
meeting each protocol is allocated to two lead reviewers who will report back on their 
findings to the main committee. In order to help them reach a decision, the reviewers 
will take into consideration the suitability of the applicant. Are they experienced in the 
type of research they are planning to undertake? Who will be conducting any tests? 
They will look at the design of the study, to see if it can meet its objectives and where 
the study is to be conducted. If it is planned to conduct research in the community, 
the reviewers will want to ensure that the safety and well-being of individual 
researchers has been considered. The reviewers will look at any risks or burdens of 
the research such as number of visits and type of procedures participants will be 
expected to undergo. They will look at the participant information sheet to see that it 
truly reflects what is written in the protocol and that it is written in a format which will 
be understood by the proposed research population. The reviewers will also check 
that measures are in place to protect the confidentiality of participants, as well as 
indemnity and compensation should the individual come to any trial related harm.  
 
The main reviewers will give a brief overview of the protocol and any ethical concerns 
they have about the study to the main committee. This will be followed by comments 
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from other committee members. The researcher will then be asked into the meeting 
room to discuss the main issues. Following their departure, the committee will discuss 
the protocol in more detail before reaching a decision. The CI is informed of the 
committee’s decision within ten working days of the meeting. The committee can give 
the application a final opinion (favourable or unfavourable), or a provisional opinion 
with request for further information or no opinion (if it is waiting for comments from a 
referee). Should the decision be unfavourable, the applicant can appeal the decision 
of the first REC. They also have the option of re-submitting the application to another 
REC for their opinion. Before commencing a clinical trial in medicinal products the 
sponsor must obtain clinical trial authorisation from the Medicines and Healthcare 
Products Regulatory Agency (MHRA 2008).  
 
Phase One trials are dealt with by specialist ethics committees. Prior to the inception 
of COREC, protocols for Phase One trials had been reviewed by the pharmaceutical 
companies and contracted research organisations. However, the Association of 
British Pharmaceutical Industries (ABPI) recognised that these committees should be 
seen to be unbiased in their reviews. They produced guidelines in 1988 to aid those 
conducting phase one trials (ABPI 1988). The requirement for ethical review for 
phase one trials changed in 2001, when they were incorporated into the EU Clinical 
Trials Directive (2001/20/EC). Under these changes, phase one trials are now 
reviewed by independent research ethics committees accredited by the UKECA. The 
ABPI guidelines were updated in 2007 (ABPI, 2007) to reflect the changes to clinical 
trials regulations.  
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Summary  
This chapter has briefly outlined the background to clinical trials and the procedure for 
gaining ethical approval. Clinical trials are necessary to further our understanding of 
disease and to ensure that new medication is safe and effective. In the past, patients 
were often enrolled into clinical trials without consent, and given little information 
about the purpose and reason for the trial. Following the Nuremberg trials, guidelines 
were issued outlining principles which ensured that the safety and well-being of 
participants were placed above the success of the clinical trial. These guidelines have 
legal standing in most countries, offering research subjects protection against harm 
and compensation should harm occur.  
 
I have looked at some of the reasons why the development of new HIV medication is 
needed. On a global level, HIV has already begun to have a negative effect on the 
world economy. Without the development of more cost effective antiretrovirals which 
have a better resistance profile, HIV will continue to adversely affect the health and 
well-being of those living with the virus. This in turn will affect their ability to work. As 
the prevalence of HIV increases, the detrimental effects of the virus will continue to 
have a devastating effect on the economy of developing countries which have the 
greatest need for growth.  Clinical trials enable researchers to test the efficacy, safety 
and tolerability of antiretroviral medications. While the number of potential trial 
participants living in the UK is small in comparison with other global areas, there is 
still a place for HIV related clinical trials to be conducted in the UK.  The knowledge 
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gained from UK based trials is crucial to improving our understanding of HIV and the 
development of innovative new treatments. In this chapter I have briefly touched on 
the role of the research ethics committee. I propose to discuss in depth their role in 
protecting participants from harm in later chapters.   
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Chapter 4 
How antiretrovirals work 
Once infected with HIV, the virus can be detected in the blood. The level of the virus 
can range from undetectable to over a million copies/ml, and is measured by taking a 
viral load test. The virus destroys the cells of the immune system, reducing the 
individual’s capability to fight infection. The British National Formulary (2011) reports 
that there are twenty-two HIV drugs licensed for use in the UK each attacking HIV in a 
different way. There are five main classes of antiretrovirals, with more being 
developed. The oldest classes of HIV drugs, the nucleoside/nucleotide reverse 
transcriptase inhibitors (NRTIs), stop HIV from replicating within cells by inhibiting the 
reverse transcriptase protein. Non-nucleoside reverse transcriptase inhibitors 
(NNRTIs) are another of the older class of antiretroviral drugs which stops HIV 
replicating within cells by interfering with HIV's reverse transcriptase protein, which it 
needs to make new copies of itself. The protease inhibitors target the HIV protein to 
stop the production of new HIV. The fusion inhibitors are a new class of HIV drug 
which targets the point where the virus locks itself to proteins on the cell’s surface. 
The other new class of drug is the integrase inhibitor, which stops HIV from inserting 
its DNA into the host cell.   
 
First line therapy usually involves giving two drugs from the NRTI class and one from 
the NNRTI class (BHIVA, 2009). However, due to the composition of the drugs, 
individuals may only need to take a couple of tablets twice a day. Some of the 
antiretroviral drugs, such as Trizivir, comprises of two or more medications given in 
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the one tablet. If an individual becomes resistant to this regimen, they will be switched 
to second or third line regimens, comprising of drugs from the other classes of drug. 
This will be informed by the results of an HIV resistance test. Second and third line 
regimens are often more difficult for the individual to take as they may include upward 
of six tablets twice daily, possibly with the addition of injected drugs. Due to the 
increased number of drugs, the individual will be at increased risk of developing side 
effects.  
 
Why new treatments are needed  
Despite the number of antiretrovirals available on the market, there is a need for new 
medications to be developed. It is very common for people to experience side effects 
to antiretroviral medication. These side effects include headache, nausea and 
diarrhoea, which can be easily treated. However, some medication can lead to the 
development of more serious side effects, such as diabetes and abnormal liver 
function. Malvestutto (2010) has also reported on an increased level of heart disease 
in individuals who have been taking antiretrovirals for a number of years. The 
development of antiretrovirals with a better side effect profile will greatly improve the 
health of people living with HIV, increase their overall prognosis and reduce the 
number of clinic visits and inpatient stays.   
 
Possibly the greatest threat to the well-being of HIV positive individuals are the 
development of antiretroviral resistant strains. HIV is a highly variable virus which 
mutates easily; this is one of the reasons why it has been so difficult to develop 
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effective treatment. Cross resistance is also common, where resistance to one drug in 
a class will result in some degree of resistance to all the other drugs in that class. 
While resistance can develop when medication is not taken correctly, Carter (2007) 
has also shown conclusive evidence for the transmission of drug resistant strains of 
the virus. This has led to BHIVA (2011) recommending that all newly diagnosed 
individuals have a HIV resistance test prior to initiating antiretroviral therapy. Initiating 
treatment for those found to have a drug resistant strain of the virus can be more 
challenging, as their choices of treatment will be more limited. Wittkop et al (2010) 
showed that individuals who had a resistant strain of HIV often need to be 
commenced on a regimen consisting of a number of tablets, which in itself can lead to 
poor adherence and the development of further drug resistance. Further studies are 
planned to establish if the long term prognosis for these individuals is worse than 
individuals with drug sensitive strains of the virus.  
 
Why recruit HIV positive individuals from LEDCs?  
In order to test the resistance profile of a new HIV medication, it is desirable to recruit 
participants who have no HIV mutations. These individuals have what is known as 
‘wild type’ virus, and are likely to have had no previous exposure to antiretroviral 
medication. As discussed in chapter 3, while access to HIV testing is becoming easier 
in LEDC’s, access to treatment remains problematic. Even if available the cost is 
often prohibitive. As such, many of those who contract HIV in LECDs will have no 
prior exposure to antiretroviral medication and will have less opportunity to develop 
antiretroviral resistant strains of the virus. This is - in part - due to the lack of 
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availability of antiretroviral medication in their country of origin. The HPA (2010) 
supports this, reporting that newly diagnosed individuals who originate from sub-
Saharan African are less likely to have acquired a resistant strain of the virus, and 
therefore have less viral mutations. In addition, many will be unaware of their HIV 
status prior to arriving in Britain and being offered HIV testing. 
 
The easiest way to measure a response to medication is to initiate treatment in 
someone with a high viral load and low CD4 count. They are closely monitored, taking 
into consideration how long it takes for virus to respond to treatment, any potential 
side effects and ease of administration. The higher the viral load, the easier it is to 
monitor response to treatment (BHIVA, 2005). The Health Protection Agency (2010) 
reported that newly diagnosed individuals who originate from sub-Saharan African 
tend to present late, having acquired HIV long before they test. Thirty-five percent of 
heterosexual women and forty-two percent of heterosexual men were found to have a 
CD4 count of less than two hundred per mm within three months of diagnosis. With 
this level of immune suppression they are at serious risk of opportunistic infection. Of 
the five hundred and sixteen people who died of HIV in 2009, seventy-three percent 
had presented with a low CD4 count. As such, newly diagnosed individuals from sub-
Saharan Africa are more likely to have a higher viral load and lower CD4 count than 
those who have contracted HIV in the UK and are diagnosed earlier in their infection. 
 
How many asylum seekers and refugees from LECDs are HIV positive? The truth is, 
we just don’t know. In the absence of any official data, Gazzard (2005) estimated that 
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twenty percent of new those newly diagnosed with HIV in the UK were asylum 
seekers or refugees. These figures arrived at using data immigration data and HIV 
prevalence data. While this data may be a starting point, it does not take into 
consideration the prevalence rates in the specific countries. For example, while we 
have robust data of HIV prevalence in Uganda due to local initiatives, countries such 
as Sudan do not collect this information. As such, these figures may underestimate 
the true extent of the problem.    
 
Physicians may be unaware of the immigration status of patients under their care. 
HIV testing is usually conducted in sexual health clinics (SHC). Under the NHS Trusts 
and Primary Care Trusts (Sexually Transmitted Diseases) Directions 2000, 
individuals attending a SHC are not obliged to give their correct name, address, date 
of birth or ethnicity. The immigration status of individuals is not required; treatment for 
sexually transmitted infections (STI’s) is free to all under the National Health Services 
(Charges to Overseas Visitors) Regulations (2011). In hospitals where HIV care and 
STI care are combined, it is possible for patients to continue using an assumed name 
and details for some time, and never be asked their immigration status. In other 
hospitals, treatment of STIs and HIV are quite distinct. If an individual is found to be 
HIV positive in the SHC, they will be transferred to the HIV clinic where there details 
and immigration status will be ascertained before commencing treatment. Until there 
is a robust method of record keeping, and what that system might look like, it will 
remain impossible to have a true number of HIV asylum seekers and refugees. 
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The HPA (2010) found that the majority of those testing positive from sub-Saharan 
Africa had not had a previous HIV test prior to coming to the UK. There may be a 
number of reasons for this. For some people, there would not be any benefit to finding 
out that they were HIV positive if they could not access treatment. For others, testing 
seemed unnecessary. As one of my patients explained; ‘My husband had died of HIV, 
my child had died of HIV, and I knew that I must have it’. For some fleeing oppressive 
regimes, health care - including HIV testing - is very low on their priorities. Once they 
have arrived in Britain they can choose to take advantage of a number of initiatives 
designed to increase testing within the African community. While these have had 
some success, there are still barriers to testing. Of these, confidentiality appears to be 
the greatest concern. Individuals are concerned that should they test positive, their 
community in the UK will be informed and the news will reach their family back home. 
Despite anti-discriminatory legislation, HIV remains a stigmatising infection. Patients 
have reported being removed from GP lists and refused dental care once their status 
has been revealed. If this reaction is seen from health care workers, it is little wonder 
that individuals decline to test despite being informed of the health benefits of testing 
and potential risks from not knowing your HIV status.  
 
Why not recruit other HIV positive populations to trials? 
Would it be possible to conduct HIV trials in the UK without asylum seekers and 
refugees?  The answer to that question depends on the type of trial. Let us start by 
looking at the types of HIV trials conducted in the UK. There are three main types: 
observation trials, vaccine trials and drug trials. In observation trials individuals are 
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followed up for a period of time. This type of trial does not involve any changes to 
medication. Vaccine trials recruit both HIV negative and positive individuals, some 
looking at ways of preventing transmission, others looking at stopping viral replication 
in the positive person. Drug trials involve the development of new classes of 
medication as well as studying the efficacy of new combination therapy. While HIV 
positive asylum seekers would be able to enrol in observation and the vaccine trial 
provided they fulfilled the study criteria, it is in drug trials that they are most valuable. 
Their lack of exposure to antiretrovirals coupled with a low CD4 count and high viral 
load make them particularly attractive to researchers. Asylum seekers and refugees 
who have developed drug resistance would also be eligible for trials on second and 
third line drugs. Of the 65,319 individuals living with HIV in the UK, the HPA (2010) 
reported that fifty-one percent (33,310) of those were heterosexual, of whom sixty-six 
percent were black African. Of the remaining thirty-four percent the majority were men 
who have sex with men (MSM), with a small proportion infected through injecting drug 
use and mother to child transmission. Despite the seemingly large pool of potential 
recruits, researchers can find it difficult to find the number of participants required to 
show significance in a trial. This is in part due to the eligibility criterion of different 
trials. For example, trials on new drugs may only want to recruit participants who are 
antiretroviral naïve. These criterions are more likely to be found in individuals from 
sub-Saharan Africa who have not been exposed to antiretrovirals, than UK born 
individuals. If we look at the HPA figures, it would appear that the majority of 
individuals living with HIV in the UK are from sub-Saharan Africa. However, the 
figures include those who have been in the UK for a number of years. These 
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individuals may have been exposed to drug resistant strains of the virus in the UK, 
making them ineligible for trials of new drugs. There is also the probability that as the 
availability of antiretroviral drugs increases in Africa we will begin to see the 
emergence of resistant strains of the virus. In time, the number of individuals with wild 
type virus will decrease. For the moment, HIV positive individuals from sub-Saharan 
Africa are more likely to have wild type viruses than their UK born counterparts and 
so are valuable in drug research.  
 
Clinical trials also require that individuals have a break between trials, to protect both 
their health and the integrity of the trial. Some of the larger centres can be involved in 
a several trials simultaneously. In these, individuals may have participated in several 
trials over the years and may not always want to enrol in another one, especially if it 
requires multiple clinic visits and changes to life style. This will also reduce the ‘pool’ 
of individuals who may be eligible to participate. We must also remember that some 
HIV positive individuals, like individuals with other chronic health conditions, may just 
want to get on with their lives and not participate in trials. Taking into consideration 
the number of HIV positive people in the UK and the number of HIV trials, it would be 
difficult, if not impossible to conduct HIV trials in the UK without recruiting HIV positive 
asylum seekers and refugees.  
 
Summary 
HIV positive asylum seekers and refugees from sub-Saharan Africa are less likely to 
have been exposed to antiretrovirals than UK born positive people. As such, they are 
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more likely to have wild type virus which is valuable when testing the response of new 
antiretroviral medication. In addition, they are more likely to present at clinics with a 
high viral load and low CD4 count, which allows researchers to more accurately 
measure the response to treatment.  
 
Due to the number of HIV trials being conducted in the UK - and the eligibility criteria 
of these trials - it would be difficult to see how HIV clinical trials could run without the 
participation of HIV positive asylum seekers and refugees.  
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Chapter 5 
Participating in clinical trials carries both risks and benefits. The extent of these risks 
and benefits depends very much on the type of trial. For example, someone 
participating in a Phase Four to establish a new indication for a licensed drug may be 
at considerably less risk than an individual who is participating in a Phase Two which 
is seeking to develop a new cancer drug. In the former, the drug will already have 
undergone safety trials while in the latter the side effect profile will have yet to be 
established. In this chapter I will focus on the specific harms and benefits HIV positive 
asylum seekers and refugees may be exposed to as a result of participating in HIV 
clinical trials. I will look at the responsibilities to prevent harm in this group and outline 
measures which would reduce these harms.   
 
What is harm? 
Beauchamp and Childress (2011) p115 define harm as thwarting, defeating or setting 
back some parties interest. This is based on their principal of non- maleficence, 
where one ought not to inflict evil or harm. HIV positive asylum seekers and refugees 
may experience harm as a result of participating in a clinical trial. I will begin with the 
potential to develop drug resistance as a result of dispersal. As discussed in Chapter 
3, HIV drug resistance can occur for a number of reasons, including failure to take 
HAART as prescribed. BHIVA (2001) reports that the virus is able to mutate if the 
level of antiretrovirals in the blood drops below a specific level. Patients are advised 
that if they are planning to stop treatment, they should first discuss it with their 
physician. Due to the different half-lives of antiretrovirals, abrupt cessation is likely to 
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lead to a resistant strain of the virus developing. All people taking HAART have a risk 
of developing drug resistance if the compliance rate falls below ninety-five percent. 
While the general HIV population have control over their drug compliance, this may 
not be the case for HIV positive asylum seekers and refugees.  
 
Development of drug resistance 
The UK Border Agency is able to disperse asylum seekers and refugees to other 
regions of the UK areas with little notice. BHIVA (2009) has raised concerns that 
asylum seekers who have been dispersed do not have time to contact their clinics to 
arrange transfer to another unit - leading to breaks in their treatment. Others have 
had HAART taken into ‘safe keeping’ on their journey, and have never seen it again. 
In the clinic where I work, several clinical trial participants have been dispersed or 
deported with little heed taken of their medical needs. Clinics are seldom told by the 
authorities that the individual has been dispersed; information about their 
whereabouts usually comes via refugee or local HIV organisations. If dispersed within 
the UK, they may be placed in areas where there is no local HIV service. Burnett 
(2010) reported that some asylum seekers find it difficult to access another centre 
due to language difficulties. Access can also be hindered while they try to establish 
that they have a legitimate right to medication. This is especially problematic for those 
asylum seekers and refugees who are no longer eligible for treatment and are 
accessing drugs via a clinical trial. It is unlikely that the authorities would allow them 
to continue participating in the trial, as this would mean arranging escorts and 
transport to clinic. They may not have sufficient medication to enable them to stop 
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HAART in a structured manner, potentially leading to the development of drug 
resistance.  
 
Stevenson (2012) expressed concerns about the treatment and care of HIV positive 
individuals who were detained prior to deportation. It is difficult to establish exact 
numbers of those affected as the HIV status of detainees is not recorded. However, 
Inegbenebor (2012) reported that individual detained in Immigration Removal Centres 
were experiencing interruptions to their treatment. Staff may have little HIV 
knowledge and be unaware of the risks of withholding or delaying HAART.   
 
Those who are deported may also be at increased risk of developing drug resistance. 
Stevenson (2012) reported that individuals who are deported are usually given very 
little notice and may not have been able to safely stop HAART. While global access to 
HAART has increased over the years, UNAIDS (2009) reported that only thirty-one 
percent of people in low to middle income countries were able to access treatment. 
This situation has deteriorated in recent months due to the economic debt crisis in 
Europe. Collins (2012) reported that suspension of round 11 of the Global Fund 
Grants has meant that countries who have previously had limited funding for HIV 
treatment have had their funding suspended. If treatment is available, it is very 
unlikely that the antiretrovirals which constitute the clinical trial HAART regime would 
be available. Indeed, in some LECDs only dual therapy is available. If available, they 
will still be under patent and will be more expensive than the generically produced 
ARVs. Treatment of resistant strains of the virus can be a challenge and will require 
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the addition of new classes of ARVs or novel combinations of drugs. Chatora (2010) 
states that the cost of second line treatment, used in drug resistance, was five times 
more expensive than standard treatment. This will place an ever greater burden on 
those with limited funds. Due to the development of cross resistance between 
different classes of antiretrovirals, individuals could have already developed 
resistance to the medications available in their home country. As such, the available 
treatment would be unlikely to be fully effective. In the West, all patients are 
encouraged to have a resistance test prior to commencing treatment or changing 
antiretroviral therapy. This enables clinicians to choose drugs which will be effective. 
Price (2011) expressed concerns about the lack of ARV resistance testing in East and 
Southern Africa. Their study showed that while resistance levels were rising, 
availability to resistance testing with available to very few. Resistance testing is of 
particular value in choosing treatment regimens for individuals who have been at risk 
including participants in clinical trials who have stopped treatment abruptly. Lack of 
effective treatment can lead to rapid viral rebound. Over a short period of time the 
immune system will fail, leading to the development of opportunistic infections and 
death.  
 
Should asylum seekers and refugees be permitted to participate in HIV clinical trials 
where they face an increased risk of development of drug resistance? I suggest that 
the benefits of participation out-weigh any harm. Asylum seekers and refugees may 
be at a greater risk of developing drug resistance due to the possibility that they will 
be dispersed or detained, leading to abrupt withdrawal of medication. Even if they are 
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aware of the risks, they may find it impossible to structure withdrawal if they are not 
permitted to access medication.  
 
However, many of these individuals may not be able to access antiretroviral therapy 
at all if they were not participating in a clinical trial. Harrigana (1999) found that those 
stopping HAART experienced a rebound in viral load and drop in CD4 count leading 
to the development of opportunistic infections and death. In contrast, those who 
remained on therapy had a much better long term prognosis. By continuing to access 
treatment via the clinical trial, the individual may be giving themselves the best 
possible chance for future good health. Some might suggest that this is just delaying 
the inevitable, as the individual may not have access to effective medication in their 
country of origin. This is certainly true. However, the deportation process can be very 
long and the outcome is by no means certain. The Home Affairs Committee (2012) 
found that forty percent of those awaiting a decision on asylum had been permitted to 
remain in the UK. While this may be more a reflection on the inefficiency of the UK 
Border Agency, it does give those in the process of seeking asylum hope. Accessing 
antiretroviral therapy via a clinical trial may not be ideal. Despite being fully informed 
of the risks of developing drug resistance and the detrimental effect this will have on 
their health, those in need of treatment may not feel that they have any other choice if 
they wish to remain well.  
 
Potential harm to others  
The development of drug resistant strains of the virus can also affect sexual partners. 
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The overall risk of contracting HIV from a single episode of unprotected sex with an 
HIV positive individual is one in three hundred. Transmission is dependent upon 
many factors such as the viral load of the infected person - if they are on treatment, 
the sub-type of the virus and if they or their partner have another sexually transmitted 
infection. If a condom is used correctly, the risk of contracting HIV can be greatly 
reduced. Those infected with a resistance strain of HIV have a poorer outcome than 
those who contract a non-resistant strain. Steingrover (2008) found that the treatment 
options with those that had the transmitted resistant strains were reduced and they 
had an increased risk of developing an HIV related illness. This is even more 
problematic in LEDCs where treatment options are limited. In LEDCs background 
health problems also increase the of HIV transmission. Malnutrition - which is 
common in LEDCs -lowers the immune system and increases the possibility of 
transmission. Ulcerating genital infections - such as chancroid - increase HIV 
transmission and are more common in LECDs. In the West, pre-exposure HIV 
prophylaxis (PREPSI) is available, which, when taken prior to sexual exposure, 
significantly reduces transmission. A short course of ARVs given to the HIV negative 
partner within seventy-two hours of unprotected sexual intercourse (PEPSE) offers a 
seventy-five percent reduction in onward transmission of the virus (Expert Advisory 
Group on AIDS, 2004). Despite this treatment being unlicensed, it is recommended 
by the British Association on Sexual Health and HIV (BASHH) (2006) and is 
accessible from accident and emergency departments and sexual health clinics. 
These options are seldom available to those at risk of transmission in LECDs.  
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HIV positive individuals may find it difficult to disclose their status to sexual partners 
potentially exposing them to resistant strains of the virus and the associated health 
risks. There still remains a significant level of stigma surrounding HIV. Disclosure 
exposes the individual to the reactions of others - possibly rejection and in some 
cases violence. An additional barrier to disclosure for individuals who have tested 
positive while in a sexual relationship may be fear of legal prosecution. Nyambe 
(2005) reported that in thirty-six out of forty-one European countries, HIV transmission 
is a criminal offence. In England and Wales, thirteen people were prosecuted 
between 2003 and 2008. All of these individuals were convicted of Reckless 
Transmission of Infection under Section 20 of the Offences Against the Person Act 
1861. (Dica, R. v R (2004) EWCA crim 1103, Konzani, F. V R (2005) EWCA crim 
706). Ten of the defendants were convicted, all receiving custodial sentences; three 
were acquitted. In addition, a large number of accusations have been made but have 
never reached the Crown Court (Crown Prosecution Service, 2008). The process of 
taking such a case to court can be intrusive and distressing for both the accused and 
the accuser as the sexual history of both parties will be investigated in detail and used 
in court.   While this legislation was intended to reduce intended transmission of the 
virus, THT (2010) has expressed concern that it may deter individuals who have been 
at risk from testing. It has added to the stigma of HIV and may have the opposite 
effect of hindering disclosure. 
 
In order to avoid disclosure, some HIV positive individuals choose to use a condom to 
protect their partner from infection. While this is certainly better than using no 
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protection, condoms are not a hundred percent effective as proved by the number of 
unintended pregnancies each year. Nor does it enable them to take advantage of 
PEPSE if the condom were to split.  
 
While the HIV positive individual may be concerned about the reaction of others, the 
difficulties in disclosure do not override their duty to those whom are at risk from 
sexual transmission. Erin and Harris (2002) suggest that HIV positive individuals have 
a strong moral duty to disclose their status to intended partners. If the intended sexual 
partner is unaware of their partners HIV status and the potential risk of transmission, 
they cannot make an informed choice about whether to have sex with them. They 
suggest that once the HIV positive individual has informed their sexual partner they 
have discharged their moral obligation. The decision to have sex and potentially risk 
contracting HIV is left to the HIV negative individual. However, this stance does not 
take into consideration other factors. The sexual partner may not have a great 
understanding of HIV, or be aware of the risks of contracting it through unprotected 
sexual intercourse. Bluthenthal (2012) found that despite health promotion 
campaigns, a number of people still believe that HIV can only be contracted through 
injecting drug use or homosexual sex. For these individuals, having knowledge of 
their partner’s status may not alert them to any potential risks. The HIV negative 
partner may also be at risk in relationships where there is a power imbalance. They 
may be financially or emotionally reliant on their partner. Even if the HIV positive 
partner were to disclose their status, they may feel powerless to instigate safe sex.  
Smith (1997) found that for some HIV negative individuals, emotional attachment to 
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their HIV positive partner may negatively influence their ability to protect themselves 
from harm. They may feel that having sex with their partner demonstrates that they 
care and are willing to share risks.    
 
Those HIV positive individuals who are receiving HAART may have a greater 
obligation to inform sexual partners as they will be aware of the benefits of treatment. 
This is particularly true of asylum seekers and refugees who have sought out clinical 
trials as a means on continuing HAART. Informing sexual partners will enable them to 
access treatment and the associated health benefits. It could be argued that those 
who are on stable treatment with an undetectable viral load are significantly less likely 
to transmit HIV sexually and therefore may not have as great an obligation to inform 
sexual partners. However, serum blood viral loads do not always correlate with the 
levels of virus present in semen or vaginal secretions. This also may not be the case 
for individuals who have developed a drug resistant strain of the virus. The sexual 
partners of these individuals have a greater risk as their treatment options are 
significantly reduced.   
 
Bennett et al (2000) suggest that the individual has a moral duty to disclose only if 
there is a significant risk of infection. This may be problematic in a sexual context. 
The HIV positive individual may have chosen not to inform their sexual partner, 
planning only to have ‘low risk’ sexual activity with their partner. During this activity, 
what begins at ‘low risk’ may escalate to ‘high risk’. 
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Protection against sexual transmission of HIV should be a shared responsibility. For 
those HIV negative individual who can understand the risks of contracting the virus 
and are not under undue pressure to have sex, being told their partners status 
enables them to make an informed choice. However, HIV positive individual should 
be aware that not all their partners will understand the risks of sexual transmission, 
while others may choose to ignore these risks.     
 
Harm caused by dispersal and deportation on the scientific validity of the trial 
During the development of trial protocols, statisticians calculate the number of 
participants needed to show statistical significance. As part of these calculations, they 
allow for a number of participants to leave without completing the trial. If the number 
of participants lost is greater than envisaged, the trial may be underpowered and 
unable to reach a meaningful conclusion. Casciani (2011) reported that The 
Immigration Authorities are under increasing pressure to clear the backlog of failed 
asylum seekers and refugees. While there is a long delay between being refused 
asylum and being deported, researchers who are planning to recruit from this 
population, but will need to take into consideration the possibility that some 
participants may be dispersed.   
 
The abrupt withdrawal of asylum seekers and refugees may also affect the safety 
profile of the trial. During each study visit, participants will have tests taken to see if 
the medication is causing any systemic changes in the body. As HIV drugs can 
remain the in body for some time, side-effects may not show immediately. If 
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dispersed or deported, any adverse effects could be unreported and not available 
when writing the safety profile of the new medication.    
 
Multiple-participation in clinical trials  
Boyce (2008) defines multiple-participation as ‘individuals participating in more than 
one trial without the knowledge of their clinician’. This practice can affect both the 
well-being of the individual and the scientific validity of the study. There are many 
reasons why individuals enrol in more than one clinical trial.  Phase One trials attract 
students or those on a gap year. Volunteers in these trials are paid for participation, in 
addition to having free food and accommodation for the duration of the trial, albeit in a 
research facility. For participants in this type of trial, additional financial reward is 
likely to be the reason for multiple-participation. While Phase Two to Four HIV clinical 
trials do not offer financial incentives to volunteers, HIV positive asylum seekers and 
refugees may benefit from multiple-participation in other ways.  
 
Multiple-participation enables individuals to stock-pile HAART which will enable them 
to continue treatment if they are dispersed or deported. For the participants who are 
supporting families in their country of origin, excess HAART can be sold and the 
proceeds sent home to purchase basic commodities such as food and fuel. For 
others, multiple-participation will enable them to send home HAART to family 
members who are also HIV positive but are not able to access treatment. 
 
When study protocols are developed, researchers ensure that trial participants are 
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not burdened by too many investigations and that the number of tests does not 
exceed safe limits. Volunteers participating in multiple trials will be exposed to more 
tests they would undertake in a standard clinical trial. For example, participants may 
be required to have x-rays as part of the trial protocol. The safe level of radiation is 
calculated based on the number of tests each individual requires. If participants are 
required to have x-rays in additional trials, they will be exposed too much higher 
levels of radiation, which can lead to health problems. Even if they are sending 
medication home or selling it, individuals will be aware that the level of study 
medication will be monitored. In order for the study medication to show on a blood 
test, it will need to be taken for a day or so before the study visit. THT (2010) reported 
an increase in calls from individuals asking if there is any danger with this practice. 
Others may be less concerned about the ramifications of over-participation. The 
benefits of the over-participation - such as continued access to treatment and 
supporting relatives - may be more attractive than the short term risk of additional 
blood tests and x-rays.  
 
The development of physical problems relating to multiple-participation not only 
affects the individual but can have a detrimental effect on the scientific validity of the 
trial, which could impact on the treatment of future patients.  Participation in a single 
trial carries some risks, but the preliminary animal research will have given 
researchers some idea of potential side-effects which might develop. Multiple-
participation carries the additional risk of interactions between ARVs, which can occur 
if the individual is swapping drugs prior to each study visit. As the researcher will have 
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no way of knowing if the volunteer is taking additional drugs, any adverse reactions 
will be attributed to the trial medication. Adverse reactions in clinical trials are 
reported to the trial data managing committee. The role of the data managing 
committee is to look at all adverse incidents which occur to trial participants. Like the 
researcher, they are likely to attribute adverse reactions to the trial drug. If the 
reaction was severe they have the power to stop any clinical trial if they consider that 
the study medication is harming participants, or to ask that further recruitment is put 
on hold until a full investigation is completed. This will delay the trial and the potential 
development of a safer and more effective treatment for HIV.  
 
Multiple-participation can affect the results of the trial in other ways. For example, 
Mulligan (2000) reported that one class of HIV medication, the protease inhibitors, are 
very effective at reducing the amount of circulating virus, but are known to cause an 
increase in lipids. If the trial is seeking to develop a new protease inhibitor with a 
better lipid profile and the participant continues to take another protease inhibitor as 
part of another trial, their lipid levels may remain high. Researchers may falsely 
assume that the trial medication had no effect on the lipid profile. While it is unlikely 
that the blood results of one volunteer could significantly skew the data, if several 
volunteers were also participating in other trials, researchers may conclude that the 
trial medication is not as effective as expected.  
 
Drug swapping is another threat to the scientific validation of the trial. Participants in 
multiple-trials may be on different drug regimens. Anecdotal evidence suggests that 
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some HIV positive asylum seekers and refugees switch ARVs prior to a hospital visit 
to ensure that the trial drug will show in blood tests. This practice can lead to the 
development of drug resistance. During the development of new ARVs, researchers 
will establish if the study drug is safe, well tolerated and has a good resistance profile. 
If the researcher is unaware the participant has been exposed to other ARVs, 
resistance is likely to be attributed to the failure in the study medication. As with the 
safety profile of trial medication, it is unlikely that any one study would have large 
enough numbers of participants who are multiple-participating to seriously skew data. 
However, physicians review the results of clinical trials carefully when considering 
ARV regimes with a patient. They may choose not to use the new ARV if they have 
concerns around the resistance profile which could result in the patient missing out on 
a potentially good drug that would improve their quality of life. Anecdotal evidence 
from researchers working with HIV positive asylum seekers and refugees from African 
Community Organisations in the UK suggests that a significant proportion of 
individuals participate in concurrent clinical trials. However, as there figures are not 
collated, there is no way to substantiate these claims at this point in time. 
 
Similar concerns are faced by individuals who ‘over participate’ in clinical trials. 
Participants in clinical trials are exposed to trial medications with unknown safety 
profiles and side-effects. They are required to have multiple clinical tests to establish 
the effects of the medication. In order to minimise these risks, individuals are required 
to wait at least twelve weeks between different trials. This enables any residual study 
medication to be excreted from the system and allows the volunteer time to recover 
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from any investigations. Individuals are clearly informed that they must not participate 
in more than one clinical trial at any one time. Despite the risks, some individuals do 
enrol in concurrent trials or do not wait the requisite amount of time between trials to 
allow the study medication to leave the body. Over-participation can also affect the 
scientific validity of the trial as there could be interactions between the residual drug 
from the previous study and the new trial drug. As before, side effects could be 
attributed to the trial medication, not to any drug interactions.  
 
Solutions to over-participation and multiple-participation 
One solution to this problem would be to exclude groups who are likely to engage in 
this behaviour from participating in clinical trials, thereby preventing them from being 
exposed to harm. This is problematic for a number of reasons. Firstly, over and 
multiple participation can be found in all types of clinical trials, not only HIV. While it 
may be possible to identify groups where there is a higher incidence of this practice 
occurring, it would not stop the practice. Secondly, only a small proportion of these 
groups would over or multiple participate. It would seem unjust to prevent the majority 
of individuals who want to participate from doing so to prevent harm to the few who 
do. Finally, prohibiting specific groups from participating in research would - in some 
situations - make it difficult to conduct research. For example, the number of HIV 
positive women giving birth each year is very small in comparison with the rest of the 
population. Clinical trials seeking to reduce mother to child transmission of HIV by 
nature need to be conducted within this population. If it were found that HIV positive 
pregnant women were more likely to over participate and were excluded from 
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participating in clinical trials, it would be very difficult to conduct research on this topic.  
 
Boyce (2003) found that of seven thousand potential volunteers who were screened 
prior to participation in Phase One clinical trials between 1997-2001, sixty-eight (one 
in a hundred) had completed another trial within twelve weeks, even though they had 
signed a statement to the contrary. This concern was addressed by changes to 
clinical trials regulations. In May 2004, the European Union Clinical Trials Directive 
2001/20/EC was put into practice in the UK through the Medicines for Human Use 
(Clinical Trials) Regulations 2004. Part 1, 1K of the regulation says that applicants to 
ethics committees should include information about procedures for checking potential 
subjects’ possible involvement with other trials. The Medicines and Healthcare 
Products Regulatory Agency (MHRA) accreditation scheme for Phase One units 
requires units to have procedures in place to prevent over volunteering. Phase One 
units are also required to include a statement on the dangers of over participating on 
the patient information sheet and consent form. The Over Volunteering Protection 
Scheme (TOPS) was set up in Phase One clinical trials units to try and prevent 
volunteers from taking part in a clinical trial too soon after a previous one, or from 
taking part in two trials at the same time. Units were concerned that volunteers were 
risking their health by receiving too many potential new medicines from which they 
may get no benefit and having excessive clinical tests, in addition to compromising 
the quality of trial results. The scheme is free to all units which conduct Phase One 
trials, and uses National Insurance numbers to check when a volunteer completed 
their last clinical trial (Association of Human Pharmacology in the Pharmaceutical 
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Industry, 2011). Volunteers do need to be informed about the scheme and to give 
permission to have their details checked. This is done as part of the consent process, 
where volunteers are advised about the risks of multiple and over-participation in 
clinical trials. Should they decline to have their details checked, they will not be 
permitted to enrol. While some prospective volunteers have been unhappy with the 
scheme, most view it as standard practice and in their best interest (Boyce, 2011). 
The scheme has also been welcomed by the research community, as it has enabled 
them to fulfil their obligation to check that volunteers are not over participating. This 
helps to protect both the safety of the volunteer and the integrity of data. By 2007, 
TOPS reported that twenty-six Phase One units were using their data base. These 
units were situated in Scotland, England, Wales and Ireland. Eighteen of these units 
were run by research organizations, five by pharmaceutical companies and three 
were linked to universities. 53, 650 volunteers have been registered. Boyce (2003) 
found that in his Phase One unit alone - when checks were conducted prior to 
screening new participants – eighty-five volunteers had applied to participate in a 
clinical trial within twelve weeks of the previous one; one volunteer was already taking 
part in two trials at the same time. By 2004, the number of volunteers participating in 
two or more trials or entering too soon after a trial had dropped to eighteen in that 
unit.  Boyce attributed this drop to volunteer’s awareness of the scheme.  
 
Despite the benefits of the TOPS scheme, it is only used in Phase One trials.  Phase 
Two to Four clinical trials, where most of the HIV trials take place, do not have a 
mechanism where researchers can check if volunteers are multiple or over 
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participating. While researchers ask potential participants if they have recently, or are 
at present, taking part in another trial, they are dependent on the honesty and 
integrity of the trial participant to answer truthfully as they have no means of 
confirming their participation. If healthy volunteers present recent needle marks at a 
Phase One unit, researchers may be alerted to the fact that they have recently taken 
part in a clinical trial. However, as many HIV positive patients have blood taken 
regularly as part of standard care, additional needle marks would not raise any index 
of suspicion. In addition, the volume of HIV clinical trials being held in the UK would 
make it time-consuming for researchers to call round all units to establish if potential 
participants were already enrolled in a trial.  
 
It should be possible to expand the TOPS scheme for Phase Two to Four trials. The 
ground-work has already been undertaken by Boyce and would only require the 
backing and co-operation of both the pharmaceutical industry and the regulatory 
authorities. The scheme would need to be adapted to take into account the specific 
challenges of asylum seekers and refugees. At present the TOPS scheme requires 
volunteers to provide a National Insurance number which is used to check if they 
have recently participated or are already participating in a clinical trial. However, 
many HIV positive asylum seekers and refugees will not have a National Insurance 
number. In addition, first names and surnames are often transposed or misspelled, 
while different family names are given which adds to the difficulty of identification. In 
order to overcome these challenges, a ‘participant passport’ could be developed for 
those wishing to participate Phase Two to Four clinical trials. This document would be 
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issued by the site where they first enrolled in a trial. For those who do not have a 
National Insurance number, passport details would also be required as well as 
Immigration documents. All participants would require a photograph, which had been 
countersigned by their physician. The individual’s details would be registered on a 
main data base, which would be secure and only accessible by participating units, 
similar to that of the TOPS scheme. As with the current TOPS scheme, individuals 
would only be permitted to enrol in a clinical trial once these checks had been carried 
out. While some might argue that this scheme would be too difficult and too 
expensive to maintain, the current TOPS Phase One scheme works remarkably well 
and is supported by both researchers and the pharmaceutical industry. Others may 
be concerned that the scheme would be too time-consuming, increasing the time 
taken to recruit to trials. However, the present scheme has not found this to be the 
case. Individuals may also be concerned about the confidentiality of the scheme and 
the inadvertent disclosure of their HIV status. These concerns would be addressed by 
ensuring that the data base could only be accessed by named individuals who had 
been vetted by the scheme administrator. All procedures should follow the precepts of 
the Data Protection Act, and all participants in Phase Two to Four Trials would be 
required to register for the scheme, reducing any concerns about stigmatising any 
particular group.    
 
Until such a scheme is in place, researchers need to be alert to the possibility of 
multiple and over-participation. When discussing clinical trials, they need to clearly 
explain the affect this practice can have both to the individual and the results of the 
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trial. Community groups can also be utilised to ensure that individuals are made 
aware of the harm this can do to their health, as well as potential harm to the 
development of new ARVs.   
 
The obligations of the participants, researchers and ethics committees in 
relation to harm in clinical trials 
Similar to protecting themselves from sexual harm, participants also have some 
obligation to protect themselves from trial related harm. To make an autonomous 
choice regarding participation, individuals need to have enough information to base 
their decision on. All clinical trial participants are given a participant information sheet 
(PIS) which should inform them of any advantages and disadvantages of participating 
as well as any risks and benefits. In the case of over and multiple participation, the 
PIS only asks participants if they are, or have recently, participated in a clinical trial. It 
does not give a reason as to why they are being asked these questions. Once 
informed of the risks, potential participants can make an informed choice to avoid 
these practices.  
 
Individuals also have an obligation to ensure that they are clear about what is being 
asked of them should they agree to participate. Outside a clinical trial, we would ask 
for an explanation if, for example, our employer asked us to do something which was 
out of the ordinary. In doing so we would be protecting our own interests. It would be 
foolish to agree to something written in the PIS that we either don’t understand or 
don’t want to do. For example, the number of additional study visits may be a 
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deterrent to some people. Others may be willing to undergo the additional visits, if 
given a clear explanation as to why they are necessary by the researcher. Potential 
participants may also need a clearer explanation of clinical procedures than the one 
provided in the PIS. I have seen a PIS where a lumber puncture was described as a 
painless procedure involving a ‘sharp scratch’ to the back. Having asked and been 
given a more detailed explanation by the researcher, the potential participant firmly 
declined to offer to participate.  
 
While the clinical trial will have had ethical approval, there may still be some level of 
harm associated with the trial. Participants may choose to disregard this harm due to 
personal beliefs or circumstances. For example, they may have had a close relative 
die of a particular condition, and wish to further their knowledge of that condition. 
Some might feel that researchers are only required to make sure the participant 
knows the risks, but they should not be responsible for eliciting why the individual has 
chosen to participate. They might argue that providing information about the trial and 
outlining any potential risks and benefits enables participants to make an autonomous 
choice. A stronger view is that they should exclude those who are at increased risk 
from taking part in the trial, if, based on their knowledge of the client group, they 
anticipate the actions of that individual. An example here would be if the researcher 
had knowledge that the prospective HIV positive participant was from a refugee 
background and would have a greater risk of developing resistance. The researcher 
might refuse that individual access to the trial to protect them from developing 
resistance. The harm, development of drug resistance, is not caused by the 
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researcher, but may be additional risks of participation. Researchers have a general 
duty of care to safeguard participants from harm, based on the principal of non-
maleficence.  While it may not always be possible to prevent harm - such as expected 
side effects of trial drugs - they can take measures to minimise these risks. This 
needs to be balanced with respecting the autonomy of the individual to make an 
informed choice based on the information given. If the benefits of participation 
outweigh the harm, the individual should be permitted to enrol in the trial.   
 
Role of the Ethics committee in preventing harm 
COREC (2009) states that the role of the ethics committees is to ‘protect the rights 
and well-being of research subjects’. One way in which they do this is by reviewing 
and giving an ethical opinion on research protocols which are submitted to them. 
When reviewing a protocol, they take into consideration the potential risks and 
burdens to participants. These can include number of study visits, the number and 
nature of any tests and the potential of the study to cause injury, distress and 
discomfort. Researchers are also required to produce a participant information leaflet 
(PIS), which outlines these risks and benefits. The PIS and the role of the ethics 
committee will be discussed in more detail in chapter 6. The REC bases its decision 
on the information given by the researcher in the protocol and the knowledge of the 
individual REC members who review the protocol. If the REC members have limited 
knowledge of the condition being investigated, they may seek the opinion of an 
expert. If the REC is of the opinion that the proposed research could be harmful to 
participants, they will require the researchers to justify why they are potentially 
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expositing participants to harm. If the researcher can demonstrate that they have tried 
to minimise the potential risks, and that the research could not be undertaken in any 
other way, the REC may decide that the research should go ahead, providing that the 
risks are fully outlined in the PIS. RECs are under some pressure from NRES not to 
reject proposals, as this could slow down research and in the case of clinical trial, see 
research being taken abroad. As such, some trials which the REC may consider ill-
conceived but of little risk to the individual participant may be accepted. Once trials 
have been approved, RECs require researchers to submit regular reports - including 
safety data - on a regular basis. Clinical trials themselves are also monitored to 
ensure that the protocol is being followed; this is assessed by auditing trial related 
documents. While the paperwork for a trial may be completed correctly, auditors have 
no means of assessing how researchers approach individuals about the trial, provide 
them with information or recruit them.   
 
Potential benefits for HIV positive asylum seekers/refugees who participant in 
clinical trials 
Information sheets relating to clinical trials inform prospective participants that they 
may not benefit from the study medication. Indeed, they may experience additional 
side effects of the study drug and be burdened by hospital visits and tests. However, 
participation in a clinical trial may benefit the participant in other ways.  
 
Potential access to treatment and care  
As I have discussed earlier, access to on-going NHS care for failed asylum seekers 
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and refugees is at best patchy, as NHS Trusts interpret the guidelines very differently. 
Individuals who have been prescribed HAART prior to their asylum claim being 
rejected should be able to continue. However, the Terrence Higgins Trust (2009) 
reported that this does not always happen. Some individuals have been told that they 
are no longer eligible for NHS care, and have been denied access to HAART. In order 
to continue treatment, individuals may consider accessing a clinical trial. While the 
trials are usually conducted in NHS premises, HAART and associated tests are 
funded by the pharmaceutical industry. Under the Declaration of Helsinki (2008), 
doctors conducting clinical trials are responsible for the physical well-being of 
individuals under their care. While this guidance relates to any potential side-effects 
as a result of the trial, it would be very unlikely that doctors would disregard any other 
health-care issues that an individual presented during the course of the study. Any 
new symptom or illness may be related to the trial drug and would need to be 
investigated, treated and recorded as an adverse reaction. As such, participants are 
advised to contact the team should they experience any unexpected physical 
symptoms during the duration of the trial. While asylum seekers and refugees may 
not be eligible for NHS treatment and care until the cause of the illness was 
established, any tests and treatment would be met by the study. Those individuals 
with a low CD4 count and high viral load may be on additional medication such as 
prophylaxis for other conditions, or taking the antibiotic cotrimoxazole to prevent PCP. 
It is likely that they would continue to have access to these medications as part of the 
clinical trial. Access to medications for other conditions would be at the discretion on 
the clinician conducting the trial. These should be discussed with the individual prior 
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to recruiting, as part of the consent process which will be discussed in chapter 7.    
 
Psychological benefits 
Participation in a clinical trial may also have psychological benefits for the individual. 
Feroze (2012) suggests that individuals living with chronic medical conditions 
experience greater levels of anxiety and depression than any other groups of 
patients. Silove (1997) also found that asylum seekers and refugees had much 
greater levels of anxiety and depression than that of the general population. Having 
both may enhance the psychological distress. Whetten (2008) described the feelings 
of those newly diagnosed with HIV. For many, initial concerns about future health are 
reduced when they commence on HAART, replaced by optimism for the future. 
However, once the availability of HAART is removed, this optimism is removed, and 
replaced by fear of the future. Participation in a clinical trial where they can continue 
HAART may alleviate some of the psychological distress and buy them some time to 
explore other alternatives. In addition, those participating in clinical trials may take 
some comfort in knowing that should they develop a medical problem, they will have 
access to medical care. Hutchinson (1998) found that psychological benefits of 
participation included being able to express concerns about their medical condition 
and concerns about long term prognosis. The Medical Foundation for the Care of 
Victims of Torture (2008) found that many asylum seekers have undergone violence 
and trauma. HIV clinical trials in the UK are usually conducted within established NHS 
clinics - where staff are experienced in dealing with these issues. They generally have 
close links with external organisations including the Medical Foundation for Victims of 
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Torture. If a participant on a clinical trial is identified as having trouble dealing with 
past experiences, they can be referred to the appropriate organisations. In addition to 
providing psychological support, the organisations may also be able to provide 
practical support, such as food and access to safe accommodation. HIV positive 
asylum seekers may also experience social problems. In addition to lack of food and 
shelter, they may find it difficult coping with a new culture and possible language 
difficulties. Participants in clinical trials will be able to access support organisations 
which work closely with clinics - who can offer a whole range of services ranging from 
practical to social support. 
 
Benefits to sexual partner  
HIV is primarily transmitted during unprotected sexual intercourse. Many people 
diagnosed with HIV are in sexual relationships. When they are initially diagnosed, 
their clinician will have advised them to practice safe sex in order to protect current or 
new sexual partners from becoming infected by the virus. They will also be advised 
that practicing safe sex will protect themselves from contracting other strains of HIV, 
which will be detrimental to their health. Condoms are recognised as the best 
protection against sexual transmission of HIV. However, even if used consistently and 
correctly, condoms may break or fall off, and they are only ninety-eight percent 
effective in preventing pregnancy if the incident were to occur during the woman’s 
fertile period. As such, those using condoms to avoid an unplanned pregnancy are 
advised to use an additional method of contraception. Studies suggest that a ninety-
five to ninety-seven percent efficacy rate is much more realistic in general use 
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(Faculty of Sexual and Reproductive Health, 2007). One can assume that if there is a 
risk of pregnancy, there is also a risk of HIV transmission. A broken condom can 
allow both the passage of sperm and seminal fluid, the latter being the vehicle for HIV 
transmission. When a patient is first diagnosed with HIV, they will be encouraged to 
bring their partner along to be tested. Safer sex will be discussed in detail, and a 
supply of condoms given. If their partner is found to be HIV negative, the use of 
PEPSE will be discussed with the couple. If a discordant couple have a condom 
incident, accessing PEPSE is considered a medical emergency. While it is available 
in A&E departments, its use is normally limited to those who have been at risk of 
contracting HIV through a needle stick injury. Despite the BASHH (2008) 
recommendation that it should be available for high risk sexual exposure to HIV, 
some staff in accident and emergency departments are not well versed in its use. HIV 
positive patients who have arrived over the weekend have been told to return on 
Monday to see the doctor in charge. As PEPSE is only effective within seventy-two 
hours of unprotected sexual intercourse, the window of opportunity for taking the 
medication has gone.  
 
While BHIVA/BASHH (2011) recommend that physicians discuss safe sex with 
patients at each clinic visit, this may be impossible due to time constraints. If the 
individual enrols in a clinical trial, the researcher will again discuss safe sex. This is of 
particular concern in trials involving new ARVs where there may be potential risks to 
an unborn child. Participants will be encouraged to use another form of contraception 
- in addition to condoms - to protect against pregnancy. The researcher will also 
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discuss the potential risks of transmission to the partner and will encourage the 
patient to bring them along to discuss safe sex. The researcher will discuss the use of 
PEPSE and will ensure that a supply is made available to the participant and their 
partner.   
 
The participant may not be in a sexual relationship when they first enrol in the trial, so 
while PEPSE will be discussed, its use may not be applicable at that point. However, 
as HIV clinical trials tend to be conducted over a long period of time, it is possible that 
participant will form a new relationship during the course of the trial. While discussing 
safe sex with participants may not be within the scope of the research, most 
researchers will be happy to discuss any concerns participants have and refer them 
to the clinic health adviser who will be able to address any issues in more depth.  
 
Participation in a clinical trial will benefit both the individual and their partner. As a 
failed asylum seeker, they may not be able to access PEPSE following a condom 
incident. However, as a trial participant they will have been given a five day ‘starter 
pack’ which will enable them to initiate treatment within the recommended time. This 
will reduce the risk of the partner contracting HIV. The medication in the starter pack 
will have been carefully considered, taking into account the trial regime of the index 
patient and the BHIVA (2010) guidelines on PEPSE. This will ensure that the PEPSE 
regime is effective and will also reduce the risk of the partner developing resistance. 
Should the partner have any questions about the medication or experience any side 
effects, they will also be able to use the twenty-four hour telephone helpline available 
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to trial participants.  
 
Health improvements 
Braunholtz (2001) and Lantos (1999) suggest that individuals participating in clinical 
trials tend to do better than those who receive standard medical care. One proposed 
reason for this is the increased length of time spent with staff. Field (2010) reported 
that GP’s were concerned that they could not fully assess a patient in the seven 
minutes they had allocated. In such a brief consultation, patients do not always have 
time to assimilate what they are being told, let alone formulate any questions. 
Patients may have health issues they wish to discuss which cannot be 
comprehensively covered in such a short visit. In contrast, when an individual is 
considering participating in a clinical trial, the researcher is required to spend time 
discussing the trial with them. Most clinical trials require that the patient is given at 
least twenty-four hours to consider participation prior to giving consent. During that 
time, they are asked to discuss the trial with other people and list any questions they 
would like to ask. When they meet with the researcher prior to signing the consent 
form, they are again asked if they have any questions. This may be the first time that 
patients have felt they have been given time and permission to ask questions about 
their illness. When the patients enrol in a trial, they usually find that the doctor or 
research nurse will spend much more time with them than they would do during a 
normal clinical consultation. This is primarily to ascertain if they have developed any 
clinical effects of the trial drug. It may also make the individual feel that they are 
valued and more inclined to attend their next study visit. Trial participants often 
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remark that they feel much more involved in their care, as they have more information 
and are actively encouraged to ask questions. For some this may be an empowering 
experience. 
 
HIV positive asylum seekers and refugees may also benefit from the Out of Hours 
service provided in clinical trials. Participants are also encouraged to contact the 
researcher should they experience any new symptoms or become unwell during a 
trial. Following the phone call they may be asked to return to clinic for an unscheduled 
visit. If this happens out of hours, the researcher will arrange to meet them in the 
hospital. Trial participants comment that this is very different from the out-of-hours 
service they have in standard practice. Patients who become unwell when the clinic is 
closed are advised to contact their general practitioner. This can be problematic if the 
GP is unaware of their HIV status. Some GPs may not be fully conversant with HIV 
infection and may suggest that unless the problem is urgent, they should wait and see 
their regular HIV consultant. This may be detrimental to their health as some HIV 
infections need urgent attention to prevent complications. Some HIV positive asylum 
seekers and refugees may not have a GP, as they may not be eligible for NHS 
treatment and care. As such, participating in a clinical trial will enable them to have 
access to medical treatment over the weekend which they would not have had 
otherwise. In an emergency, patients are advised to attend their local accident and 
emergency department. In contrast, Gunn (1998) and Peppercorn (2004) found no 
difference in outcomes of those who participated in clinical trials to those who did not. 
It is difficult to apply the findings of their study to HIV positive asylum seekers and 
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refugees as their cohorts were all eligible for health care.  For HIV positive asylum 
seekers and refugees, the main benefit of participation would be continued access to 
treatment.  
 
West (2005) suggested that any improvements the participants experience during a 
trial may be due to staff following protocols rather than providing additional care. 
Again, HIV positive asylum seekers and refugees were not represented in the cohort. 
 
Summary 
Participation in clinical trials for all HIV positive individuals carries both risks and 
benefits. While the risks of participating in a clinical trial may be greater for asylum 
seekers and refugees - due to potential of developing drug resistance - the benefits of 
participation outweigh any harm.  
 
Unless antiretroviral therapy is stopped in a structured manner, resistant strains of 
HIV will develop. HIV positive asylum seekers and refugees are at a greater risk of 
developing drug resistance as they may be detained or deported with little notice, 
resulting in abrupt withdrawal from treatment. Should they develop a resistant strain 
of the virus, treatment options are reduced. Even if treatment is available, which it 
may not be if they are deported, it is likely to be much more expensive than standard 
therapy and may not be as effective.  
 
While these are strong arguments against participation, the potential benefits of 
95 
 
participation for HIV positive asylum seekers and refugees outweigh any harm. While 
they may be an increased risk of developing drug resistance, asylum seekers and 
refugees are at more immediate risk if they are unable to access HAART. Without 
participating in clinical trials these individuals would be unable to have continued 
access to antiretroviral therapy, and within a few weeks without therapy they will see 
an increase in their viral load and a decrease in CD4 counts, leading to the 
development of opportunistic infections and eventually death.  
 
Not all HIV positive asylum seekers and refugees will benefit from participation in a 
clinical trial. They may not respond to study medication, or develop side effects which 
necessitate stopping HAART. Others may not be eligible to participate for clinical 
reasons. For those that do enrol in clinical trials - provided that they are aware of the 
risks of developing drug resistance and can take measures to reduce these risks - the 
immediate risk of death is greater than the long term effects of drug resistance.  
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Chapter 6 
Consent – provision of information. 
Introduction 
The Declaration of Helsinki (2008) Article 24, states that participants in clinical trials 
should be provided with both written and verbal information about the proposed trial. 
While this may appear to be a simple requirement which is easily fulfilled, researchers 
often struggle to provide information sheets (PIS) which are easily understood by 
prospective participants. Several studies have shown that participants do not 
understand what they have read in the PIS. Akkad (2006) asked individuals who had 
participated in various types of clinical trials to complete a questionnaire which would 
assess their understanding of the information they had been given.  Joffe (2001) 
conducted a similar study asking individuals who had participated in cancer trials to 
complete a questionnaire to assess their understanding of the trial. Both found that 
participants had understood the trial to some extent, but were unclear as to the 
difference between standard treatment and drug giving in a clinical trial setting. Some 
believed that they would benefit from participating, despite being told otherwise by the 
researcher. All were satisfied that they were no coerced to participate, and felt that 
they had been treated well by research staff. While I am glad that the participants 
reported that they were well treated, I am a little concerned about their lack of 
understanding of the information they had been given. While the participants were 
given information, it does not appear from these studies that researchers made any 
effort to check that the participants had understood what they were consenting to.  
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In this chapter I will look at how the provision of information to prospective 
participants can be improved, including the challenge of providing information to HIV 
positive asylum seekers and refugees. This chapter will first focus on the limitations of 
the current system. I will argue that changes need to be made in order to enhance 
understanding for all participants. In the second half of the chapter I will discuss ways 
to improve the provision of information to prospective participants. I will argue that 
Research Ethics Committees (RECs) need to be more proactive when reviewing 
applications, to ensure that the PIS reflect the information needs of the target 
population.  
 
Importance of consent 
Seeking informed consent respects the individual’s autonomy. Harris (2004) 
suggested that the need for consent arose from the desire to respect the autonomy of 
autonomous beings. In clinical research, individuals who are thinking about 
participating should be given enough information on which to base that decision. 
Ensuring that they have enough information to make an informed choice helps to 
support their autonomy. Mclean (1997) suggests that good research should not only 
be scientifically sound but must also at all times respect the participant. Failing to 
provide adequate information demonstrates lack of respect for the prospective 
participant. This view is supported by Kale (1997) who states that research without 
the patient’s consent is unethical in any part of the world because it violates the 
fundamental right to autonomy and self-determination.  While I have no disagreement 
with this assumption, I would also add that consent based on ambiguous or unclear 
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information is also unethical. Consent cannot be said to be informed if the participants 
understanding of the trial bears no resemblance to the aims and objectives stated in 
the PIS. For example, many HIV positive asylum seekers and refugees do not have 
English as a first language. While they may be able to understand spoken English, 
and have some degree of literacy, some may have difficulty reading and 
understanding participant information sheets. For this population, the provision of an 
information sheet alone may not be sufficient to guarantee understanding. If 
participants cannot understand the information they have been given, they cannot 
give informed consent. As such, research conducted under these conditions may be 
unethical. Let us look at this in more detail. As well as respecting the participants’ 
autonomy, the provision of information in the consent process also helps both the 
researcher and the individual to avoid unrealistic expectations. As discussed 
previously, some HIV positive asylum seekers and refugees erroneously believe that 
enrolling in an HIV clinical trial will support their asylum claim. Those who enrol in a 
trial for this purpose only to find that their participation was not taken into 
consideration, and that their appeal has been unsuccessful, will be very angry and 
may believe that they have been misled by the researcher. Has the researcher 
behaved in an unethical manner? They have followed the NRES guidance by 
providing the prospective participant with a PIS, waited twenty-four hours before 
providing them with an opportunity to discuss any issues, and only after that sought 
consent. They didn’t set out to deceive the individual by failing to mention immigration 
issues. Indeed, they could argue that immigration did not cross their mind when 
discussing the study. As such, it would appear that they have not intentionally meant 
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to cause harm or distress to the participant. However, the omission of information 
reflecting their immigration status in the PIS may have caused that individual to enrol 
in a trial under a false assumption. It could be argued that the prospective participant 
should have asked this question of the researcher as they had sufficient time to 
consider any questions prior to enrolling in the trial. While it is unrealistic for the 
researcher to be aware of every issue that could influence each individual’s decision 
to participate in a clinical trial, it is not unreasonable to expect researchers to be 
aware that those approached to participate in HIV clinical trials may be asylum 
seekers or refugees. As such, the information in the PIS should reflect the issues 
which are specific to this population. This will enable prospective participants to 
consider all pertinent information prior to agreeing to participation. This lack of 
understanding was reflected by McCluskey (2005). She found that individuals 
recruited to HIV vaccine trials displayed flawed beliefs about the trial. She reported 
that prospective participants were ‘misinformed, made erroneous assumptions and 
had unrealistic expectations of the trial’. Some of these individuals thought that they 
could become infected as a result of the study, while others thought that participating 
in the trial would afford them lifelong protection from future exposure to HIV. In both 
cases, the participants had been given a participant information sheet. It is unclear 
why they did not understand the information. The language used in the participant 
information sheet may have been too technical for the individual to understand, or 
they did not take time to read it or discuss it in more detail with the researcher. It is 
clear that HIV positive asylum seekers and refugees have specific needs in relation to 
the provision of information about clinical trials. If researchers are aware of these 
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needs and do nothing to address them, they are failing to demonstrate respect for the 
individual’s autonomy.      
 
Provision of information-current practice 
Various research bodies have provided guidance on the elements which should be 
included in a patient information sheet, in order for individuals to make an informed 
choice when deciding to participate in a clinical trial. The WHO (1993), g.3.states that 
in order for informed consent to be valid, a researcher has to:  
 Communicate to the prospective subject all the information necessary 
for adequately informed consent 
 Give the prospective subject full opportunity and encouragement to ask 
questions 
 Exclude the possibility of unjustified deception, undue influence and 
intimidation 
 Seek consent only after the prospective subject has adequate 
knowledge of the relevant facts and of the consequences of 
participation, and has had sufficient opportunity to consider whether to 
participate. 
 Obtain from each prospective subject a signed form as evidence of 
informed consent 
 
This view is supported by the Medicines for Human Use (Clinical Trials Regulations) 
2004 which states that; ‘A person gives informed consent to take part in a clinical trial 
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only if his decision…. is given freely after that person is informed of the nature, 
significance, implications and risks of the trial’… Mason and McCall (1991,p98) go on 
to add ‘the patient’s consent must be based on four lines of explanation: the purpose 
of the experiment, the benefits to the patient and society, the risks involved and the 
alternatives open to the subject’. 
 
The Declaration of Helsinki (Article 24) requires researchers to inform potential trial 
participants of the aims, methods, anticipated benefits, potential harm and hazards of 
participation as well as their right to withdraw from the trial after giving consent.  
The International Conference on Harmonization ICH (1996) lists eight basic elements 
which should be included in the participant information sheet: 
1. A statement that research is being conducted, its purpose, duration, and 
description of experimental procedures to be employed 
2. Description of foreseeable risks and discomforts to the subject 
3. Potential benefits to subjects and others 
4. Description of alternative treatments 
5. Statement regarding confidentiality of records 
6. Arrangement for compensation should the subject be harmed 
7. Contacts for further information or redress 
8. Statement that participation is voluntary and participants can leave without any 
negative consequences on further treatment  
 
These elements are incorporated in both the Royal College of Physicians (1990) 
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s.7.14, and the Association of the British Pharmaceutical Industry (1992) guidelines 
for producing participant information sheets.  
 
While these guidelines differ on minor points, they all allow prospective participants to 
be informed of the nature of the trial, including any risks and benefits. They also all 
state that the trial is voluntary. However, none of the guidelines suggest how the 
researcher can be assured that the prospective participant has understood the 
information they have been given. It would appear that providing information alone is 
enough to fulfil the guidelines. As I illustrated earlier, researchers and participants 
may have a very different understanding of the information provided. As such, 
participants could agree to participate without fully understanding the implications.   
 
In the previous chapter I briefly discussed the role of the ethics committee in 
preventing harm to clinical trial participants. In this chapter I will look more closely at 
the role of the ethics committee in the provision of information to prospective 
participants. As part of the process to gain ethical approval for a clinical trial, 
researchers are required to submit participant information sheets (PIS) with the other 
trial documents to the ethics committee. NRES (2011) provides a range of PIS 
templates for various types of trials in addition to comprehensive guidance for the 
researcher. Researchers are permitted to develop their own PIS; however this should 
contain the eight basic elements described above. NRES (2009, 5.1.2) suggests that 
the length of PIS should reflect the type of study. For example, studies with little 
intervention and minimal risk such as those involving administering questionnaires 
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are likely to need a shorter PIS than a more complex high trial which involves clinical 
investigations and the administration of study medication.  
 
In recent years pharmaceutical companies have justifiably become more concerned 
with possible litigation from trial participants. KPMG (2011) reported that 
pharmaceutical companies had paid US$19.8 billion to settle US law suits. As such, 
the PIS produced by these companies have increased in length to incorporate every 
potential side effect to reduce the company’s liability. It is not unusual for prospective 
participants to be given a PIS that is more than twelve pages long, which includes 
information both about early animal studies, as well as all manner of side-effects 
displayed in first-in-man studies, (which may or may not have been as a result of the 
medication). Some sections are written by company lawyers and are meaningless to 
the lay reader. While the company is to be applauded for providing detailed 
information for the prospective participant, it is likely that an excessively long and 
detailed information sheet may hinder rather than enhance understanding. Some 
trials provide a short one page summary of the trial - to enable prospective 
participants to see if they would be interested in the trial. They are then advised to go 
on to read the full version if they are considering participating. Again concerns have 
been raised that decisions are being made on the short form, as the full version is too 
daunting to read.  Information which could be pertinent to that individual, such as time 
spent in the trial, could be missed. Some researcher’s ethical interests may also 
advocate for a longer PIS, to ensure that prospective participants are given enough 
information about the trial, thus enabling them to give informed consent.  
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Despite the NRES (2007) guidance on producing written information, the REC I sit on 
regularly reviews submissions which include incomprehensible PIS. They are often 
too long, too technical, unclear, and don’t fully reflect the aims and objectives outlined 
in the protocol. Researchers are required to modify these prior to gaining ethical 
approval. The amended forms are reviewed by the sub-committee, which may or may 
not include a lay member. These are generally improved, but while they may be 
easier to understand for the REC member, they may still be difficult to understand by 
a lay individual. While lay members of the REC may not be medical, they are 
generally educated to a high standard. What is comprehensible to them may not be 
understood by participants. Ethics committees recognize the short comings of the 
PIS. Ames (2008) was keen to elicit the view of members of research ethics 
committees on the standard of patient information sheets for randomized controlled 
trials. The committees were asked to offer suggestions on ways to which information 
could be improved.  Members of the ethics committees were concerned that the 
patient information sheet did not fully explain randomization. They felt that it was 
unlikely that trial participants could make an informed choice on the information given. 
Those interviewed suggested that trial participants should be provided with more 
information about the methodology of randomized controlled trials in language 
understandable to wider public. They go on to suggest that this should be followed-up 
with a face to face explanation by a researcher who is well versed in randomization 
and able to answer any questions. If RECs are aware that of the short comings of 
PIS, why do they still approve them? This may be in part due to pressure not to slow 
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down research. Pharmaceutical companies contribute a substantial amount to the 
economy of the UK. In its 2010 report, the ABPI found that the pharmaceutical 
industry brings greater economic benefit to the UK than any other high-tech industry, 
figures which were supported by The Office of Health Economics (2010). Slowing 
down research by increasing the time to approve trials could drive researchers away 
from the UK to other countries, where it may be easier to gain approval. Subtle 
pressure may be placed on RECs not to slow down research by rejecting studies.  
 
Some of the challenges of incomprehensible information could be addressed by 
utilising patient group representatives in the development of the PIS. NRES (2011) 
already recommends involving patient group representatives in study, but this 
suggestion is not always acted on. One of the advantages of such groups is the 
insight they are able provide on the target population. In HIV trials, voluntary 
organisations such as Body and Soul and Positively Women have developed a strong 
relationship with researchers and have been consulted on user involvement in 
research, as well as the design of participant information sheets. While the RCP 
(2007) found that asylum seekers and refugees were difficult engaging in research, 
this has not been the case with HIV voluntary organisations.  Many provide support 
for this group and are in regular contact with members. Groups may be willing to 
facilitate engagement with researchers whom they have developed a trusting 
relationship. By working with user groups, researchers can develop PIS’s which are 
easily understood and culturally appropriate. They can also use this as an opportunity 
of ‘sounding out’ the target population to see if the proposed research would be 
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feasible within the population. One of the disadvantages of utilising patient groups is 
that they may not be representative of all the target populations. For example, a 
group of Somali men could not provide insight into the needs of Ugandan women. 
There may also be peer pressure on individuals to get involved with research.  
 
Once the PIS has been developed, it should be piloted with patient group 
representatives. This process will highlight any recurring problems which arise such 
as the phrasing of specific sections. The researcher could also ask the group’s views 
on how to engage with prospective participants. For example, I was involved in a 
study where the target population was HIV positive teenagers. As part of the study, 
the young people were expected to complete a two hour visit where they were asked 
to complete questionnaires and undergo neurocognitive tests. Prior to the 
neurocognitive element of the visit, they were offered refreshments to aid their 
concentration. For the pilot study we provided healthy fruit and sandwiches. The 
focus group were less concerned about the two hour visit than our ‘appalling’ choice 
of food! They suggested we switch to doughnuts and crisps, which would be much 
more attractive to teenagers. Acting on their suggestion, we changed to the less 
healthy option for the main study, which was much appreciated by participants. The 
group also suggested conducting interviews after school and at weekends, which 
again has proved to be popular with the participants in the main study.  
 
In addition to the content of the PIS, RECs also review the language. Aspinall (2005) 
suggests that the number of people who have difficulty understanding written English 
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in the UK ranges from between 400,000 to 1.7 million. This includes those who have 
English as a first language. The Royal College of Physicians (2007, 5.51) estimates 
that ‘spoken English is more often absent then present’ in adult refugees. In order to 
aid understanding, NRES (2011, 5.1.4) suggests that the PIS is written in simple, 
non-technical terms which will be understood by lay people. It goes on to give very 
clear guidance on how to assess the readability of the PIS and suggests that it should 
be sent to organisations such as the Plain English Society who will offer guidance if 
needed. Understanding technical terms used in participant information sheets can be 
a challenge for all prospective research participants. This is especially problematic 
when the trial participant does not have English as a first language, such as the 
majority of HIV positive asylum seekers and refugees. All too often RECs review 
clinical trials where the researcher has identified that the target population does not 
have English as a first language. Despite this, they do not plan to translate the PIS, 
stating that they will only recruit individuals who can understand English. While this 
does not take into account those individuals who can understand English but may 
have difficulty with the written language, it also excludes a large number of the target 
population who may contribute valuable clinical information to the study. The Royal 
College of Physicians (2007) states that asylum seekers and refugees may have 
specific health needs. However, if they are excluded from research due to lack of 
English, it is unlikely that these needs will ever be identified or acted on. Those 
researchers who do identify that their intended target population does not have 
English as a first language may arrange for the PIS to be translated. However, this 
too may be problematic. In some African countries - such as Uganda - there may be 
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several languages in general use. It would be impractical to produce such a wide 
range of PIS. As such, some individuals may be unable to access the PIS in a 
language they can understand and would have no information to base their decision 
to participate, thus being unable to give informed consent.  
 
Once the REC has approved a trial the researcher can begin to recruit. NRES (2011) 
suggests that prospective participants have at least twenty-four hours to read and 
consider the PIS prior to giving consent. There may be exceptions to this; for 
example, in trials involving emergency situations it would be impossible to delay 
treatment. At first glance, providing prospective trial participants with information 
looks easy. They are presented with the information sheet by a member of the 
research team and asked to read and discuss it with relatives and friends. Following 
this, they arrange an appointment to meet with a member of the research team who 
asks if they have any questions based on what they have read. Once these have 
been satisfactorily answered, the individual is asked to sign the consent form. 
Unfortunately, this process is seldom as streamlined in practice as it is in theory. 
Participants may lose the information sheet and miss follow-up appointments with 
research staff. By the time they attend the rescheduled appointment with research 
staff, they may have forgotten the initial discussion, thus restarting the process.     
 
Information about the trial can be communicated by any member of the research 
team. How this information is given may influence the individual’s decision to 
participate. The initial discussion of the trial may be left to the less experience 
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members of the research team such as junior doctors. In the UK, the General Medical 
Council (2009) requires that undergraduate doctors have communication training. 
Each medical school sets its own criteria and the amount of training varies between 
institutions. As in all disciplines, communications skills are perfected over time. There 
will be some junior doctors who are confident and competent communicating with 
patients, while others might find it more challenging. Their communication training 
may have equipped them to communicate bad news and to take a sensitive history, 
but they may not yet have developed the skills to ask patients to participate in a 
research study which may or may not benefit them. Experienced researchers are able 
to deal with questions such as ‘what would you do if you were in my position’? Those 
with less confidence are often reluctant to provide a response to this question. While 
this may be due to their concerns of unduly influencing the individual, it often makes 
for a very stilted conversation with the likelihood that the potential participant feels 
that their questions have not been fully answered. Sokol (2007) suggests that this can 
be addressed by phrasing the response to enhance the individual’s understanding of 
the study. He suggests that that answering questions forms part of informed consent 
process and enhances good patient centred care. In addition to enhancing the 
understanding of clinical trials, these communication skills can be adapted to enhance 
communication in other clinical settings. In contrast, Brown (2000) found that junior 
members of the research team may feel under pressure to recruit participants. 
Whether this is a real or perceived concern, it may affect the way in which information 
about the trial is conveyed to patients. They may present information about the trial in 
a more positive light, playing down any potential risks or burdens to the prospective 
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participant. I feel that communication with patients is a very important skill. As well as 
imparting knowledge about care, it enables patients to discuss concerns they may 
have about their own health and that of loved ones. As part of their training, junior 
doctors will be expected to give patients the results of tests including cancer. The 
skills they have learned to give such a difficult diagnosis can be transferred to discuss 
clinical trial, which is by far much less daunting. What may be more problematic is 
knowing how much information to give a prospective participant. As we have seen, 
the information contained in PIS varies. The researcher should be familiar with the 
trial protocol, which contains a more detailed account of the trial than can be found in 
the PIS. Less experienced researchers may stray away from the standard text in the 
PIS, and give background information which is not pertinent to their participation. 
Some participants may also want more information than is provided, while other may 
be disinclined to read even the basic information.  
 
The Royal College of Physicians (2007) states ‘the impracticality of giving full 
information has led to the saying there is no such thing as informed consent’. Gillon 
(2001) also supports this stance stating that fully informed consent is not attainable as 
it is always possible to add more information than that already given. In order to 
address this issue, Gillon suggests that the term ‘informed consent’ should be 
replaced by ‘adequate consent’ for less onerous trials, or ‘extensive consent’ for those 
trials carrying a greater possibility of risk to the individual. He suggests that the level 
of information provided to the individual should reflect the risk involved in the study. 
The two tiered system would require researchers conducting ‘simple’ trials, such as 
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those involving minimal risk to the participants, to provide a very short patient 
information sheet for participants followed by a short discussion. These individuals 
would then be required to give ‘adequate consent’ prior to participation. More risky 
trials would require the participant to give ‘extensive consent’. This would involve 
providing the participant with a longer and more complex information sheet and 
require the researcher to spend additional time with the individual to ensure that they 
have understood what is required of them. While this is similar to the current NRES 
guidance where the length of the PIS should reflect the type of study, the current 
guidelines require all information sheets to contain the basic eight elements of 
consent. Gillon’s model also challenges the current thinking that there should only be 
one level of consent. Is it possible to have different levels of consent based on the 
provision of information? I find Gillon’s model problematic for two reasons. The first of 
these concerns the level of information provided for those in the ‘adequate’ consent 
group. The eight elements already required by NRES contain basic information which 
is applicable to all types of studies. It is very unlikely that prospective participants 
would not wish to be informed about the purpose of the trial or to know if there are 
any risks and/or benefits of participation. They will want to know that they are under 
no obligation to participate, and if they do choose to participate any information they 
give will be treated with confidence. They will also want to know that there are 
arrangements in place should they be harmed and to have a contact number for the 
researcher. Without such a basic level of information, it is difficult to see how 
prospective participants can give even ‘adequate’ consent.  
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The second problem I have with Gillon’s model is who would decide if the information 
provided would lead to ‘adequate’ or ‘extensive’ consent. For some trials, the decision 
would be easy. Research which involved only the administration of a questionnaire 
would generally need a less extensive PIS than that of a clinical trial or a new 
medication. However, leaving the decision of which level of consent a trial would 
require to the researcher could lead to disparity. To illustrate, let us look at a fictional 
trial medication for acne.  Researcher one may be paternalistic and wish to spare the 
participant worry. As such, he may choose to provide them with the adequate 
information sheet which does not outline the potential side-effects of the study. His 
rationale may be based on the small possibility of actual side effects against the worry 
the participant may experience thinking about these side effects.  Unlike researcher 
one, researcher two may have a strong bias as to the potential good of the trial 
medication. To encourage participation he may provide participants with ‘adequate’ 
information, which again does not mention side effects. In contrast, researcher three 
believes strongly in maintaining the patient’s autonomy. He might feel that the patient 
should be given as much information as possible to make an informed choice about 
the new medication. This researcher firmly believes that participants in all studies - 
even those felt to carry minimal risk - should be given extensive information. From 
this we can see that even if Gillon’s model were to be adopted, guidelines would need 
to be established outlining what trials would require adequate and extensive 
information.   
 
While Gillon’s model offers different levels of information leading to adequate and 
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extensive consent, Eriksson (2004) suggests that potential participants should be 
able to choose the level of information they want about the trial, as potential 
participants are often discouraged by the length of the PIS and would rather base 
their decision to participate on the discussion they have with the researcher. Like 
Gillon, he suggests that there should be two information sheets for potential 
participants - one with limited information of the trial and a more extensive sheet for 
those individuals who want more information. However, unlike Gillon, he suggests 
that participants are allowed to choose which level of information they want. This is 
supported by Smith (2010) who found that some individuals ‘devour’ information 
about trials, while others ‘can’t be bothered putting on their glasses’. At present, 
NRES (2011, 5.1.3) suggests that a summary sheet can be provided in more complex 
trials.  This should include the voluntary nature of participation, what the study 
involves, risks and benefits and alternatives to participation. If participants go on to 
express an interest in the trial they are provided with a longer PIS which contains 
additional information. While Eriksson’s model offers the participants more choice 
than Gillon’s, it does not fully ensure that participants have a basic level of information 
to base their consent. Participants who have read only the short version could be 
missing vital information which would influence their decision to participate.   
 
Eriksson and Gillon have both offered solutions to the challenge of ensuring that 
individuals are provided with enough information to give informed consent.  Gillon 
suggests that there should be two levels of information, followed by participants giving 
either adequate or extensive consent. Eriksson suggests that the researcher should 
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offer the patient the choice of a long or short version of the PIS, leaving them to 
decide what level of information they need. I do not think that Gillon’s two tiered 
system of consent would be practical or indeed effective, nor do I think that 
participants should be given a choice of information sheets. However, I do concede 
that the current method of providing information to prospective participants is not 
effective. While I would argue that it is not necessary - or indeed practical - for 
participants to be informed about every aspect of the trial; I would argue the 
importance of keeping the eight elements. The current NRES guidelines suggest that 
researchers produce a summary sheet in addition to the main PIS for more complex 
trials. There is the risk that participants only read this and disregard the rest of the 
information. It is also impossible to compel prospective participants to read 
information sheet, no matter how long or short they are. Nor do we really know many 
participants actually read the PIS.   
 
Some individuals actively choose not to read the PIS, preferring to be guided by the 
information they receive from research staff. Despite some researchers feeling that 
the research participant does not require in-depth information about any proposed 
trial, most researchers/doctors would be very reluctant to consent a prospective 
research participant who refuses to receive any information. Researchers have a 
legal obligation under the Declaration of Helsinki (2008) to provide information which 
will enable the individual to make an autonomous choice on whither to participate in a 
clinical trial. Steiner (2006) strongly feels that research participants should not be 
permitted to reject information. He is concerned that by choosing not to have 
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information about the trial, the individual puts himself at risk of being taken advantage 
of by an ‘over enthusiastic’ researcher. Kihlbom (2007) disagrees with Steiner, 
arguing that patients are exercising their right to autonomy by giving negatively 
informed consent. It would appear that it is the duty of medical staff to protect 
participant’s autonomy by providing information, while potential participants can 
exercise their autonomy by choosing not to read that information. Let us look at some 
reasons why the individuals might opt-out of the information process. Some may have 
a genuine belief that the research project has great worth and want to participate, no 
matter how onerous the study or the potential risks of participation. Others may have 
been asked to participate by a trusted doctor and have enough faith in that doctor to 
feel assured that they will not be put at risk by participating. While the study doctor 
may be assured that the risk to the individual would be minimal, they could be 
unaware of personal circumstances where participation would be contrary to the 
beliefs of the individual. For example, the participant could be of a faith that does not 
eat meat and may be unaware that the study medication is presented in gelatine 
based capsules. While participation will not cause any physical harm, the individual 
may be psychologically distressed. Had the individual read the information 
themselves, they would have been aware of this and declined to participate. I would 
agree with Steiner that individuals should not be permitted to reject information, not 
because this could lead them to be taken advantage by doctors, but because without 
information they will not know what is required of them. For example the trial 
medication may require the individual to avoid strong sunlight, as it has the potential 
to cause painful rashes. The participant may have booked a holiday in a sunny 
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country where he plans to participate in outdoor sports.  Within two days of starting 
his holiday he develops a rash caused by the interaction between the sun and the trial 
medication, forcing him to remain indoors.  This could have been avoided had he 
chosen to read the PIS.   
 
Limitations of the current system 
As we have seen, one of the disadvantages of the PIS is that some prospective 
participants don’t fully read it, even if it is presented in lay terms. Sections describing 
the commitment of participants are often skimmed over. Depending on the nature of 
the clinical trial, they may need to make several visits to the hospital or trial site. 
Some visits can last several hours; they may have to undergo blood tests, have x-
rays and may have to fast on several visits. If they are frail or infirm, attending all the 
required visits can be difficult; some individuals may have problems with mobility and 
need to be accompanied to hospital. In this situation, the support of a relative or friend 
is vital to their ability to participate. Therefore, the PIS should clearly outline both the 
risks of participating and any potential inconvenience this may cause. Attending clinic 
visits can also prove challenging for patients who are working. I was involved in 
recruiting individuals to a clinical trial which required medication to be taken before 
bed. On a study visit, one of the participants reported missing several doses of trial 
medication. When asked why he was having difficulty, he disclosed that he worked 
shifts, alternating a week of days with a week of nights. While he was aware from the 
PIS that he was required to take the study medication at specific times, he had not 
really taken his shift pattern into account when agreeing to participate. The 
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researcher cannot be expected to have in-depth knowledge of the lifestyle of each 
prospective participant, and can only hope that the individual will be able comprehend 
what impact participation may have to them.  
 
I have discussed the different types of PIS. No matter what format is used, some 
individuals still seem unable understand what they have read. There may be several 
reasons for this, one being therapeutic misconception. The term ‘therapeutic 
misconception’ originated with Appelbaum (1982). It is defined as ‘patients believing 
that clinical trials are designed to benefit those who enrol in them’. The aim of 
research and clinical care differ in that clinical care intends to treat the patient while 
research seeks to answer specific questions. Participants in clinical trial may benefit, 
but any improvements are secondary to the research question. De Melo-Martin 
(2008) found that therapeutic misconception was greatest in trials where the 
researcher was also the patient’s physician. Despite having been clearly informed 
that they may not benefit from participation, trial participants felt sure that their doctor 
would not ask them to enter if they would not benefit from doing do. I think this is an 
understandable assumption. The General Medical Council (2010) guidelines require 
doctors to ‘protect and promote the health of patients and the public’. It is not 
therefore unreasonable for patients to expect their doctor to act in their best interest. 
As most researchers in HIV clinical trials are also participant’s clinicians, therapeutic 
misconception may be a real concern. In the UK, HIV care is generally provided in 
specialist units. These tend to be based in major cities, with patients living in rural 
areas having to travel long distances to attend clinics. BHIVA (2005) found that 
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seventy percent of patients remained with the same unit where they were diagnosed. 
The reasons listed included confidence in the skill of medical staff, friendliness of staff 
and that they felt assured that their confidentiality would be maintained. Their doctor 
will already have discussed HIV treatment with them, and will be aware of any 
problems they have experienced over the years. A relationship of trust will have been 
established, where the patient is confident that the doctor would act in their best 
interest with regard to their treatment and care. It can then be very difficult for the 
patient to accept that the doctor, in his research role, would ask them to consider 
participating in a clinical trial which may not be of benefit to them. They may believe 
that the doctor has inside information about the trial and is not permitted to tell them 
that the proposed new drug is better than the treatment they are already taking. While 
their doctor is able to assure them that the trial will be conducted as safely as 
possible and the possibility of harm has been minimized, he cannot offer assurances 
that the proposed regimen may be beneficial to them. The researcher themselves will 
be in a state of equipoise regarding the study medication; the evidence available to 
them may suggest that the treatment could be beneficial, but they will not know for 
certain until the trial is completed. The difficulty for the researcher is convincing the 
participant that they don’t know if the study HAART will be better than the treatment 
they are already taking. Should anything untoward occur during the clinical trial the 
patient may blame the doctor, believing that he/she could have prevented any harm. 
This in turn could jeopardize the future doctor/patient relationship. Clinicians who are 
involved in research need to be aware of therapeutic misconception and take 
particular care when discussing clinical trials with their own patients. They should 
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reiterate that they themselves do not know if the trial medication will benefit the 
individual, or if they will experience side effects as a result of the trial medication. 
They could at this point restate the process for informing staff of side effects, which 
might strengthen this statement. If at all possible, it would be advisable for the 
clinician to avoid recruiting their patients to trials, and appoint another member of the 
research team instead. However, this may be difficult in smaller clinics or where the 
trial is seeking to answer a specific clinical question where the clinician is regarded as 
a specialist.  
 
Another possible reason for individuals failing to understand clinical trials may be the 
way in which they are presented. Moss (2002) suggests that information about clinical 
trials is heavily weighted in favour of the potential benefits of participation, which 
patients may find misleading. This may be true to some extent, as one only has to 
look at information about clinical trials available on patient web sites to see that they 
are generally optimistic. Sites, such as ClinicalTrials.gov contain information about 
HIV clinical trials. These web sites include inclusion and exclusion criteria - an 
optimistic description of the trial but no information about potential side effects of 
participating. However, if an individual is interested in participating they are directed 
to contact a researcher. At this point, they will be given a PIS and so will have an 
opportunity to discuss the trial in more detail. The researcher should outline both the 
advantages and disadvantages of participation, including any side effects. However, 
the individual may be focused on the positive information he read initially and pay little 
heed to what he has been told. HIV positive individuals also discuss clinical trials on 
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web based forums. These sites have little or no input from clinicians or 
pharmaceutical companies. The information posted can be inaccurate and 
misleading.  
 
Dawson (2009) suggests that while there may be a failure on the part of researchers 
to provide patient friendly information which can be easily understood, it is more likely 
that the failure to understand clinical trials reflects the human ability to comprehend 
certain types of information. He states ‘The fact that a significant number of 
participants do not understand is not just a rogue result from a single study, but the 
persistent finding of numerous studies’. He goes on to suggest that if it is impossible 
to obtain informed consent, it makes no sense to require it. Dawson’s claims are in 
part supported by others. Stead (2005) interviewed a group of patients who had 
participated in a randomised controlled trial on diabetes. They had met with the 
researcher, who was also their clinician, in a Glasgow hospital. The participants had 
been given a PIS, which contained the requisite elements and had been approved by 
a REC, and were given over twenty-four hours to read it. This was followed by a 
discussion with the researcher, who answered any further questions. When 
questioned after the interview, the researcher was assured that the participants had 
been given enough information to enable them to give informed consent. This view 
was in sharp contrast with the opinion of the trial participants. Most of the group 
complained that the PIS was very difficult to understand. One patient quoted… ‘The 
first paragraphs a disaster. ‘A randomised, double-blind study to compare the 
durability…..’ Hello, hello-it’s English I speak!’ They felt that the information sheet was 
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written in technical terms, which they did not comprehend. Many of the participants 
also had difficulty with the concept of randomisation. The participants were informed 
that they would be assigned to one of three arms. One group would receive the study 
drug, the next continue with standard treatment and the final group would receive a 
placebo. They were also told that neither they nor the doctor would know who was in 
which group. Despite reading about this in the PIS and having had the information 
verbally from the doctor, many of the group continued to believe that they would 
receive active treatment and that their doctor would know which arm of the trial they 
were assigned to.  
 
The patients also had difficulty with the concept of equipoise. Even though they had 
been informed that the trial was comparing a new treatment for diabetes with 
standard therapy, and that there was not enough data yet to prove that the new 
treatment worked, most of the potential participants assumed that the new treatment 
must be better than the established treatment. The use of placebos was also not well 
understood. The participants were aware that a placebo was a ‘dummy drug’, and 
had been informed some of the patients would be given a placebo for a short while. 
They were informed that patients would be closely monitored and offered ‘rescue 
therapy’ if their blood sugar became too high. Despite this information, most of the 
group displayed a therapeutic misconception believing that they would receive active 
treatment while on the trial. They were very upset when they learned that they may 
have not been given active treatment, as they felt that it was the duty of the doctor to 
heal. By not ensuring that they were in the active arm of the trial, they felt as if the 
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doctor had failed in his/her duty. The majority of the trial participants felt that the 
researcher, who was also their clinician, would not have asked them to consider 
participating in the trial if there was any possibility that they would not benefit from it. 
They went on to say that the experience of research would have a negative impact on 
their future dealings with health care professionals, as they could not trust their 
doctor. Stead concluded ‘The consent of these people gave must have been 
‘informed’, but the information was certainly not comprehended’. Kenyon (2004) also 
found a lack of understanding in women who had participated in a gynaecological 
trial. Individuals were asked to complete questionnaires following participation to 
establish what they believed were the aims and objectives of the trial. While the PIS 
was highly valued as a source of information, the participant’s interpretation of 
information did not reflect the true nature of the study. Poor recall of trial information 
was seen in fourteen percent of responses. While these studies had very different 
aims and were conducted in different locations, the issues raised by participants are 
very similar. Researchers felt that they had fulfilled their obligation by providing 
information sheets and discussing the trial, and were satisfied that the participants 
had understood enough to give informed consent. This is in contrast with the views 
held by the participants who found the PIS difficult to understand, and had not fully 
understood the explanation given by researchers.  
 
The basic elements of informed consent outlined by the International Conference on 
Harmonization (ICH) guideline for good clinical practice (1996) focuses on the 
provision of information on the clinical trial for the prospective participant. The World 
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Health Organization (1993) guidelines go a little further, requiring the researcher to 
seek consent only if they are satisfied that ‘they (the subjects) have adequate 
knowledge of the facts’. No mention is made as to how the researcher might establish 
that the ‘subject’ has this knowledge, or what constitutes ‘adequate knowledge’. While 
the lack of understanding will not affect the results of the trial, can researchers truly 
be seen to respect the autonomy of the individual if they don’t ensure that participants 
understand the information they have been given? Beauchamp and Childress (2001) 
state that for informed consent to be morally satisfactory the individual needs to 
demonstrate competence by understanding the provision of information and then 
making a decision based on that understanding. They suggest that while it may be 
unreasonable to fully inform an individual in some circumstances - such as complex 
medical procedures - it is possible to ensure that individuals are adequately informed 
in order for them to make an informed choice. We have seen that the provision of the 
PIS alone may not be sufficient to provide information about trials. While I would 
agree with Dawson that participants have difficulty understanding PIS, I would 
disagree that this justifies removing the requirement to seek informed consent. I 
believe that there must be a more effective way of communicating information. 
Individuals have the capacity to understand complex information and act upon it. For 
example, we have seen a rapid expansion in the communications industry. Items 
such as internet enabled telephones and digital books are common place. The 
instructions that come with these items are often very complex, yet most people have 
no difficulty understanding how to use them. How does the way in which we process 
this information differ from information given in a PIS? Certainly, some of the 
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concepts found in the PIS - such as the use of placebos - are not common in 
technology. However, some aspects of new technology can be just as challenging. 
We need to look at how people learn and understand, and apply this knowledge to 
developing new and more effective methods of communicating trial information.  
 
Can we improve the information giving process?  
If we agree that the provision of the PIS alone is not enough to engender 
understanding about a clinical trial, what steps can we take to improve understanding 
using the tools already at our disposal? Current practice requires researchers to 
discuss the proposed trial with potential participants and answer any questions they 
might have following the provision of a PIS. This is often viewed by researchers as a 
formality prior to obtaining consent, and they may not spend enough time with the 
individual to check if they had understood the trial. Katz (1984) was concerned that 
the provision of information, as outlined above, did not facilitate understanding. As 
such, he trialled a model based on conversation where informed consent was viewed 
as a mutual and participatory process. The individual was encouraged to ask 
questions and share ideas with the person taking consent. This enabled the person 
taking consent to have a clearer understanding of the participant’s understanding and 
how involved they wanted to be in the process. Brody (1999) further developed this 
conversational model of consent, where the researcher spoke with the client, not to 
them. In this model the process of obtaining consent is part of an on-going dialogue 
with the individual. It encourages them to ask questions, which they may have felt 
self-conscious about raising in the traditional consent process. It also encourages 
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them to change their mind should they realise that participating does not meet their 
expectations. Participants are much more involved in the research process and are 
likely to have greater understanding about the trial and what it means to them than 
those consented by the standard method. They may feel more motivated to follow all 
the requirements of participation, such as attending clinic visits, if they are better 
informed of the importance this has on the outcome of the study.  
 
Bhopal (2008) looked at ethical codes for undertaking research with ethnic minority 
populations. He began by hypothesising that research with ethnic minority groups 
could be problematic due to cultural and language differences. He states that while it 
is not practical to create separate codes for all ethnic minority groups, researchers 
need to consider potential influences which might require a different approach to 
research. He felt that this approach could include arranging for information to be 
translated into appropriate languages, or to arrange same sex interviewers. He 
argues that in order to offer a fair and just approach to research all research 
participants should be treated equally. I strongly support his hypothesis. Cultural 
practices can affect research, and prior knowledge can be invaluable in overcoming 
potential problems. For example, when I first started working as a researcher with the 
African community, I could be waiting for up to an hour for participants to arrive. I 
finally asked a colleague, who is from Uganda, for advice. When she had stopped 
laughing, she explained that in Africa people generally had a much more relaxed 
attitude to time keeping. I was already aware of this having lived in Africa for many 
years, but had not applied this knowledge to my clinical work. While a relaxed attitude 
126 
 
to time may only be an inconvenience in a clinical setting, the research setting is quite 
different.  Blood samples in the trial had to be collected at specific times as they were 
collected by a courier and shipped to a central laboratory. She suggested that I 
approach time keeping in a different way. When scheduling their next appointment, 
she suggested that I should ask participants if they would be keeping British or 
African time. I was initially quite concerned about taking this approach, feeling that 
they would think that I was being rude and insensitive. However, all of the participants 
were very amused by the question, some asking if I had been given inside information 
into African time-keeping! I was able to use this opportunity to inform them why time 
keeping was important during the study. Time keeping did improve, but so too did my 
clinical practice. I arranged for appointments to be half an hour earlier than they were 
scheduled which meant that even if participants were late, I still had time to get the 
blood couriered to the lab on time. Had I taken into consideration the cultural 
differences around time keeping prior to recruiting, I would have been less anxious 
and more able to deal with late appointments. I have taken this lesson into 
consideration and now always include a section on why time keeping is important 
when I am writing participant information sheets. Cultural aspects play a significant 
role when conducting research. 
 
Hill (2006) held focus groups with African women, asking for their input in designing a 
PIS and consent form which would be readily understood by them. The tool which 
they developed was very different to the guidelines provided by NRES. It involved the 
use of metaphors to explain complex concepts and the use of visual aids. The groups 
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felt that it was important to provide information in small portions over multiple visits, 
where the individual has time to discuss the research in a relaxed setting, and have 
any questions answered prior to giving consent. This is in contrast to the current 
method where provision of information and consent is completed in two visits. The 
groups also felt that it was important for researchers to have a good understanding of 
the cultural background of the prospective participants, in order to contextualise 
questions.  
 
While the conversational method described by Hill would certainly ensure that 
information is provided in a culturally acceptable manner, it is likely that there would 
be resistance from researchers in the UK setting. Multiple visits would require them to 
spend much longer with participants, which may not be possible if they have clinical 
commitments. Conversational methods of information giving may be more difficult to 
use with individuals who do not have English as a first language, such as HIV positive 
asylum seekers and refugees. However, some HIV researchers in the UK are 
beginning to look at different ways of imparting trial information to ethnic minority 
groups. While these practices are not yet wide spread they are proving to be 
effective. One method which has proven successful builds on the close relationships 
developed by clinics and community support groups. African HIV community groups 
have arranged for clinicians to be present on specific trials which their members have 
expressed an interest at an informal community event. It was agreed that the clinician 
would present at the end of the meeting, following the support group but after food. 
This timing allowed those who did not want to ask questions themselves to pass on 
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their questions to the chairperson. It was also established that this was not to be 
viewed as a recruitment opportunity by the clinician. Those who wanted further 
information about the trial/were interested in participating could collect a PIS at the 
end of the session and contact the researcher at a later date. Participants have 
reported that they have benefited from this format. They felt more likely to ask 
questions about trials in this type of setting without feeling that they had to commit to 
participate. They also felt supported to ask questions by their peers. The clinicians 
also found the experience useful. Apart from gaining an insight into concerns voiced 
by the community, they also found the social setting helped to further their 
understanding of African culture, including the cuisine. This is an adaptation of the 
conversation method discussed by the participants in Hill’s focus group. While it does 
not involve multiple information giving sessions, it does allow potential participants the 
opportunity to ask questions which they may not feel able to do in a one-to-one 
setting. This may result in a better understanding for the individual on what 
participation would entail, enabling them to make an informed choice. However, 
concerns still remain about lack of comprehension if the individual does not have 
English as a first language. Both groups suggested that the use of visual aids such as 
CDs and DVDs could be used to provide information to individuals who cannot read 
or understand English. While it may be impractical to have written translations of all 
documents, provision of information in an oral format can be tailored for the individual. 
Recordings could be made of the information given to the participant by the 
researcher during the initial trial visit translated by the interpreter. This would be 
dependent on the researcher having access to recording materials and the participant 
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having the necessary equipment to view the information. The use of conversation 
methods to convey trial information should be used as a supplement to enhance 
understanding of the clinical trial, but should be supported with a PIS.  
 
We have seen that both conversational and PIS methods of providing information 
may be hampered by the individuals lack of understanding of English, or the 
researchers lack of other languages. While the individual’s level of English may be 
sufficient for day to day use, it may be insufficient to understand trial information. In 
order to overcome language difficulties researchers may utilize the services of 
interpreters. If an interpreter is to be used, they should be an accredited translator, 
holding the Institute of Linguists’ Diploma in Public Service Interpreting or a similar 
qualification. Interpreters should also be aware of the need for confidentiality, and 
have signed a contract to that effect. While interpreters employed by the NHS are 
bound by the same confidentiality as all other NHS employees, trial participants may 
still be concerned that they will relay their HIV status to their community. This is of 
particular concern if the individual comes from a minority group where there is a 
strong possibility that they will be known to the interpreter. As well as concerns about 
individual confidentiality, it can be difficult for prospective volunteers to deal with the 
interpreter’s response to their HIV status. I have had interpreters decline to translate 
as they have recognized the name of a family member and felt that it would not be in 
either of their interests if they were to identify themselves to a relative.  
 
Researchers themselves may need to be trained to work with translators. Phelan 
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(2003) suggested that doctors often give a long, technical explanation to interpreters 
and expect them to impart this information to patients. In clinical research, this can be 
particularly difficult, when patients need to have a clear understanding in order to 
make an informed choice. It may be useful for researchers to develop a closer 
working relationship with the organizations which are tasked to provide interpreters. 
The researcher and organization could work together to develop a training package 
for interpreters - giving an overview as to the aims and objectives of clinical trials. 
This would help to ensure that interpreters have a greater understanding of research 
and understand the need to providing an accurate translation of patient information. It 
may also be useful to use the same interpreter throughout the trial. This will both 
reduce the need for the researchers to have to explain a specific trial to a range of 
individuals as well as allaying any concerns the participant may have of disclosing 
personal details to a range of individuals.  
 
Some prospective trial participants bring a relative with them to translate. This 
practice is discouraged for many reasons. In HIV trials, it is easy to assume that the 
relative is aware of the individual’s status if they have been brought to translate by the 
patient/research participant. However, this is not always the case. One of my 
colleagues was placed in the unenviable position of a having a relative interpret the 
PIS for an HIV trial only to be asked ‘So, is my relative HIV positive’? The patient 
thought that it would be an ideal opportunity to inform their relative of that they were 
HIV positive. This was not a view shared by either the researcher or the relative, who 
were both quite upset by the experience. Even if the relative who is translating is fully 
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aware of the health status of the prospective participant, their level of English may not 
be sufficient to translate and understand the PIS. Breen (1999) found that twenty-
three–fifty-two percent of adhoc interpreters misinterpreted words or phrases. This is 
a real concern in the research setting, where understanding is necessary prior to 
giving consent. If participants are not given the correct information on which to base 
their decision to participate, any consent given would be void. The relative may also 
have strong views on trials and may translate the information in such a way as to 
influence the individual’s decision to participate. For these reasons, it is generally 
agreed that if the information cannot be provided in the patient’s native tongue or a 
neutral translator be provided, the individual should be excluded from participation. 
While this could hamper recruitment to clinical trials, it is better than recruiting 
individuals who may not have sufficient understanding of the information to give 
informed consent.  
 
A useful alternative to face-to-face interpretation is the use of telephone translation 
services, such as Language Line. This service is widely used in NHS premises and 
by some of the larger HIV charities. This form of interpretation can be very useful for 
individuals who are concerned about confidentiality as the interpreter is not visible to 
the prospective volunteer. However, this service has its limitations. Unlike 
conventional interpretation services where an interpreter is booked for a specific time, 
telephone interpreting is dependent on having an interpreter on hand who speaks the 
required language. It may be time consuming in a clinical trial setting waiting for an 
interpreter to be found. It can also be problematic passing the phone from person to 
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person if there is not a hands free telephone available. This may also break-up the 
spontaneity of the discussion, and some important aspects can be missed. 
 
Having given the participant information about the trial can researchers be sure that 
they have understood it? The answer to this must be no. Some researchers try to 
overcome this by asking participants to recount a brief outline of the trial. While this 
may give the researcher an insight into the participant understanding, it cannot 
comprehensively cover all aspects of the trial. Stead (2005) suggests another way to 
check understanding would be to pilot the PIS within the target population and follow 
that with a questionnaire. This would enable the researcher to identify any recurring 
problems of understanding and perception and modify the text as necessary prior to 
submitting it for ethical approval. This is supported by NRES (2011) who recommend 
the involvement of patient groups in research. However, having the PIS proof read by 
the target population does not guarantee that it will be understood by an individual 
participant. Is it possible to check participants understanding? Ames (2008) suggests 
that the participant should be given the PIS to read, which is then followed by a short 
multiple choice questionnaire to assess their understanding. Depending on the 
answers they have given, the researcher should provide a more detailed explanation 
on those aspects which needed clarity. While I think that Ames suggestion has some 
merit in that researchers spend more time discussing the trial, my overall opinion is 
that it would deter individuals from participating. Few people enjoy examinations and 
this method, for some, would feel like being back at school. It would also be of little 
use to participants who did not have a good understanding of written English, such as 
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HIV positive asylum seekers and refugees, excluding them from a process which they 
wished to participate in. It is also likely that this method would require additional or 
longer visits to the clinic, which could also act as a deterrent. However, I do accept 
that researchers need some method to ensure that participants have a basic 
understanding of any trial. Unlike Ames, I do not feel that it is necessary for 
prospective participants to complete a questionnaire to check their understanding. 
Nor do I think it is necessary for prospective participants to make numerous visits to 
see the researcher prior to commencing the trial. It is current good practice for 
researchers to take time to discuss the PIS with prospective participants and address 
any concerns they may have. It is not enough to ask the individual ‘Have you read the 
information sheet? Do you have any questions? Good, sign on the dotted line’. This 
happens all too often. The individual is often discouraged from asking questions, and 
can feel foolish if they do so. The information giving process should comprise of open 
questions about the main aspects of the trial. These open questions should be 
designed to facilitate a two way conversation between the researcher and prospective 
participant, but not give the individual the impression that they are being interrogated. 
During this process, the researcher can correct any misconceptions about the trial 
and encourage the individual to ask any questions which they might have. Some may 
have difficulty understanding concepts such as randomisation, equipoise and 
placebos. The researcher may need to work with patient groups to deliver this 
information in language which can be easily understood by prospective participants. 
When discussing the trial, the researcher will need to take into account that the 
prospective participant may have difficulty articulating the aims and objectives of the 
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trial. This may in part be due to language difficulties, but may also reflect their 
educational background. While individuals may not be able to give a technical 
explanation of the study, they should be able to demonstrate that they have 
understood the risks and benefits of participating and be aware how participation 
could impact their daily activities.   
 
There may be resistance from researchers to change. Some may be concerned that 
they do not have the skills to use conversational methods and would need additional 
support and training.  Others may opt to delegate consent taking to another member 
of the research team who is more skilled in communication. It is of no concern which 
member of the research team undertakes this task, as long as they are able to 
communicate in an effective manner. Some might argue that they do not have time to 
spend away from their clinics. Others may be concerned that better information may 
result in a reduction in the number of participants; after being fully informed of their 
obligations some individuals could decide this is not for them. While these points are 
valid, the additional methods of providing information provide an opportunity to 
discuss the trial with a large number of individuals. They may in turn discuss the study 
with others, thereby increasing the number of potential participants. Better informed 
participants will be aware of any burdens associated with the trial and may be less 
likely to drop out at a later date. Further research would be needed to support the 
claim that these additional methods do indeed increase recruitment and retention to 
trials. We have seen the standard process does not always convey information. In 
order to ensure that consent is informed, the research community may need to re-
135 
 
think how information is provided to trial participants in general - and HIV positive 
asylum seekers and refugees in particular. 
 
Conclusion 
I this chapter I have argued that the current methods of providing information to HIV 
positive asylum seekers and refugees is not effective. No matter what their 
background, those participating in clinical trials appear to have difficulty understand 
the information they have been given. Their lack of understanding could be based on 
inadequate provision of information, how the information was imparted or - as 
Dawson says - people just don’t understand. Possibly, it is a combination of all three. 
Two questions remain. Should researchers permit individuals to participate in clinical 
trials where there is doubt that they have understood information they have been 
given, and if they do so can they be said to be respecting that individual’s autonomy? 
Furthermore, having agreed to participate when they do not fully understand a trial, 
can the individual really have been said to have given informed consent? 
 
I will start by addressing the first question. It is very difficult for researchers to 
measure exactly how much information an individual has retained. The individual 
could have understood but been unable to articulate that understanding. They may 
appear to have understood, but have missed pertinent information. Researchers 
should be able to clearly demonstrate that they have taken every practical step to 
explain the clinical trial to the individual, taking into consideration cultural factors. 
However, I would argue that if there are any doubts about understanding, researchers 
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should weigh up the potential harm the participation may incur as a result of 
participation. In trials which carry minimal risk, such as where participants have to 
complete a questionnaire and give a blood sample, the individual is unlikely to come 
to any harm even if they cannot fully demonstrate understanding to the researcher’s 
satisfaction. For more complex trials, the risk to the individual would be much higher. 
For example, participants may agree to a lumber puncture having failed to understand 
that this is likely to be painful. If there is a risk of harm and the participants 
demonstrates a lack of understanding, they should not be permitted to participate. 
Some would argue against this stating that the individual has a right to self-
determination. In daily life we certainly have the right to make choices based on 
information which we have misunderstood. I would argue that this is different in the 
clinical trials setting. Even if the participant agrees to a procedure without fully 
understanding it, the researcher still has a duty of care to ensure that the patients are 
not harmed by participation. If he were to recruit a participant and then subject them 
to a procedure that had not been understood, resulting in pain or discomfort, they 
would be failing in that duty. 
 
I will now look at the second question of informed consent. Participants do not need 
to aware of every nuance of the trial, but should be able to demonstrate a basic 
understanding. As we have seen earlier, it is always possible to add additional 
information. I would argue that the participant should - at minimum - know what 
participation in the trial would mean for them. This includes any risks and benefits and 
how much time they will need to dedicate to participation. If they cannot demonstrate 
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this basic information, any consent they give will certainly not be informed.  
 
We have looked at different methods to communication trial information. NRES 
(2011) provides comprehensive guidance for researcher to support them in designing 
information sheets. Despite these guidelines, PIS are often written in very technical 
terms which are meaningless to the target population. This is of particular concern 
where clinical trials involve HIV positive asylum seekers and refugees. While many 
will be able to understand spoken English, they may have difficulty reading and 
understanding the PIS. The NRES guidelines (2011) state that ‘providing an 
information sheet is just one part of seeking consent’. Despite this, NRES provides 
little guidance to researchers or RECs on what these additional methods might be. 
There is also no guidance on how these methods could be presented to the REC. For 
example, the REC I sit on was asked to review a particularly complex clinical trial. 
The researcher had included a very long PIS which attempted to describe the trial, 
but which many members of the REC had difficulty understanding. The researcher 
attended the committee meeting where he was asked to clarify exactly what was 
expected of the participant. He produced a flip chart and equipment and went on to 
give a very clear and entertaining demonstration on the use of the medical device 
under investigation and the impact this would have on the participant. He explained 
his team used this method to impart information to patients in a clinical setting, and 
planned to do so for prospective participants in the trial. When he was asked why he 
had not included this in the PIS, he stated that there was no place to describe the 
demonstration in the ethics submission. This outlines the challenges researchers face 
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when they wish to utilize addition methods of providing information. If we are to give 
weight to the findings of Hill (2006), the use of demonstrations may be more 
acceptable and effective when describing clinics to individuals from sub-Saharan 
Africa, including HIV positive asylum seekers and refugees. Therefore researchers 
planning to conduct research with this population should be supported to utilize 
innovative methods of information giving.  
 
The role of the REC is pivotal to the information giving process. As part of their role, 
they review PIS to ensure that it reflects the trial protocol and provides enough 
information to enable the individual to make an informed choice. Researchers are 
required to make changes to the PIS prior to gaining approval for the trial. While the 
subsequent draft is generally improved, it may still be lacking in clarity. These 
‘improved’ information sheets are often approved as RECs may be reluctant to delay 
the clinical trial due to pressure from NRES. In order to improve provision of 
information, RECs need to be more open to novel and innovative methods, whilst 
ensuring that individuals have enough information to make an informed choice. RECs 
should support researchers to be more creative in the provision of trial information, 
especially for individuals who have language or cultural needs. While this will be 
challenging and would need support from NRES, it would improve the provision of 
information. Unless improvements are made it is likely that information given to 
participants in clinical trials will remain a written exercise, used to tick regulatory 
boxes but not really support understanding.  
 
139 
 
Chapter 7 
Consent -Vulnerability and voluntariness  
Being HIV positive alone may not increase an individual’s vulnerability in the 
research setting. For example, one of my patients is a solicitor in full-time 
employment. He has his own home, a long-term partner and good social support. 
While being HIV positive may make him vulnerable in some aspects of his life, his 
decision to participate in an HIV clinical trial was based on a desire to contribute 
towards the development of future treatment. In contrast, another patient is a 
Sudanese refugee who is appealing to remain in the UK on compassionate grounds. 
He is not permitted to work, is dependent on benefits and lives in a hostel with little 
support. While he did not really want to enrol in the trial, he felt that participation 
would give weight to his asylum claim. While both these patients are HIV positive, the 
Sudanese patient is more vulnerable in the research setting due to his asylum status.  
 
In the previous chapter I looked at the issue of providing information in a way which 
enables the individual to understand the proposed trial and thereby give informed 
consent to participate in it. Once the researcher has ensured that the individual has 
understood the aims of the clinical trial and is aware of any risks and benefits of 
participating, can they then go on to assume that the individual is in a position to give 
informed consent to participate? The answer to that is no. In order to give valid 
consent, the individual needs to have information on which to base their decision, to 
be competent to make that decision, and give their consent voluntarily. Whilst poor 
information undermines voluntariness, there are other factors which can influence the 
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individual’s decision to give informed consent. This chapter seeks to address some of 
the issues which are specific to HIV positive asylum seekers and refugees 
participating in clinical trials in the UK.  
 
In this chapter I will begin by discussing the role of vulnerability in the research 
setting. Some researchers do not consider that HIV positive individuals are more 
vulnerable than any other research participant. I will argue against this view and 
outline areas which may increase their vulnerability in the research setting. I will go on 
to argue that while they may be more vulnerable, they should not be excluded from 
research provided that steps are taken to minimise the increased risk. In the second 
half of the chapter I will discuss the role of ethics committees in protecting those 
considered vulnerable, and look at ways in which ethics committees could be more 
proactive in research involving HIV positive asylum seekers and refugees.  
 
While all individuals are vulnerable to some degree when participating in clinical trials, 
some individuals may be more vulnerable than others. Traditionally groups such as 
prisoners, children, etc. are considered vulnerable by NRES. If a researcher intends 
to conduct research on these populations, he is first required to justify why the 
research cannot be conducted with another study population. For example, 
researchers will only be able to establish the efficacy of antiretrovirals in children by 
conducting trials in HIV positive children. If the REC accepts that the use of a 
vulnerable population is justified, the researcher then has to outline the measures 
which he intends to take to protect the individual’s autonomy, protect them from harm, 
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and protect them from exploitation.  
 
Who is vulnerable in research? 
While researchers are required to protect the vulnerable in the research setting, there 
is no consensus on who is to be considered vulnerable. For example, the Declaration 
of Helsinki (2008) outlines in detail measures researchers are required to take to 
protect vulnerable research subjects without providing a definition of those considered 
to be vulnerable. The Council for International Organizations of Medical Sciences 
(CIOMS 2002) does provide researchers with a definition of those who may be 
considered vulnerable. These include ‘those who are relatively (or absolutely) 
incapable of protecting their own interests because they may have insufficient power, 
intelligence, education, resources, strength or other needed attributes to protect their 
own interests’. While this definition clearly outlines the attributes of the individual, it 
may not be very helpful for researchers who are tasked with identifying a vulnerable 
population. For example, it would be unlikely that all participants in the trial lack 
intelligence. Identifying specific groups who may be more vulnerable may be easier 
than looking at individual characteristics.  
 
The International Conference on Harmonisation Good Clinical Practice (ICHGCP 
1996) guidelines expands the list of those considered vulnerable to include those 
within a hierarchical setting. There guidelines state: 
 
Individuals whose willingness to volunteer in a clinical trial may be unduly 
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influenced by the expectation, whether justified or not, of benefits 
associated with participation; or of a retaliatory response from senior 
members of a hierarchy in case of refusal to participate. Examples are 
members of a group with a hierarchical structure, such as medical, 
pharmacy, dental and nursing students, subordinate hospital and 
laboratory personnel, employees of the pharmaceutical industry, 
members of the armed forces, and persons kept in detention. Other 
vulnerable subjects include patients with incurable diseases, and persons 
in nursing homes, unemployed or impoverished persons, patients in 
emergency situations, ethnic minority groups, homeless persons, 
nomads, refugees, minors and those incapable of giving consent. 
 
The ICHGCP guidelines reflect the requirement of NRES for researchers to justify the 
inclusion of vulnerable individuals and, if they are selected, what means will be 
applied to protect their rights and welfare. Unlike the NRES guidelines, the ICHGCP 
identify refugees as a vulnerable group.  
 
I am now going to look at some of the varying accounts of vulnerability and highlight 
some of the common themes.  
 
Leight (2003) defines vulnerable populations as social groups who have increased 
susceptibility due to adverse health outcomes. These groups are less likely to have 
access to health resources, and be at greater risk than the general population. Her 
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definition is supported by Reeder who also highlights that the lack of access to health 
care increases the vulnerability of the individual. I agree with both writers. Those of us 
fortunate to have access to NHS treatment do not worry about becoming unwell, 
knowing that we will be able to access medical care should we need it. Those who do 
not have access to this service worry about what will become of them should they 
need this care and be unable to pay for it. While antiretroviral medication is now 
available for HIV positive asylum seekers and refugees, they can still be charged for 
any other health related illness. As such, the fear of becoming unwell is very real to 
this population. 
Kottow (2003) discusses the difference between vulnerability and susceptibility. He 
states that all human beings are vulnerable and as such we should all be afforded the 
same protection in research ethics. He suggests that the principle of justice should 
offer protection to all who are ‘vulnerable’ i.e. all human beings, while those who are 
‘susceptible’ need a specific intervention. This feels to me very much like vulnerability 
under a different name. Kottow offers a list of criteria to distinguish those who are 
predisposed to additional harm. These include the poor, undernourished or those 
lacking in medical care. He suggests that labelling individuals as vulnerable is 
misleading. He prefers the term susceptible. He offers a definition of vulnerable as 
being intact but fragile, while susceptible suggests injured and predisposed to 
additional harm. He suggests that having an awareness of the difference between 
those who are vulnerable and those who are susceptible should help to remove the 
double standards in research ethics.  He states that if the term vulnerable is replaced 
by susceptible, it would offer more protection to those who are already 
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disadvantaged. I disagree with Kottow for a number of reasons. Those considered 
vulnerable in the research setting at the moment tend to belong to specific groups, 
such as children and prisoners; the individual characteristics of that person are not 
taken into consideration. Firstly, and on a pragmatic level, identifying individuals who 
are susceptible to additional harm through poverty, lack of food or medical care may 
be very difficult in the research setting. Researchers are unlikely to want to ask 
questions which are, for many of us, of a sensitive and personal nature. While asking 
these questions on an individual basis would enable researchers to take each 
person’s circumstances into consideration, what they do with that information is 
difficult. Would they have to say to the person; ‘I’m sorry you can’t participate, you are 
too poor?’ This might further increase the isolation felt by that individual, whose 
decision to participate may have been based on an altruistic desire to help. While the 
system we have in place at the moment is not perfect, it does allow researchers to 
identify vulnerable populations and identify measures they plan to take to protect that 
group. Reimbursement of travel to all participants will enable less wealthy individuals 
to attend appointment and not be out of pocket. Secondly, Kottow suggests that 
labelling those who are poor, undernourished or lacking in medical care as 
susceptible will somehow afford them special protection. This is no different than the 
present system where vulnerable populations are identified and researchers initiate 
measures to protect them. I find it difficult to see how labelling individuals as 
‘susceptible’ could afford additional protection to those in need. Accepting that there 
are individuals whose particular circumstances may increase their risk in clinical trials; 
would it not be more effective to raise the standard of care for all clinical trials 
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participants, so that all are afforded a high standard of care, no matter what their risk? 
This would reduce the need for labelling and the possibility of stigmatising those 
already disadvantaged, and would ensure that those who want to participate in 
clinical trial are supported to do so.  
 
Levine (2004) argues that the concept of vulnerability is both too broad and too 
narrow. By too broad, she suggests that so many groups in research are now 
considered vulnerable that the concept of vulnerability has lost its force. She suggests 
that being labelled as vulnerable only offers limited protection. In contrast to Kottow, 
she argues that by focusing on group characteristics of vulnerability, we are in danger 
of overlooking other factors which put research participants at risk of physical harm, 
such as flawed trial design. She goes on to argue that defining all members of a 
group as vulnerable does not take into account the individual characteristics of the 
members of that group. She argues that people can be vulnerable in some situations, 
but not in others. She suggests that all those involved in research should develop a 
standard tool to identify the vulnerable. This will enable the research community to 
provide a more targeted form of protection. I agree with Levine to some extent. Firstly, 
by nature of participating in trials most participants are to some extent vulnerable. 
They are exposed to new drugs, procedures and processes which may - to some 
degree -render the individual vulnerable to harm. The term vulnerable should only be 
applied to those who are at increased risk from participation over and above the 
background risk. I also agree that defining all members of a group as vulnerable does 
not take into consideration the individual characteristics. For example, those recruited 
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to HIV clinical trials will all be HIV positive. However some participants will be in full-
time employment, have English as a first language and have agreed to participate for 
altruistic reasons. In contrast, other HIV positive participants may be refugees, have 
little English and have enrolled in the trial in the hope that it will positively influence 
the outcome of any asylum application. While both groups may be vulnerable due to 
their medical condition, those in the former group have additional characteristics 
which increase their vulnerability in the research setting. Finally, Levine suggests that 
researchers should get together to develop a tool to identify the vulnerable. This may 
have some merit, but it is difficult to see how this would work in practice. As we have 
seen, researchers have very differing views on what constitutes vulnerability in the 
research setting.  
 
Kipnis (2004) argues that individuals are vulnerable in the research setting if they 
have a medical condition for which there is no known cure. He suggests that 
researchers choose these patients for research due to their vulnerability as they may 
be willing to undergo risks that other research participants would not, due to the fact 
that they have no other option. He argues that research with individuals who have a 
terminal illness where there is no safe effective treatment can be acceptable, 
provided that they are informed and aware that the treatment may not be effective. I 
agree that this group are vulnerable in the research setting for the reasons Kipnis 
outlines. Those with no viable treatment options may take risks in the hope of 
expanding their lifespan. I disagree that researchers target this group due to their 
vulnerability. While it is true that this group are vulnerable due to their medical 
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condition, Phase Two to Four trials require individuals who have the condition which 
may respond to the trial medication. The participant’s vulnerability and medical 
conditions are intertwined; researchers have no choice but to recruit from this 
population. How does this relate to HIV treatment? HIV is now regarded as a chronic 
manageable condition. However, overtime the virus can become resistant to 
treatment. Those who have developed resistant strains of the virus will eventually 
succumb to opportunistic infections and die. For this group the only option to extend 
their lifespan is to participate in clinical trials involving new classes of antiretrovirals. 
These participants are vulnerable due to their medical condition but are recruited to 
trials because they have a resistant virus.  
 
While it may be difficult to outline all the ways in which individuals may be vulnerable, 
I believe that a working definition for the purpose of research should include those 
who lack competence, have compromised voluntariness and have physical or 
psychological impairment. Using the above definition I will now go on to show how 
HIV positive asylum seekers - as a group - are vulnerable in the research setting and 
will argue that they should be considered as a vulnerable population by NRES.  
 
Lack competence 
When recruiting to a clinical trial, researchers must ensure, (as far as possible) that 
the prospective participant is competent to consent. They may not have sufficient 
English to understand the aims and objectives of the trial and the risk of participation, 
or they may lack capacity to consent.  In chapter 6 I discussed measures which would 
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enable those with language problems to participate, including the translation of written 
materials, and the use of informed translators. I will now discuss those who lack 
capacity to consent. The Adults with Incapacity (Scotland) Act 2000, the Mental 
Capacity Act 2005 and the Medicines for Human Use (Clinical Trials) Regulations 
2004 require that those without capacity should be involved in the decision to 
participate. Researchers should ensure that the content of trial information provided 
for these prospective participants can be understood by them. These PIS should be in 
a clear format and should include an overview about the trial as well as any risks and 
benefits of participation. Researchers also need to take additional time discussing the 
study with this group, answering any questions in lay terms. If there is any question 
that the participant does not have the capacity to consent, and the trial involves 
investigational medicinal products, the is the Medicines for Human Use (Clinical Trial) 
Regulations 2004 requires the investigator to seek consent from a legal 
representative. The legal representative is under no obligation to undertake this role if 
they do not wish to. Seeking consent from a legal representative may be problematic 
if the potential participant is HIV positive. In order to give informed consent the legal 
representative will be required to read the PIS, which will outline that the trial is 
seeking to recruit HIV positive participants to take part in a drug trial. The legal 
representative may not be aware of the HIV status of the prospective participant; thus 
breaching the individuals confidentiality. As we have seen earlier, those who are HIV 
positive still face stigma. Should the individual regain capacity, they could find 
themselves ostracised by their community. Some might argue that the potential harm 
caused by a beach in confidentiality outweighs the potential benefits of participation in 
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the clinical trial. However, there are some research questions which can only be 
answered by enrolling those who lack capacity. For example, Yanofski (2008) 
highlighted the need for further research looking at the interactions between 
antiretrovirals and antidepressant medications. Since this article was written, new 
classes of antiretrovirals have been licensed, which are necessary to treat drug 
resistant virus. Individuals who are developing drug resistance and are also being 
treated for depression may benefit from these drugs, but research will be needed to 
establish whether these new antiretrovirals are safe to take with antidepressants. 
Cohen (2009) also found higher levels of depression in HIV positive asylum seekers 
and refugees than both the general population and those who have HIV who are not 
asylum seekers and refugees. Clinical trials are needed to establish the safest and 
most effective of treating HIV positive individuals with depression. This type of trial will 
need to recruit depressed patients, some of whom may lack capacity or loose 
capacity during the trial should their mental health deteriorate. If researchers can 
justify the importance of conducting research with this population, I would suggest 
that there is a case for appointing an independent legal representative if the HIV 
status of the individuals is unknown to family and friends. It may be difficult to ask the 
family if they are aware of the individuals HIV status without breaching confidentiality 
as this is often kept a secret. However, it is standard practice in all HIV clinics to 
record who the patient has disclosed to. An independent legal representative could be 
appointed to consent in these situations.  
 
Compromised voluntariness 
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I will now look at ways in which HIV positive asylum seekers and refugees may be 
vulnerable due to compromised voluntariness. For a decision to be considered 
voluntary, the individual should be free from undue influence. There are different 
forms of undue influence; coercion, perceived coercion, rational persuasion, 
manipulation and undue inducements. Our clinic works closely with a local HIV 
support organisation, where clinic staff give an update on new developments in HIV 
on a monthly basis. At the end of these sessions we have a question and answer 
session where members of the group pick a topic they want to discuss. On several 
occasions this has been around clinical trials. Many of the members of the support 
group have participated in trials, and the majority of those who have not have been 
asked to do so. One of the issues which have been discussed several times is 
recruitment to clinical trials. Members of the support group stated that they feel under 
pressure from medical staff to participate in clinical trials. This view is reflected by 
Nelson and Merz (2002) who believe that certain behaviours on the part of the 
researcher can persuade, manipulate or coerce potential research participants. The 
support group I have spoken with have given a number of reasons for this, which I will 
give examples of during this section.  
 
I will begin by looking at coercion and perceived coercion and will use examples given 
by the support group to illustrate how this could influence the individual’s decision to 
participate in a clinical trial. The Oxford Dictionary defines coercion as impelling or 
forcing into obedience. The individual does not have to give into this force, it is 
enough that they felt under pressure to comply. In its guidance document on good 
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clinical practice in clinical trials, the Institute of Clinical Research (1996) requires 
researchers to meet stringent criteria in the process of obtaining consent. In point 
4.8.3 it expressly instructs investigators that “Neither the investigator, nor the trial 
staff, should coerce or unduly influence a participant to participate or continue to 
participate in a clinical trial.” As mentioned in the previous chapter, most HIV 
physicians are involved in clinical research, recruiting from patients who attend their 
clinics. As HIV treatment is life long and patients are seen on a regular basis, it is not 
unusual for doctors and patients to get to know each other over a number of years. 
Patients may be grateful for the care provided over the years and feel an obligation to 
enrol in a clinical trial as they perceive this as helping their doctor. Their cultural 
background can make it more difficult to refuse a request from someone perceived to 
have a high status. Most doctors who have experience working with clients from sub-
Saharan Africa are aware of the power imbalance and will take that into consideration 
when discussing clinical trial. However, there are others who exploit their position to 
increase recruitment to a trial. For example; Dr A suggests that he might not have 
time to write a letter of support for patient B, but he might be able to make time if 
patient B was one of his special research patients. While patient B does not really 
want to participate, he does need the letter of support as his immigration appeal is 
due next week. As such, he reluctantly agrees to participate. The doctor has not said 
out-right that he would not write the letter. It may be that the doctor only meant that he 
would not be able to write the letter immediately and would eventually get round to 
writing it. However, the patient perceived that the letter would not be written unless he 
agreed to participate. Perceived coercion can be as detrimental to valid consent as 
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actual coercion. Patients might feel that despite the doctor’s assurance that they will 
not be disadvantaged by declining to partake in a clinical trial, any refusal may 
jeopardise support for their staying in the UK. Even experienced researchers may be 
unaware that the way in which they ask patients to participate in a clinical trial can be 
open to misinterpretation. One member of the support group recounted that she had 
been asked to participate in a trial following a discussion with the doctor about her on 
going asylum appeal. She assumed that the offer to enrol was linked to the asylum 
appeal and agreed to participate thinking that it would support her application. Having 
worked with the doctor in question for several years, I asked her permission to 
discuss this with her. The doctor was horrified to think that the patient had linked her 
appeal with the trial, and arranged to discuss it with the patient at the earliest 
opportunity. The patient did decide to continue with the trial but was now very clear 
that it would not help her asylum claim. The doctor also resolved to be more careful 
about when she discussed clinical trials in the consultation. This outlines the need for 
those in in a position of power to take care when discussing trials with asylum 
seekers and refugees.  
 
The obvious solution to the problem of coercion or perceived coercion would be for 
doctors who have a dual role as researcher and clinician not to enrol their own 
patients in clinical trials. Indeed, this is the NRES ‘gold standard’. However, this may 
not be practical for several reasons. In smaller units there is usually only one doctor 
who has responsibility for the clinical trial. If he is also responsible for the patient’s 
care then the patient may have no choice but to see him. While most trials employ 
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research nurses who could discuss the trial with the participant, there may be aspects 
of the trial which will need to be discussed with the principal investigator, which is the 
doctor. In larger hospitals, HIV units can have several doctors who may be involved 
with the same trial. In this case, it may be possible for another medic to discuss the 
trial and take consent. If the patients’ doctor is the only one who can consent, and the 
patient is keen on participating, he may suggest that the patient attend another unit 
for study visits. This too may be problematic. There may not be another hospital 
involved in the same trial within easy travelling distance. The prospective participant 
may be reluctant to travel long distances, especially if the trial involves numerous 
study visits. Additionally, it may have taken the prospective participant some time to 
overcome their fear of stigma and discrimination and to build up a trusting relationship 
with medical staff. They may be reluctant to see someone else or be concerned that 
they might encounter someone they know in a new hospital and have to explain why 
they are there.  
 
Another form of undue influence is manipulation. The Cambridge dictionary defines 
manipulation as ‘controlling someone or something to your own advantage often 
unfairly or dishonestly’. HIV positive asylum seekers and refugees could be 
manipulated to enrol in clinical trials in a number of ways. One of the participants 
attending the support group had been told by a researcher that the immigration 
authorities looked favourably on those who people who participated in trials. Luckily, 
she discussed this with her solicitor prior to enrolling and was informed that this was 
not the case. However, she was clear that had it been true, she would have enrolled 
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in the trial.  
 
Other participants felt that they had not been given enough information by 
researchers prior to agreeing to participate and thus felt that they had been 
manipulated into participating due to their lack of knowledge. This was the case for 
two of the members of the support group who had enrolled in the clinical trial for the 
antiretroviral Fusion (T20), which needs to be injected at regular intervals to be 
effective. The participants stated that the researcher had omitted to mention that the 
preparation of these medications was very time consuming. Participants found 
themselves having to plan their normal activities around their next dose. When 
challenged by other members of the support group, they said that the PIS had 
specified the preparation time, but had not bothered to read this information feeling 
certain that the researcher would have informed them of any important aspects of the 
trial. It is possible that the researcher had genuinely not considered that preparation 
time would influence the decision to participate, but the members of the support group 
felt it more likely that he did not want to lose prospective participants as it was a 
difficult trial to recruit to.  
 
Prospective participants can also be manipulated to participate if they are led to 
believe that they will benefit from the trial. While researchers may have reasonable 
grounds to suspect that the trial medication could be effective, they are not in a 
position to give a categorical assurance to research participants that this will be the 
case. Some of the support group stated that they had agreed to enter a clinical trial 
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because their doctor seemed to be really enthusiastic about the new drug.  
 
While these methods may be employed by researchers, the most common method of 
encouraging participation is by employing rational persuasion.  Rational persuasion 
involves presenting a case based on facts that the individual already knows to 
persuade them to act in a certain way. For example, rational persuasion may be used 
to persuade a cyclist to wear high visibility clothing at night to reduce the risk of being 
hit by a car. The cyclist will know that he is more likely to be seen if he is wearing a 
fluorescent vest. He will also be aware that cyclists have a greater risk of being 
involved in road traffic collisions than other road users. Despite not being keen on 
wearing high visibility clothing, it is difficult for him to argue that this is not a sensible 
course of action to take. The researcher could employ this method to recruit to an HIV 
clinical trial. For example, the prospective participant is developing a drug resistance. 
Despite taking treatment as prescribed, his CD4 count is falling and he has a high 
viral load. He is aware that he will need to change to another class of antiretrovirals 
which will be more efficacious, and that his choice is limited due to the drug 
resistance. The researcher informs him that he is recruiting to a new drug trial on a 
new class of antiretroviral which could be effective in those with his type of drug 
resistance. If the researcher is aware that the prospective participant understands the 
need to change treatment and that the new trial drug has the potential to work, he 
could employ rational persuasion as a means of encouraging participation.   
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I will now look at inducements in clinical trials. Under clinical trials regulations 
researchers are permitted to offer inducements to trial participants, though these 
inducements must not be so large as to influence participation in clinical trials.  These 
often take the form of vouchers or merchandise with the study label, such as 
sunglasses for those participating in studies relating to sun screening products. 
Researchers are also expected to recompense participants for any out of pocket 
expenses, such as travel and sustenance. The Nuffield Council on Bioethics (2002) 
does not have a problem with inducements unless they are excessive or if people are 
desperate, such as those who are in need of health care in developing countries. The 
Belmont Report (1979) defines undue inducements as ‘an offer of an excessive, 
unwarranted, inappropriate or improper reward or other overture in order to obtain 
compliance’ and goes on to state that inducements in clinical trials can be problematic 
if the offer is large enough to override the individual’s better judgement. The CIOMS 
guidelines state that ‘if inducements are to be offered that should not be so large, 
however, or the medical services so extensive as to induce prospective participants to 
consent to participate in research against their better judgement’.  
 
Researchers need to carefully consider inducements if they plan to recruit HIV 
positive asylum seekers and refugees to clinical trials.  UK nationals who agree to 
participate in clinical trials may do so for a variety of reasons. They may have an 
altruistic desire to help others; they may be generally interested in research and want 
to have the opportunity to experience participation in a clinical trial. Others may be 
motivated to contribute to research for personal reasons, such as the development of 
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a disease in a loved one. Apart from participants in Phase One trials, which I do not 
intend to discuss here, very few will agree to enrol in a clinical trial for financial 
reasons, as the inducements are deliberately so small so as to not be a motivation for 
participation. Lott (2005) suggests rewards which the general population would not 
consider an incentive may be viewed as such by those who have very little. I agree 
that this may be the case for HIV positive asylum seekers who have no access to 
funds. For example, trial participants who are UK nationals would tend to view a thirty 
pound voucher per study visit as surplus pocket money. For HIV positive asylum 
seekers and refugees this may be the only funds they have access to and will use the 
voucher for basic essentials, such as food. This small inducement may be enough 
incentive to encourage participation.   
 
Non-financial rewards for participation, such as medical treatment and care, may also 
be viewed as an inducement. Most UK nationals who are eligible for NHS treatment 
do not have any concerns about being charged for medical care even if out of work, 
as the NHS provides free treatment to all who are eligible. This is not the case for HIV 
positive asylum seekers and refugees. As discussed earlier, while they may 
theoretically have access to antiretroviral therapy, it is still subject to the interpretation 
of the NHS regulations by individual trusts. Some who are eligible may be charged 
and told that they can no longer access treatment until they pay. Some choose to 
access treatment via a clinical trial to ensure that they have continued access to 
treatment without the need to endure the legal quagmire. While they are a participant 
in a clinical trial they will also see medical staff during their routine study visits, where 
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they will be able to discuss any new health issues. The researcher can arrange 
clinical investigations to establish if the condition is related to the study medication. If 
it is related, it will be treated as a study related condition. Unrelated conditions would 
not be eligible for treatment either under the clinical trial or under the NHS. Is it ethical 
for researchers to investigate conditions which cannot be treated? It could be argued 
that if the prospective participant is informed during the consent process that new or 
unrelated conditions will not be treated under the clinical trial, and they agree to 
participate with that knowledge, the researcher has no obligation to treat. It could also 
be argued that the researcher will not know if the condition is trial related unless he 
conducts investigations, therefore the investigations are an intrinsic part of the study. 
However, if the investigations prove not to be study related, is it ethical for the 
researcher to withdraw the individual from the study without treatment, even if the 
individual has agreed this on the consent form? The Principal Investigator in HIV 
clinical trials is a doctor. Each doctor has a duty of care to his patients, whether in a 
clinical setting or research setting. I would argue that when the participant is enrolled 
in the clinical trial, the researcher assumes a duty of care towards that individual, 
including treating for any conditions which arise while the participant is under the care 
of the researcher. It would be unethical for the researcher to discharge having 
established that he has a condition which needs treatment without arranging for that 
treatment to be made available. If the participant is not eligible for NHS treatment and 
care, the researcher should arrange for the treatment to be available through the trial 
budget.  
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Harris (2010) states that the current guidelines - such as the CIOMS outlined above - 
are generally unsympathetic to the use of inducements in clinical trials. He also 
suggests that the CIOMS rational for these guidelines such as ‘someone without 
access to medical care may or may not be unduly influenced to participate, in 
research to receive such care’ are confused.  
 
He goes on to explore the factors which make an inducement undue. He does not 
believe that the level of the inducement undermines better judgement, or that the 
inducement influences the individual’s decision to participate. He suggests that if this 
premise were true then 
 
‘all jobs with attractive remuneration packages would constitute ‘undue’ interference 
with the liberties of subjects and anyone who uses their better judgement to decide 
whether a total remuneration package plus job was attractive would have been unduly 
influenced’.  
 
Harris differentiates between inducements which are undue, and undue inducements. 
The former refers to the nature of the inducement, not to the fact that it is being 
offered. The latter is the improper offering of inducements, improper because no 
inducements should be offered. He suggests that the guidelines refer to undue 
inducements, which are ‘wrongly understood and wrongly applied’. I do not agree with 
Harris’ premise that the level of inducement undermines better judgement, or that the 
inducement influences the individual’s decision to participate. Many people would be 
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tempted to enrol in a clinical trial despite the risks if they were offered a large sum of 
money. This amount would vary depending on the personal situation of those asked. 
Certainly HIV positive asylum seekers and refugees who have no access to funds 
could be easily induced to participate against their better judgment. However, Harris’ 
definition of an undue incentive could certainly be applied in this situation. It would be 
improper to offer inducements in this situation.  
HIV positive asylum seekers and refugees may regard on-going health care as an 
inducement to participate in a clinical trial. The challenge researcher’s face in HIV 
trials is how to avoid inducements if participation in itself is the inducement. For many 
HIV positive asylum seekers and refugees, the inducement to participate is access to 
medical staff and antiretroviral medication. Researchers cannot remove this 
inducement, for they are integral to the conduct of the study. In order to address this 
issue, I want to return to the Belmont Report’s definition of inducement ‘an offer of an 
excessive, unwarranted, inappropriate or improper reward or other overture in order 
to obtain compliance’. I would agree that the provision of antiretrovirals may be 
viewed as an inducement, but I do not believe that the inducement is undue. As such, 
I believe that there is no intrinsic problem with permitting HIV positive asylum seekers 
and refugees to enrol in HIV clinical trials. While it would be correct to assume that 
some participants enrol in the clinical trial as a means of accessing treatment, others 
do not. We cannot assume that all HIV positive asylum seekers and refugees enrol in 
clinical trial for the sole purpose of accessing treatment and care. Indeed, some may 
have the same motivation as other individuals, such as a desire to further clinical 
knowledge and help future patients. While researchers may be aware that some 
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participant’s motivation for enrolling in the trial is to access treatment, they are not 
setting out with the sole intention of recruiting from this population. The provision of 
antiretrovirals is an intrinsic part of the clinical trial. Providing them to participants 
cannot be considered ‘excessive, unwarranted, inappropriate or improper’ as 
inducement. However, the individual’s lack of recourse to medication by any other 
means may certainly induce them to participate. While the researcher may not be 
offering treatment as an inducement, would the individual agree to participate in the 
trial if they could access treatment by any other means? Researchers could try to 
address this by assessing those potential participants who are HIV positive refugees 
and asylum seekers with a view to excluding those to whom access to an 
antiretrovirals may be an inducement. However, it is difficult to see how this could be 
achieved given that not all HIV positive asylum seekers and refugees enrol for the 
sole reason of accessing treatment and care and those who do are unlikely to state 
this is their reason for doing so. If we agree with Harris, it is the nature of the 
inducement which makes it undue. If antiretrovirals are an integral part of the clinical 
trial, it is difficult to see how they could be considered as an undue inducement in a 
clinical trial. 
 
 
Psychological impairment   
HIV positive asylum seekers and refugees may also be vulnerable in the research 
setting due to the physical and psychological effects of both HIV and their refugee 
status. I do not intend to discuss vulnerability due to lack of access to antiretrovirals 
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as this has been covered in pervious chapters. Instead I will look at some of the 
psychological aspects of HIV which can increase vulnerability in HIV positive asylum 
seekers and refugees in the research setting.  
 
Kalichman (2010) reported that stress - coupled with poverty and lack of access to 
adequate diet - influenced the ability of HIV positive individuals to adhere to 
treatment. This is certainly a situation which I have seen reflected in clinical practice 
in London. HIV positive asylum seekers and refugees often report that they are 
unable to take their antiretrovirals as prescribed. They may be housed with strangers 
in a hostel situation and be unable to store their medication as required for fear of 
others finding them and thus being alerted to their HIV status. Others report that they 
have had no money to purchase food and so have had to take their antiretrovirals on 
an empty stomach, which for some reduces absorption. Those who have failed their 
asylum appeals in the UK are not permitted to work - neither do they have access to 
social care. The National AIDS Trust (2010) reported that many of these individuals 
are dependent on voluntary organisations for the basic essentials. While this group 
may have access to antiretrovirals, the effects of poverty and lack of food increases 
their risk of developing drug resistant strains of the virus.  
 
Antelman (2007) also reported high levels of anxiety, depression and posttraumatic 
stress disorder in asylum seekers. Many bear the scars of interrogations and torture, 
while a large number of both women and men reported being raped. Some have seen 
family members and loved ones killed and have suffered unimaginable terror fleeing 
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from oppressive regimes. These issues can have devastating and long term effects 
on the individual. They can also influence how they deal with others they perceive to 
be in a position of authority, such as medical staff. For example, during a routine 
hospital visit, the researcher may ask if they would be interested in participating in a 
clinical trial. They will be informed that participation is voluntary and that they are 
under no obligation to enrol. They will also be informed that their treatment at the 
clinic will not change should they decline to participate. However, their previous 
experiences make it difficult to believe that they will not face sanctions if they defy 
authority, in this case the researcher. In order to protect themselves from any 
retribution, they agree to participate.   
 
Leaning (2001) suggests that refugees’ lack of legal rights increases vulnerability. 
This is certainly true of those HIV positive asylum seekers and refugees who access 
clinical trials as a means of having continued access to treatment and care. They may 
not have chosen to participate if they had other options. They are also at risk of 
dispersal and deportation, which could affect their ability to continue to take 
antiretrovirals, potentially leading to the development of drug resistant strains of the 
virus.   
 
While antiretrovirals have an important role in maintaining health, their ability to cross 
the blood-brain barrier may be limited. Heaton (2011) reported that HIV related 
neurocognitive impairment remains prevalent in this population, despite access to 
antiretrovirals. The effects of this impairment are subtle and may be missed by those 
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who have limited clinical experience. Valcour (2011) found that when questioned, 
patients seldom reported having any noticeable neurocognitive problems. However, 
on testing they had marked neurocognitive delay. If this condition is as prevalent as 
described, will it influence the individual’s ability to consent for participation in clinical 
trials? The CHARTER study, described by Valcour, began recruitment in 1997 in the 
USA. It recruited 1600 HIV positive individuals’ at all clinical stages and on a range of 
antiretrovirals. Half the participants were male, and half were either black American or 
African American. The number of refuges and asylum seekers was not reported. All 
the recruits underwent neurological testing under controlled conditions. The study is 
being extended to establish what - if any - effects these results have on the day to 
day functioning of HIV positive individuals. For the moment, it is unclear if these 
results will affect the individual’s ability to understand and consent to clinical trials. 
However, the CHARTER study also reported high levels of suicide and suicidal 
ideation in the study population. The study did not record the immigration status of 
individuals so it is not possible to establish if the suicide risk was increased in this 
sub-population.  
 
It would appear that HIV positive individuals are vulnerable to some extent due to the 
psychological effects of HIV. This psychological vulnerability is increased in those 
who are also asylum seekers and refugees.  
 
Should vulnerable populations be permitted to enrol in clinical trials? 
I have outlined some of the ways in which HIV positive asylum seekers and refugees 
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are vulnerable in the research setting. Some might argue that if this population is so 
vulnerable in the research setting they should not be permitted to participate in clinical 
trials. I disagree with this statement. Despite their vulnerability, I believe that this 
group should not be excluded form research. I will now go on to give reasons 
supporting this.  
 
Is it necessary to recruit HIV positive asylum seekers and refugees to HIV clinical 
trials? Given their vulnerability, why recruit from this population at all? Some might 
consider that it would be more ethical to conduct HIV research on less vulnerable 
populations. Leaning (2001) suggests that the risk to refugees and asylum seekers 
from participating in research should not stop research from going ahead. Some 
research questions can only be answered by research within that population. I agree 
with Leaning and believe that the inclusion of HIV positive asylum seekers and 
refugees is essential to the development of new antiretrovirals. Antiretrovirals trials 
need to recruit HIV positive individuals to participate; it would be impossible to 
establish the safety, efficacy and resistance profile of new drugs without including this 
population. HIV positive individuals who are antiretroviral naïve are particularly 
valuable in the development of new drugs. UK nationals are more likely to be 
treatment experienced. Even those newly diagnosed may have acquired drug 
resistance, which excludes them from some clinical trials. However, asylum seekers 
and refugees are more likely to be antiretroviral naïve, which increases their value to 
researchers. In order to demonstrate the efficacy of new treatments, clinical trials 
need to have enough power to show a statistical significant. Given the number of HIV 
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clinical trials being conducted in the UK, I believe that it would be difficult to recruit 
fully to trials without the inclusion of HIV positive asylum seekers and refugees. 
Leaning goes on to remark that while the inclusion of refugees and asylum seekers is 
needed, there is little guidance on conducting research in refugee populations for 
researchers. She also believes that refugees and asylum seekers should be classed 
as vulnerable as this would afford them some protection in the research setting.  
 
Lott (2005) suggests that vulnerable populations are attractive to researchers 
because of their vulnerability. This may be true to some extent in HIV positive 
populations. For example, an inexperienced researcher may be under pressure to 
recruit to an HIV clinical trial. He has a large cohort of patients, the majority of whom 
are eligible for NHS treatment and care; he has tried to recruit from this population 
with limited success. However, some of his patients are refugees and asylum seekers 
who are appealing to remain in the country on compassionate groups, and require 
him to complete medical reports to support that application. While both groups are 
HIV positive, those entitled to NHS treatment and care will not be dependent on the 
researcher to provide letters of support for immigration authorities. The researcher 
cannot exploit that vulnerability to compel them to participate in a clinical trial.   
 
One way to stop vulnerable individuals from being exploited would be to exclude them 
from research. This method was employed by The South African Clinical Trials 
Regulatory Authority. It had become concerned that vulnerable populations were 
being coerced into trials, indeed between 1997 and 1998, the number of clinical trials 
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increased by forty percent. These participants tended to have low levels of literacy 
and come from impoverished backgrounds. They were paid for their participation and 
some were also offered food vouchers. In order to combat what The South African 
Clinical Trials Regulatory Authority viewed as exploitation, it declared that all Phase 
One HIV trials participants should have completed twelve years of formal education. 
This was intended to protect participants by ensuring that they were able to 
understand the aims of the trials and give informed consent. However, as less than 
twenty percent of the population achieved this level of education, many of those who 
would have wished to participate were not able to do so. The response of the 
authorities certainly reduced the number of individuals who could be recruited to 
clinical trials, potentially limiting exploitation of vulnerable. I have a problem with this 
response for a number of reasons. While the increase in numbers recruited was 
undeniable, there was no evidence that this was due to coercion. If this were the case 
it would signify that the vast majority of researchers were acting in an unethical 
manner, which I feel to be unlikely. The South African Clinical Trials Regulatory 
Authority also justified this response on the inability of participants to understand 
consent forms. The low literacy levels of those participating in research reflect the 
levels seen in the general population. A more sensible approach would have been to 
require information to be imparted in a way which addressed the literacy levels. 
These individuals did not lack intelligence and capacity; they had not had the benefit 
of secondary education. Restricting access to the better educated skews any data 
collected as it is not representative of the population. The final point I take issue with 
is that it is the implication that it is wrong for individual benefit from participation. 
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While researchers can’t offer participants’ assurances that they will benefit from the 
trial medication, there are other advantages of participation. Steiner (2006) suggests 
that these include improved personal health, the positive feeling that comes from 
giving to others and being treated as partners in the research. For this vulnerable 
population the health benefits may include access to medical care, as well as access 
to food vouchers which will combat malnutrition and thus provide health gains. These 
participants were also being paid each time they attended a study visit. The 
authorities felt that this was an inducement, which could influence the individual’s 
participation. The researchers argued that the amount of money was not large 
enough to be considered an inducement and that it was necessary to offer payment 
to ensure that participants returned for follow-up visits. The researchers concern that 
participants would not return unless they were paid would suggest that payment did 
influence participation. Why do we consider it wrong to pay participants when we 
think that it is OK to get paid for our time and effort in other situations? Many of us go 
to work each day. We have agreed our role with our employer, go to work each day, 
fulfil our duties and get paid for our efforts. This is no different from research 
participants. They agree to participate, attend study visits and get paid. These 
individuals are giving their time to the researcher. They will be undergoing clinical 
tests which may be painful and may be taking trial medication which could have side 
effects. Is it wrong to reward them for their efforts? Of course not. However, it would 
be wrong for the researcher to exploit their need for money to get them to participate 
in the clinical trial in the first place.  
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Harris (2010) states that we have a moral obligation to participate in scientific 
research, which can prevent serious harm and provide significant benefits. 
Participating in clinical trials benefits society by finding cures for diseases. He states 
that we have a moral obligation to help others ergo we should participate in clinical 
trials. He does go on to say that research should be underpinned by the obligation of 
the researcher to do no harm. As such, he must weigh up the harms and benefits and 
be able to justify the rational for the research. I agree with Harris that we have a moral 
obligation to help others, and that this could be fulfilled by participating in a clinical 
trials. However, I might have compelling reasons why I can’t participate and wish to 
help others in other ways. Indeed, there are not enough clinical trials worldwide to 
allow us all to participate, even if we had the desire to do so. If we agree that we have 
a moral obligation to participate in clinical research, it would be wrong to deny HIV 
positive asylum seekers and refugees the right to participate in clinical trials. 
However, they too can opt out of participation if they so choose. Harris goes on to 
suggest we have an obligation under justice to contribute to research. We all benefit 
from the fruits of research therefore we reciprocate. While I agree with this in general 
terms, it can be problematic in HIV research where the HIV population is small. The 
number of HIV trials is increasing year after year; there are observational trials, drug 
trials, and neurological based trials. The notice boards in clinics are papered with 
information about forthcoming trials and how important these are. If it were not for the 
requirement to have a break between trials, individuals could move from trial to trial 
year on year. Researchers stress the importance of these trials and are often 
unaware that the individual has trial fatigue and just needs some time to be a person, 
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not a clinical trial statistic.  
 
HIV positive asylum seekers and refugees are particularly vulnerable due to their lack 
of access to health care. While they may legally be entitled to antiretrovirals while 
waiting to be deported, they may find it difficult to overcome obstacles to access 
these drugs. In addition, while they can access emergency services, they are not 
entitled to NHS treatment and care and may be charged if they become unwell. In 
order to have regular access to antiretrovirals and medical treatment, some HIV 
positive asylum seekers and refugees enrol in clinical trials.  They may not have 
chosen to enrol in a clinical trial if they had any other means of accessing care; 
without continued access to treatment and care they are at risk of developing 
opportunistic infections and eventually death. Some argue that HIV positive asylum 
seekers and refugees vulnerability - due to their need access treatment and care - 
precludes them for participation in clinical trial. I would suggest that those who enrol 
in trials as a means to access treatment do so after having carefully weighed up their 
choices, and choosing the option which has the best outcome for them. Some might 
argue that this need to access care invalidates consent. Wilkinson (2003, p.80) 
presents an alternative to this. He states that it would be quite bizarre to rule out the 
possibility of valid consent if the individual has no acceptable alternatives. He gives 
two reasons for reaching this conclusion. He begins by saying that it is difficult to 
specify non-arbitrarily what counts as a sufficient number of good alternatives. HIV 
positive asylum seekers and refugees have limited options. None of these options are 
ideal, but some may be some more attractive than others. Secondly, he thinks it 
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strange that if one had an entirely free choice between option X, which is extremely 
good, and option Y, which is extremely bad, than that the person could not validly 
consent to X because of lack of acceptable alternatives. Let us apply this to our HIV 
positive asylum seeker. Option X would be accessing health care and option Y would 
be death. It would be bizarre if the individual chose death when the other option is so 
much more attractive.  
 
I believe that there are compelling reasons to permit HIV positive asylum seekers and 
refugees to enrol in clinical trials, despite their increased vulnerability in the research 
setting. They have the same moral obligations to participate in research as the rest of 
society, and should not be denied the opportunity to contribute if their decision to do 
so is given freely. Some may enrol as a means of accessing health care, which for 
them would be a benefit of participation. Provided that the risks of participating do not 
outweigh their health care needs they should be allowed to participate. Singh (2006) 
suggests that over protectionism can lead to unethical outcomes. I believe that over 
protectionism in the form of denying HIV positive asylum seekers and refugees 
access to clinical trial can result in lack of medical treatment and care leading to ill 
health and death. This would be unethical and detrimental to this population.  
 
The role of the ethics committee in protecting vulnerable populations.  
As part of their role, RECs ensure that researchers take the appropriate measures to 
protect vulnerable populations from harm. Neither the Declaration of Helsinki nor the 
Council for International Organisations of Medical Sciences (CIOMS) specifically 
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mentions refugees when discussing vulnerable participants. In the UK, HIV positive 
asylum seekers and refugees are not recognised as a vulnerable population by 
NRES. It is left to the discretion of the individual researcher to indicate on the ethics 
application form if they consider this group to be vulnerable, and then outline what 
measures they plan to take to address any ethical issues of recruiting them to a 
clinical trial. I am a member of a research committee which reviews HIV clinical trials 
on a regular basis. While I recognise that researchers are not required to recognise 
refugees and asylum seekers as a vulnerable population, I find it quite concerning 
that many of these doctors fail to highlight any ethical considerations.  Indeed, a few 
have argued that those living with HIV are no more vulnerable in the research setting 
than any other population. All work within the HIV setting and care for patients who 
are asylum seekers and refugees. They will have attended multidisciplinary meetings 
where other team members such as social workers and psychologists discuss issues 
which have a bearing on the patient’s well-being. In their clinical role they are 
responsible for writing supporting letters for asylum appeals. It is inconceivable that 
these doctors will be unaware of the vulnerability of this group of patients in a clinical 
setting. However, they seem unable to relate this to clinical research. Provided that 
there are no other ethical issues, the REC seldom challenges the assertion of the 
researcher and grants approval for the study.  
 
Nicholson (2002) too does not preclude vulnerable individuals participating in a 
clinical trial. However, he does stipulate that the level of vulnerability should be 
reduced as far as possible by researchers and research ethics committees. He 
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suggests that this can be achieved by ensuring that the individual has understood the 
research, is free from duress and able to give voluntary informed consent. While I 
agree with Nicolson that RECs need to do more to protect the vulnerable, I believe 
that they need to do much more than just checking understanding and ensuring that 
participants are free from duress.  
 
I do not believe that RECs go far enough to protect the interests of HIV positive 
asylum seekers and refugees in the research setting. This may be due to the lack of 
knowledge about the needs of HIV positive asylum seekers and refugees. It may also 
be due to the desire not to slow down research which was discussed earlier in this 
chapter. Some might argue that the failure of NRES to consider HIV positive asylum 
seekers as a vulnerable population constrains RECs to what measures that 
researchers can take to address any vulnerability in clinical trials. While identifying 
this population as vulnerable would undoubtedly afford them more protection, RECs 
can take measures under the existing guidelines which will afford an increased level 
of protection to this population. If HIV researchers have not highlighted any ethical 
considerations in their application, the REC can ask if they expect HIV positive 
refugees and asylum seekers to be included in the study population. If they confirm 
that this population will be included, they should be asked to outline any ethical 
concerns and what measures they intend to take to address these issues. 
Researchers who say that they do not intend to recruit from this group should be 
asked if they have considered the demographics of the proposed research 
population. Unless the researcher specifies a group that is unlikely to include HIV 
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positive asylum seekers and refugees, The REC should - as above - ask him to 
outline any possible ethical considerations and measures he would take to address 
these. I believe that the REC is justified in asking for these measures. Their role is to 
protect the well-being and safety of trial participants. Unless these measures are 
taken, HIV positive asylum seekers and refugees will continue to be vulnerable in the 
research setting.  
 
Summary 
In this chapter I have outlined some of the reasons why I think HIV positive asylum 
seekers and refugees should be considered as a vulnerable population in research. 
These are multifactorial; this group suffers from chronic ill health from a condition 
which requires lifelong treatment to keep it under control. While HIV positive asylum 
seekers and refugees are legally entitled to antiretrovirals until they are returned to 
their country of origin, they may find barriers to treatment due to local bureaucratic 
practices. In addition, while they can access emergency treatment for other 
conditions, on-going treatment is still chargeable. While antiretrovirals can stop viral 
replication, they too have side effects. As such, those who have the virus are at 
increased risk of developing depression and other psychological conditions. 
Depression too is more common amongst asylum seekers and refuges, with HIV 
positive asylum seekers and refugees at the greatest risk from psychological distress. 
Their refugee status also engenders them more vulnerable. They may find it difficult 
to decline participation in a clinical trial if they are asked to do so by someone they 
perceive to be in a position of authority, such as a doctor. They are often reliant on 
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medical staff to provide letters of support for asylum claims. The individual’s cultural 
background can also make it difficult to refuse a request which comes from someone 
with a perceived higher social status, such as a doctor.  
 
Despite their vulnerability, there are measures which can be taken which will afford 
HIV positive asylum seekers and refugees additional protection in the research 
setting. Firstly, NRES should recognise that asylum seekers and refugees are a 
vulnerable population in research and add them to the list of those considered 
vulnerable on the IRAS application form. The REC should ask researchers who are 
conducting HIV clinical trials if they plan to recruit from this population and if so what 
measures they have in place to protect them. Those who lack capacity should not be 
excluded from research but an independent legal representative should be appointed 
to consent on their behalf if the family are unaware of the individuals HIV status. 
While I consider HIV positive asylum seekers and refugees to be vulnerable in the 
research setting, I do not believe that this should stop them from participating in 
research. I believe that employing the measures outlined above will reduce the risk of 
harm, thus enabling them to participate in clinical trials if they so wish.  
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Chapter 8- Conclusion 
While HIV cannot be cured, it can now be kept under control with antiretroviral 
medications. In countries such as Britain, where there is access to treatment, HIV is 
now considered to be a long-term medical condition similar to diabetes. Public 
awareness of HIV has also improved. While some stigma remains, campaigns by 
both the government and HIV charities have done much to dispel myths around 
transmission. In contrast, the outlook is poor for those who either live in areas where 
they have no access or are unable to afford treatment. Until 2012, HIV positive 
asylum seekers and refugees in Britain who had their asylum claims refused were not 
eligible for treatment. In order to continue treatment, some enrolled in clinical trials. 
While the majority of asylum seekers and refugees now have access to treatment and 
care, there still remains confusion around the eligibility criteria. THT (2012) reports 
that HIV positive individuals are being denied treatment that they are legally entitled 
to receive, or being charged for treatment which should be free to them. As such, 
some individuals may be afraid to access treatment which they are eligible for. Some 
are also concerned that the eligibility criterion will change yet again, leading to further 
withdrawal of treatment. This assertion may be justified to some extent in light of 
David Cameron’s recent speech (2013) where he outlined the governments is plans 
to ‘toughen up’ on asylum seekers and refugees. As such, some asylum seekers and 
refugees choose to access clinical trials as a means of accessing treatment. 
 
In this thesis I have looked at some of the ethical issues surrounding the recruitment 
of HIV positive asylum seekers and refugees to HIV related clinical trials in Britain. 
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While all participants in clinical trials are vulnerable to some extent, I have shown that 
HIV positive asylum seekers and refugees are at a increased risk. Despite this, HIV 
positive asylum seekers and refugees are not given specific consideration in the 
research setting. In this final chapter I will reiterate what I believe to be the main 
areas for concern and outline what measures should be taken to address these 
issues.  
 
Researchers applying for ethical approval for studies in the UK are required to do so 
using the IRAS system. Researchers are asked if they plan to recruit from vulnerable 
populations and are provided with a list of those considered to be vulnerable by 
NRES. If the intended target group is considered to be vulnerable, the researcher 
must outline what measures they intend to take to ensure that the participants are not 
further disadvantaged by participating in the trial. Their responses are assessed by 
the REC prior to issuing approval. HIV positive asylum seekers and refugees are not 
listed as a vulnerable population on the IRAS application form. It is left to the 
discretion of individual researchers if they want to identify them as such and outline 
what steps they plan to take to address their needs. We have seen that HIV positive 
asylum seekers and refugees are vulnerable in the research setting. They are 
vulnerable due to their immigration status; they may feel under pressure to enrol in 
trials as they need letters of support from their physician to submit to immigration 
authorities. They are vulnerable because they have HIV; without access to medical 
treatment their prognosis is very poor. Participation in a clinical trial may be one 
means of accessing treatment. They may be vulnerable due to their cultural 
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background; they may find it difficult to decline to participate in a clinical trial if asked 
to do so by someone they perceive to have a high social standing. They may be 
vulnerable due to lack English as a first language; they may not understand 
requirements of trial participation. Unless they are identified as a vulnerable 
population they will continue to be at increased risk in the research setting. In order to 
rectify this, NRES should recognised HIV positive asylum seekers and refugees as 
vulnerable. Once they are identified as a vulnerable population, researchers will then 
be required to identify the measures they intend to take to deal with issues, which 
should include all of the measures listed below.  
 
We have seen that some HIV positive asylum seekers and refugees enrol in multiple 
clinical trials and may also over-participate by enrolling in back to back trials. This 
practice is not confined to HIV positive individuals enrolling in clinical trials but is seen 
in other study populations who are not HIV positive. This practice can be dangerous 
for the individual, who may be subjected to numerous clinical tests and drugs. It can 
also affect the integrity of the trial data. The TOPS scheme has proven to be very 
effective in reducing this practice in Phase One trials, where a register is kept of 
participants and available to other trail centres. Participants are required to give a 
unique form of identification, such as a passport or NI details shared with other trials 
In order to rectify. The TOPS scheme should be expanded to include Phase Two to 
Four clinical trials in order to reduce the risk of multiple and over-participation. This 
may be more challenging for trials involving asylum seekers and refugees as many 
will not have passports or NI numbers. However, all asylum seekers and refugees are 
179 
 
issued with documents from the immigration authorities and the current system could 
be adapted to accept these as a form of identification. As with the current scheme, 
consent to checking should be a prerequisite to enrolling in a clinical trial. All PIS 
should be required to expand the section asking if participants have recently or are 
currently participating in a clinical trial to outline the potential risks of over and multiple 
participation. Researchers may argue that the cost of funding such a scheme would 
be prohibitive, or that research would be slowed while checks were taking place. 
However, the current TOPS scheme has not found this to be a problem. Until the 
scheme has been expanded to cover all clinical trials, prospective participants will 
continue to enrol in multiple trials and over participate. Those who do so put 
themselves at risk and also affect the integrity of trial data.  
 
Researchers are required to provide trial information to prospective participants, 
including the aims and objective of the trial, and risks and burdens. NRES provides 
comprehensive guidance as well as templates which are available to researchers. 
There are very specific issues which are relevant only to HIV positive asylum seekers 
and refugees. I would argue that this information is necessary for them to make an 
informed choice about participation and should be added to the list of templates 
available to researchers. This information should include the risk of developing drug 
resistant strains of the virus should they have to abruptly stop treatment through 
dispersal or deportation. Participants should be clearly informed that it is unlikely that 
participation in the trial will positively influence the outcome of any asylum application. 
Participants should be informed of the risks of over and multiple participation. The 
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current PIS informs participants that their treatment and care will not be affected 
should they decline to participate. I would suggest that this statement be 
strengthened for HIV positive asylum seekers and refugees. Participants should be 
informed that they are under no obligation to participate even if asked to do so by 
their clinician.  
 
Despite following guidance, PIS are often not user friendly and may not be 
understood by the target population. NRES suggests that researchers liaise with 
patient groups when considering developing research protocols. I would suggest that 
one area where the expertise of local groups can have the greatest impact is in the 
development of PIS. Not only are the groups aware of language and cultural issues, 
they will be able to discuss the most appropriate ways to raise the topic with 
community groups. NRES should strengthen their position and move from suggesting 
that researchers involve patients groups to making it a mandatory requirement. Joint 
collaboration between researchers and community groups will ensure that the PIS not 
only contains the essential information about the trial, but that the information is 
presented in a culturally appropriate and easily understood format. The sheet should 
then be piloted with a group of participant representatives who were not involved in 
the development of the PIS. NRES guidance does not limit researchers from 
providing information only in written form. Some community groups have suggested 
that they would prefer information verbally in a group setting, or by other auditory 
forms such as tape or DVD. This format could be very useful if potential participants 
have low levels of literacy. It could also be utilized to provide information in the 
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participants own language in situations where it is difficult to find an interpreter, for 
example if the participants has a first language which is not common. However, 
researchers should also be required to translate the PIS when this is practical. At 
present, researchers often state that it is not cost effective to translate the PIS, 
despite the target population not having English as a first language. The REC has no 
means to compel them to do so. The cost of translation should be factored in the trial 
budget if the majority of prospective participants are identified as belonging to a 
population that does not have English as a first language, and are not likely to have a 
good understanding of English. Researchers should be expected to give a reasonable 
explanation to the REC if they are not planning to do so and offer alternative ways of 
imparting information.  
 
Many HIV positive asylum seekers and refugees will not have English as a first 
language. While they may be able to understand basic spoken language they could 
have difficulty understanding the concepts of a clinical trial. Most researchers now 
have access to interpreters who are able to translate trial information. While these 
interpreters may be very skilled, they could have very little understanding of clinical 
trials and may find it difficult to impart this information to participants. The training for 
interpreters does not include translating in clinical trials. In order to rectify this NRES - 
in conjunction with governing bodies of interpreters - should set standards for 
interpreters working within clinical trial settings and develop an accredited training 
program.  
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Possibly the greatest risk to clinical trials participants who are HIV positive asylum 
seekers and refugees is the risk of being dispersed or deported resulting in the 
development of drug resistance. Individuals are seldom given any notice that they are 
being moved by authorities and may not have had time to collect antiretroviral 
medication. Others may not be permitted to take medication with them or have it 
removed by authorities for safe keeping. Patients themselves may be unaware that 
they will be at a increased risk of developing drug dependency if they have to stop 
their antiretroviral medication in an unstructured manner such as this. As outlined 
above the participant information sheet should clearly outline the risks of developing 
drug resistance. Researchers should consider providing all participants with a 
‘withdrawal pack’ of antiretroviral medication. This would include details of how to 
safely stop treatment thereby reducing the likelihood of developing drug resistance. I 
would argue that the authorities responsible for the dispersal or detention of refugees 
and asylum seekers should ensure that they have policies and procedures in place to 
deal humanely with HIV positive individuals, and reduce the potential for exacerbating 
HIV related health problems while they are in custody. This is a concern not only for 
those participating in clinical trials, but for all HIV positive asylum seekers and 
refugees. As the authorities are responsible for the safely of detainees, it is 
reasonable for them to remove medication initially to check that it has been 
prescribed. However, there is often a long delay before this confirmation comes and 
an even longer delay before the treatment is recommenced. During this time, the 
individual may be at risk of developing drug resistance. Detainees have also voiced 
concerns about how staff treat HIV positive individuals, such as wearing gloves and a 
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mask while talking to them. In order to address these issues I would suggest that a 
working party be established comprising of the Immigration Authorities, detention 
centres and representatives of BHIVA and BASHH. This working party should 
establish guidelines to ensure seamless treatment for HIV positive detainees. It would 
be relatively easy for HIV physicians to give all HIV positive asylum seekers a three 
day supply of treatment and a letter confirming that the individual is on treatment. This 
could be given to the officials when the individual is detained, ensuring that the 
participant has enough medication until they are seen by a medical officer. There 
should be closer liaison with HIV physicians to ensure that medical problems are 
addressed in a timely manner to reduce the risk of complications.  All staff working in 
detention centres should have mandatory training on HIV. In addition to explaining the 
importance of continued treatment, it will also allay some of the concerns staff have 
regarding transmission.  
 
Research Ethics Committees are pivotal in ensuring that the specific needs of HIV 
positive asylum seekers and refugees are being considered. The role of the REC is to 
protect the interests of those participating in research while supporting the 
development of new medications or knowledge gained through knowledge. These two 
aspects can conflict when pressure is placed on the REC to approve clinical trials at 
their first presentation. Minor issues such as providing translations of the PIS may be 
overlooked if the trial has no other obvious ethical concerns. However, the REC has a 
responsibility to ensure that information provided to participants is in a format which is 
culturally and linguistically appropriate to them. As such, they should actively support 
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researchers who utilise alternative methods of providing trial information, such as the 
use of visual aids and group discussions. RECs should ask researchers who plan to 
conduct research with HIV positive participants what provision they have made for 
asylum seekers and refugees. Those who state that they do not plan to recruit from 
this population should be challenged; the likelihood that they will not recruit an asylum 
seeker or refugee is very small.  
 
In conclusion, while the inclusion of HIV positive asylum seekers and refugees in 
clinical trials raises ethical concerns, they should be supported to participate in clinical 
trials if their decision to participate is based on information they can understand, that 
their decision to participate is given freely with no coercion and that they aware of 
both the risks and benefits of participation. There has been very little published on the 
issues relating to the participation of HIV positive asylum seekers and refugees in 
clinical trials. In this thesis I have highlighted some of the issues which contribute to 
what is already known of this topic. If the recommendations I have made in this 
chapter are implemented, it would go some way to addressing the specific needs of 
this population should they choose to participate in clinical trials.  
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